Document And Entity Information
Document And Entity Information | 12 Months Ended |
Dec. 31, 2023 shares | |
Document Information [Line Items] | |
Document Type | 20-F |
Document Registration Statement | false |
Document Annual Report | true |
Document Period End Date | Dec. 31, 2023 |
Document Transition Report | false |
Document Shell Company Report | false |
Entity File Number | 000-29374 |
Entity Registrant Name | EDAP TMS SA |
Entity Incorporation, State or Country Code | I0 |
Entity Address, Address Line One | Parc d’Activites la Poudrette-Lamartine |
Entity Address, Address Line Two | 4/6, rue du Dauphiné |
Entity Address, Postal Zip Code | 69120 |
Entity Address, City or Town | Vaulx-en-Velin |
Entity Address, Country | FR |
Title of 12(b) Security | American Depositary Shares |
Entity Central Index Key | 0001041934 |
Trading Symbol | EDAP |
Security Exchange Name | NASDAQ |
ICFR Auditor Attestation Flag | true |
Entity Common Stock, Shares Outstanding (in shares) | 37,103,779 |
Entity Well-known Seasoned Issuer | No |
Entity Voluntary Filers | No |
Entity Current Reporting Status | Yes |
Entity Interactive Data Current | Yes |
Entity Filer Category | Accelerated Filer |
Entity Emerging Growth Company | false |
Document Financial Statement Error Correction [Flag] | false |
Document Accounting Standard | U.S. GAAP |
Entity Shell Company | false |
Current Fiscal Year End Date | --12-31 |
Document Fiscal Year Focus | 2023 |
Document Fiscal Period Focus | FY |
Amendment Flag | false |
Auditor Name | KPMG S.A. |
Auditor Firm ID | 1253 |
Auditor Location | Lyon, France |
Business Contact | |
Document Information [Line Items] | |
Entity Address, Address Line One | Parc d’Activites la Poudrette-Lamartine |
Entity Address, Address Line Two | 4/6, rue du Dauphiné |
Entity Address, Postal Zip Code | 69120 |
Entity Address, City or Town | Vaulx-en-Velin |
Entity Address, Country | FR |
Contact Personnel Name | Blandine Confort |
City Area Code | 33 |
Local Phone Number | 4 72 15 31 50 |
Contact Personnel Email Address | bconfort@edap-tms.com |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Current assets | ||
Cash and cash equivalents | € 43,471 | € 63,136 |
Current portion of net trade accounts and notes receivable | 17,858 | 13,421 |
Other receivables | 1,380 | 1,522 |
Inventories | 15,112 | 11,780 |
Other assets, current portion | 659 | 660 |
Total current assets | 78,480 | 90,518 |
Non-current assets | ||
Property and equipment, net | 6,471 | 4,200 |
Operating lease right-of-use assets | 1,722 | 1,784 |
Intangible assets, net | 1,084 | 725 |
Goodwill | 2,412 | 2,412 |
Deposits and other non-current assets | 651 | 656 |
Deferred tax assets | 729 | 829 |
Total assets | 91,548 | 101,123 |
Current liabilities | ||
Trade accounts and notes payable | 11,297 | 6,647 |
Deferred revenues, current portion | 4,049 | 4,050 |
Social security and other payroll withholdings taxes | 1,695 | 1,550 |
Employee absences compensation | 860 | 798 |
Income taxes payable | 77 | 219 |
Other accrued liabilities | 4,506 | 3,873 |
Short-term borrowings | 2,466 | 1,846 |
Current obligations under finance leases | 195 | 224 |
Current portion of operating lease obligations | 898 | 901 |
Current portion of long-term debt | 1,553 | 1,601 |
Total current liabilities | 27,596 | 21,708 |
Non-current liabilities | ||
Deferred revenues, non-current | 643 | 264 |
Obligations under finance leases | 433 | 324 |
Operating lease obligations, non-current | 882 | 899 |
Long-term debt, non-current | 1,997 | 3,587 |
Other long-term liabilities | 3,075 | 2,710 |
Total liabilities | 34,626 | 29,492 |
Shareholders' equity | ||
Common stock, €0.13 par value; 37,373,312 shares issued and 37,103,779 shares outstanding at December 31, 2023 €0.13 par value 37,197,731 shares issued and 36,910,925 shares outstanding at December 31, 2022 | 4,851 | 4,776 |
Additional paid-in capital | 120,908 | 113,952 |
Retained earnings | (63,549) | (42,372) |
Cumulative other comprehensive loss | (4,487) | (3,829) |
Treasury stock, at cost 269,533 shares at December 31, 2023 and 286,806 shares at December 31, 2022 | (800) | (897) |
Total shareholders' equity | 56,922 | 71,632 |
Total liabilities and shareholders' equity | € 91,548 | € 101,123 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - € / shares | Dec. 31, 2023 | Dec. 31, 2022 |
CONSOLIDATED BALANCE SHEETS | ||
Common stock, par value | € 0.13 | € 0.13 |
Common stock, shares issued | 37,373,312 | 37,197,731 |
Commons stock, shares outstanding | 37,103,779 | 36,910,925 |
Treasury stock | 269,533 | 286,806 |
CONSOLIDATED STATEMENTS OF INCO
CONSOLIDATED STATEMENTS OF INCOME (LOSS) - EUR (€) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenues | € 60,423,000 | € 55,108,000 | € 44,065,000 |
Total cost of sales | (36,012,000) | (30,916,000) | (25,643,000) |
Gross profit | 24,411,000 | 24,193,000 | 18,422,000 |
Research and development expenses | (6,963,000) | (4,920,000) | (3,402,000) |
Selling and marketing expenses | (22,626,000) | (16,379,000) | (10,732,000) |
General and administrative expenses | (14,634,000) | (7,152,000) | (5,900,000) |
Income (loss) from operations | (19,813,000) | (4,257,000) | (1,612,000) |
Financial (expense) income, net | 1,079,000 | 236,000 | 145,000 |
Foreign currency exchange gain (loss), net | (1,799,000) | 1,925,000 | 2,360,000 |
Income (loss) before taxes | (20,533,000) | (2,096,000) | 893,000 |
Income tax (expense) benefit | (644,000) | (837,000) | (193,000) |
Net income (loss) | € (21,177,772) | € (2,933,058) | € 699,890 |
Basic income (loss) per share (in EUR per share) | € (0.57) | € (0.09) | € 0.02 |
Diluted income (loss) per share (in EUR per share) | € (0.57) | € (0.09) | € 0.02 |
Basic Weighted average shares outstanding (in shares) | 36,996,722 | 34,392,598 | 32,129,047 |
Diluted Weighted average shares outstanding (in shares) | 36,996,722 | 34,392,598 | 32,422,871 |
Product | |||
Revenues | € 60,423,000 | € 55,108,000 | € 44,060,000 |
Goods | |||
Revenues | 42,333,000 | 38,462,000 | 29,040,000 |
Total cost of sales | (23,302,000) | (20,528,000) | (16,181,000) |
RPP's and leases | |||
Revenues | 6,176,000 | 5,617,000 | 4,968,000 |
Total cost of sales | (4,541,000) | (3,387,000) | (3,108,000) |
Spare parts and services | |||
Revenues | 11,914,000 | 11,030,000 | 10,052,000 |
Total cost of sales | € (8,169,000) | € (7,000,000) | (6,354,000) |
Other revenues | |||
Revenues | € 6,000 |
CONSOLIDATED STATEMENTS OF COMP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - EUR (€) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) | |||
Net income (loss) | € (21,177,772) | € (2,933,058) | € 699,890 |
Foreign currency translation adjustments | (478,000) | (596,000) | (554,000) |
Provision for retirement indemnities | (141,000) | 282,000 | 77,000 |
Deferred tax for retirement indemnities | (39,000) | 73,000 | (48,000) |
Comprehensive income (loss), net of tax | € (21,836,000) | € (3,173,000) | € 175,000 |
CONSOLIDATED STATEMENTS OF STOC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY - EUR (€) | Common stock | Additional paid-in capital. | Retained Earnings / (Loss) | Other comprehensive income (loss) | Treasury stock | Total |
Balance at Dec. 31, 2020 | € 3,830,000 | € 66,548,000 | € (40,139,000) | € (3,064,000) | € (928,000) | € 26,248,000 |
Balance (in shares) at Dec. 31, 2020 | 29,165,316 | |||||
Net (loss) / income | 700,000 | 699,890 | ||||
Translation adjustment | (554,000) | (554,000) | ||||
Stock-based compensation | 1,900,000 | 1,900,000 | ||||
Capital increase | € 559,000 | 21,173,000 | 21,732,000 | |||
Capital increase (in shares) | 4,300,820 | |||||
Provision for retirement indemnities | 77,000 | 77,000 | ||||
Deferred tax for retirement indemnities | (48,000) | (48,000) | ||||
Balance (in shares) at Dec. 31, 2021 | 33,466,136 | |||||
Balance at Dec. 31, 2021 | € 4,389,000 | 89,621,000 | (39,439,000) | (3,589,000) | (928,000) | 50,054,000 |
Net (loss) / income | (2,933,000) | (2,933,058) | ||||
Translation adjustment | (596,000) | (596,000) | ||||
Stock-based compensation | 2,103,000 | 2,103,000 | ||||
Capital increase | € 388,000 | 22,228,000 | 22,616,000 | |||
Capital increase (in shares) | 3,444,789 | |||||
Treasury stock disposition | 31,000 | 31,000 | ||||
Provision for retirement indemnities | 282,000 | 282,000 | ||||
Deferred tax for retirement indemnities | 73,000 | 73,000 | ||||
Balance (in shares) at Dec. 31, 2022 | 36,910,925 | |||||
Balance at Dec. 31, 2022 | € 4,776,000 | 113,952,000 | (42,372,000) | (3,829,000) | (897,000) | 71,632,000 |
Net (loss) / income | (21,178,000) | (21,177,772) | ||||
Translation adjustment | (478,000) | (478,000) | ||||
Stock-based compensation | 6,865,000 | 6,865,000 | ||||
Capital increase | € 74,000 | 90,000 | 164,000 | |||
Capital increase (in shares) | 192,854 | |||||
Treasury stock disposition | 97,000 | 97,000 | ||||
Provision for retirement indemnities | (141,000) | (141,000) | ||||
Deferred tax for retirement indemnities | (39,000) | (39,000) | ||||
Balance (in shares) at Dec. 31, 2023 | 37,103,779 | |||||
Balance at Dec. 31, 2023 | € 4,851,000 | € 120,908,000 | € (63,549,000) | € (4,487,000) | € (800,000) | € 56,922,000 |
CONSOLIDATED STATEMENTS OF ST_2
CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY | ||
Issuance costs | € 1,954 | € 1,961 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - EUR (€) | 12 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | ||
Cash flows from operating activities | ||||
Net income (loss) | € (21,177,772) | € (2,933,058) | € 699,890 | |
Adjustments to reconcile net income (loss) to net cash generated by (used in) operating activities: | ||||
Depreciation and amortization | 1,913,000 | 1,605,000 | 1,920,000 | |
Share based compensation | 6,865,000 | 2,103,000 | 1,900,000 | |
US Paycheck Protection Program loan Forgiveness | (187,000) | |||
Change in allowances for doubtful accounts & slow-moving inventories | 422,000 | 124,000 | 363,000 | |
Change in long-term provisions | 159,000 | 79,000 | (350,000) | |
Net capital loss on disposals of assets | 1,000 | 266,000 | 142,000 | |
Deferred tax expense (benefit) | 42,000 | 48,000 | (563,000) | |
Operating cash flow before changes in working capital | (11,775,000) | 1,292,000 | 3,925,000 | |
Increase/Decrease in operating assets and liabilities: | ||||
Decrease (Increase) in trade accounts and notes and other receivables | (4,910,000) | (1,974,000) | (103,000) | |
Decrease (Increase) in inventories | (4,212,000) | (4,482,000) | 166,000 | |
Decrease (Increase) in other assets | (12,000) | (82,000) | (210,000) | |
(Decrease) Increase in trade accounts and notes payable | 5,281,000 | 1,143,000 | (38,000) | |
(Decrease) Increase in accrued expenses, other current liabilities | 950,000 | 1,079,000 | 706,000 | |
Net change in operating assets and liabilities | (2,903,000) | (4,316,000) | 520,000 | |
Net cash generated by (used in) operating activities | (14,678,000) | (3,024,000) | 4,445,000 | |
Cash flows from investing activities: | ||||
Additions to capitalized assets produced by the Company | (2,583,000) | (1,570,000) | (1,161,000) | |
Acquisitions of property and equipment | (1,179,000) | (613,000) | (393,000) | |
Acquisitions of intangible assets | (534,000) | (137,000) | (92,000) | |
Decrease (Increase) of other financial assets | 1,000 | 13,000 | ||
Increase in deposits and guarantees | (50,000) | (58,000) | (6,000) | |
Net cash generated by (used in) investing activities | (4,344,000) | (2,378,000) | (1,638,000) | |
Cash flow from financing activities: | ||||
Proceeds from capital increase | [1] | 21,960,000 | 21,289,000 | |
Proceeds from stock-option exercise | 261,000 | 688,000 | 442,000 | |
Proceeds from long term borrowings, net of financing costs | 286,000 | 1,058,000 | ||
Repayment of long term borrowings | (1,586,000) | (803,000) | (1,401,000) | |
Repayment of obligations under financing leases | (242,000) | (350,000) | (406,000) | |
Increase (decrease) in bank overdrafts and short-term borrowings | 656,000 | (38,000) | (717,000) | |
Net cash generated by (used in) financing activities | (911,000) | 21,741,000 | 20,266,000 | |
Net effect of exchange rate changes on cash and cash equivalents | 268,000 | (388,000) | (585,000) | |
Net increase (decrease) in cash and cash equivalents | (19,665,000) | 15,952,000 | 22,488,000 | |
Cash and cash equivalents at beginning of year | 63,136,000 | 47,183,000 | 24,696,000 | |
Cash and cash equivalents at end of year | € 43,471,000 | € 63,136,000 | € 47,183,000 | |
[1] The net proceeds from capital increase of €21,960 thousand relate to the Company’s successful common stock offering in September 2022 and of €21,289 thousand relate to the Company’s successful common stock offering in April 2021 – refer to Note 17-1. |
CONSOLIDATED STATEMENTS OF CA_2
CONSOLIDATED STATEMENTS OF CASH FLOW (Parenthetical) - EUR (€) € in Thousands | 1 Months Ended | 12 Months Ended | ||||
Sep. 30, 2022 | Apr. 30, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||
Proceeds from capital increase | € 21,960 | € 21,289 | € 21,960 | [1] | € 21,289 | [1] |
[1] The net proceeds from capital increase of €21,960 thousand relate to the Company’s successful common stock offering in September 2022 and of €21,289 thousand relate to the Company’s successful common stock offering in April 2021 – refer to Note 17-1. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2023 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 1— SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 1-1 Nature of operations EDAP TMS S.A. and its subsidiaries (‘‘the Company’’) are engaged in the development, manufacturing, promotion and distribution of advanced minimally-invasive ultrasound technologies for both diagnosis and treatment of urological diseases. We have introduced the Focal One® Robotic HIFU (high-intensity focused ultrasound) system around the world including Europe, U.S., Latin America, and parts of Asia. With the addition of the ExactVu™ Micro-Ultrasound system, we offer customers a complete solution from diagnosis to treatment of prostate disease. The Company also produces and distributes systems for the treatment of urinary tract stones. These technologies include the Sonolith® i-move lithotripter system based on Extracorporeal ShockWave Lithotripsy (ESWL) technology and advanced surgical laser systems. We also derive revenues from the distribution of urodynamics products and urology lasers. Net sales consist primarily of direct sales to hospitals and clinics in France and Europe, export sales to third-party distributors and agents, and export sales through subsidiaries based in Germany, Italy, the United States and Asia. The Company purchases the majority of the components used in its products from a number of suppliers but for some components, relies on a single source. Delay would be caused if the supply of these components or other components was interrupted and these delays could be extended in certain situations where a component substitution may require regulatory approval. Failure to obtain adequate supplies of these components in a timely manner could have a material adverse effect on the Company’s business, financial position and results of operations. 1-2 Basis of preparation These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). 1-3 Management estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles (‘‘U.S. GAAP’’) requires management to make estimates and assumptions, such as business plans, stock price volatility, duration of standard warranty per market, duration and interest rate of operating leases, price of maintenance contracts used to determine the amount of revenue to be deferred and life duration of our range of products. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. 1-4 Consolidation The accompanying consolidated financial statements include the accounts of EDAP TMS S.A. and all its domestic and foreign owned subsidiaries after elimination of intercompany balances and transactions. We do not have any significant interests in any variable interest entities. 1-5 Revenue recognition The Company’s revenue consists of: - Sales of goods (devices and consumables), where invoicing generally takes place upon delivery. Consumables revenues included in sales contracts are deferred until delivery. - Revenue-per-Procedures (“RPP”) and leases: they comprise (i) revenues on a per treatment basis which are invoiced after each treatment, or in advance, or on a periodic basis, (ii) leases of devices, which are generally invoiced on a monthly or quarterly basis, and (iii) lease components arising from multiple-element arrangements, where specific sales terms are negotiated in accordance with each customer’s individual requirements and which are generally invoiced based on contract terms, - Sales of spare parts and services (maintenance, upgrades, mobility and others). Spare parts are invoiced when delivered. Regarding services, invoicing is performed either on a subscription basis (in advance or at the end of the period) or when performed. Sales of our medical devices and sales of disposables, sales of RPPs and leases, and sales of spare parts and services, are all net of commissions. The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due between one to three months from date of invoice. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and its customer, the rights of the goods or services and their payment terms can be identified, the contract has commercial substance, collectability of the contract consideration is probable, it is approved and the parties are committed to their obligations. Our sale arrangements may contain multiple elements, including device(s), consumables and services. For these multiple-element arrangements, the Company accounts for individual goods and services as separate performance obligations: (i) if a customer can benefit from the good or service on its own or with other resources that are readily available to the customer, and (ii) if they are a distinct good or service that is separately identifiable from other items in the multiple-element arrangement. The Company’s sale arrangements may include a combination of the following performance obligations: device(s), consumables, leases and services (such as, but not limited to, warranty extension). For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the goods or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the goods and services, geographies, and type of customer. The Company regularly reviews standalone selling prices and updates these estimates as necessary. The Company recognizes revenue when the performance obligations are satisfied by transferring control over the goods or service to a customer. The Company’s revenue consists of the following: Sales of goods: Sales of goods are and have historically been comprised of sales net of commission of medical devices (ESWL lithotripters and HIFU devices) and net sales of disposables (mostly Focalpaks in the HIFU division and electrodes in the ESWL division). Sales of goods also includes products such as micro-ultrasound devices, urology lasers and urodynamics devices distributed through our agents and third-party distributors. For devices and disposables, revenue is recognized when the Company transfers control to the customer (i.e. when the customer has the ability to direct the use of, and obtain substantially all of the remaining benefit from, the device or disposables), which is generally at the point of delivery, depending on the terms of the arrangement (i.e. when the customer can use the goods to provide services or sell or exchange the good), and based on contractual incoterms. Installation-related costs are immaterial in the context of the contract with the customer and do not constitute a distinct performance obligation. The Company’s sales arrangements do not provide a right of return. The goods are generally covered by a period of one Sales of RPPs and leases: Sales of RPP and leases include the revenues from the sale of treatment procedures and from the leasing of machines. For RPP, we provide machines to clinics and hospitals for free for a limited period, rather than selling the devices. These hospitals and clinics perform treatments using the devices and usually pay us based on the number of individual treatments provided. Revenues from leasing of machine are considered as immaterial. Revenues related to the sale of treatments invoiced on a ‘‘Revenue-Per-Procedure’’ (‘‘RPP’’) basis are recognized when the treatment procedure has been completed. Revenues from devices leased to customers under operating leases are recognized on a straight-line basis. Regarding multiple-element arrangements with a lease component, a portion of the contract is allocated to the lease component on the basis of observable market prices applied by the Company for similar devices under operating leases. The lease component is recognized on a straight line basis over the contractual period. Other immaterial components under the contract are recognized in accordance with their nature. Sales of spare parts and services: Revenues related to spare parts are recognized when spare parts are delivered to distributors who perform their own maintenance services. Spare parts used in the performance of EDAP’s own maintenance and repair services are generally not recognized separately, unless a type of spare part is specifically excluded from the maintenance contract terms. Revenues related to Services mainly consist of maintenance contracts which rarely exceed one year and are recognized on a straight line basis over the term of the service period as the customer benefits from the service equally throughout the service contract period. For services rendered when no maintenance contract is in place or for services not included in the scope of a maintenance contract, revenues are recorded when services are performed. The Company recognizes revenue for extended warranties included in the multiple-element arrangements as a separate performance obligation in Sales of services on a straight-line basis over the extended warranty period. In the majority of countries in which the Company operates, the statutory warranty period is one to two years and the extended warranty covers periods beyond this statutory period. Standard warranties do not constitute a separate performance obligation. The Company accrues for the warranty costs at the time of sale of the device through the multiple-element arrangement. Distributors: As part of its sale process in countries other than continental France, when the Company does not have a local subsidiary, sales of goods to end-customers are performed through agents and distributors. Such agents and distributors are primarily responsible for the sales’ process, bear the inventory risk, and are free to determine the sale prices. Sales of goods to agents and distributors are recognized when the control is transferred to the related agent or distributor which generally occurs based on contractual incoterms. Deferred revenue: Deferred revenue for the periods presented primarily relates to service contracts where the service fees are billed up-front, generally quarterly or annually, prior to those services having been performed, and consists primarily of billing or cash receipts in advance of services due under maintenance contracts or extended warranty contracts. The associated deferred revenue is generally recognized ratably over the service period. Disaggregation of revenue: Disaggregation by primary geographical market, and timing of revenue recognition is reported in Note 18. Contract Balances: Details on contract liabilities are reported on Note 11. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. This relates mainly to maintenance services. 1-6 Costs of sales Costs of sales include all direct product costs, costs related to shipping, handling, duties and importation fees, as well as certain indirect costs such as service and supply chain departments expenses. Indirect costs are allocated by type of sales (goods, RPP and leases, spare parts and services) using an allocation method determined by management by type of costs and segment activities and reviewed on an annual basis. 1-7 Shipping and handling costs Shipping and handling costs are not considered as performance obligations. Shipping and handling costs are recorded as a component of cost of sales. 1-8 Cash equivalents and short term investments Cash equivalents are cash investments which are highly liquid and have initial maturities of 90 days or less. Cash investments with a maturity higher than 90 days are considered as short-term investments. There is no short-term investment at December 31, 2023. 1-9 Accounts Receivable The Company maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio. In establishing the required allowance, management considers historical losses adjusted to take into account current market conditions and the Company’s customers’ financial condition, the amount of receivables in dispute, and the current receivables aging and current payment patterns. The Company reviews its allowance for doubtful accounts quarterly. Past due balances over 90 days and over a specified amount are reviewed individually for collectability. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Write-offs for 2023 and 2022 approximated €1 thousand and €640 thousand, respectively. The Company does not have any off-balance-sheet credit exposure related to its customers. 1-10 Inventories Inventories are valued at the lower of cost and net realizable value. Cost is either the manufacturing cost, which is principally comprised of components and labor costs for our own manufactured products, or purchase price for urology products we distribute. Cost is determined on a first-in, first-out basis for components and spare parts and by specific identification for finished goods (medical devices). The Company establishes reserves for inventory estimated to be obsolete, unmarketable or slow moving, first based on a detailed comparison between quantity in inventory and historical consumption and then based on case-by-case analysis of the difference between the cost of inventory and the related estimated market value. 1-11 Property and equipment Property and equipment is stated at historical cost, net of accumulated depreciation and impairment. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful life of the related assets, as follows: Leasehold improvements (in years) 10 or lease term if shorter Equipment (in years) 3 — 10 Furniture, fixtures, fittings and other (in years) 2 — 10 Equipment includes industrial equipment and research equipment that has alternative future uses. Equipment also includes devices and treatment probes that are manufactured by the Company and leased to customers through operating leases related to Revenue-Per-Procedure transactions. This equipment is generally depreciated over a period of five 1-12 Long-lived assets The Company reviews the carrying value of its long-lived assets, including fixed assets and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be fully recoverable. Recoverability of long-lived assets is assessed by a comparison of the carrying amount of the assets (or the Group of assets, including the asset in question, that represents the lowest level of separately-identifiable cash flows) to the total estimated undiscounted cash flows expected to be generated by the asset or group of assets. If the future net undiscounted cash flows is less than the carrying amount of the asset or group of assets, the asset or group of assets is considered impaired and an expense is recognized equal to the amount required to reduce the carrying amount of the asset or group of assets to its then fair value. Fair value is determined by discounting the cash flows expected to be generated by the assets, when the quoted market prices are not available for the long-lived assets. Estimated future cash flows are based on assumptions and are subject to risk and uncertainty. 1-13 Goodwill and intangible assets Goodwill represents the excess of purchase price over the fair value of identifiable net assets of businesses acquired. Goodwill is not amortized but instead tested annually for impairment or more frequently when events or change in circumstances indicate that the assets might be impaired. When impairment indicators are identified, the impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, including goodwill. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. For the purpose of any impairment test, the Company relies upon projections of future undiscounted cash flows and takes into account assumptions regarding the evolution of the market and its ability to successfully develop and commercialize its products. Changes in market conditions could have a major impact on the valuation of these assets and could result in additional impairment losses. Intangible assets consist primarily of purchased patents relating to lithotripters, purchased licenses, a purchased trade name and a purchased trademark. The basis for valuation of these assets is their historical acquisition cost. Amortization of intangible assets is calculated by the straight-line method over the shorter of the contractual or estimated useful life of the assets, as follows: Patents (in years) 5 SAP Licenses (in years) 10 Other licenses (in years) 5 Trade name and trademark (in years) 7 1-14 Treasury Stocks Treasury stock purchases are accounted for at cost. The sale of treasury stocks is accounted for using the first in first out method. Gains on the sale or retirement of treasury stocks are accounted for as additional paid-in capital whereas losses on the sale or retirement of treasury stock are recorded as additional paid-in capital to the extent that previous net gains from sale or retirement of treasury stocks are included therein; otherwise the losses shall be recorded to accumulated benefit (deficit) account. Gains or losses from the sale or retirement of treasury stock do not affect reported results of operations. Treasury stocks held by a company cannot exceed 10% of the total number of shares issued. 1-15 Warranty expenses The Company provides customers with a warranty for each product sold and accrues warranty expense at time of sale based upon historical claims experience. Standard warranty period may vary from 1 year to 2 years depending on the market. The warranty expense is incurred at time of accrual and not when paid. Warranty expense amounted to €134 thousand, €112 thousand and €110 thousand for the years ended December 31, 2023, 2022 and 2021, respectively. 1-16 Income taxes The Company accounts for income taxes in accordance with ASC 740, ‘‘Accounting for Income Taxes’’ Under ASC 740, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured by applying enacted tax rates and laws to taxable years in which such differences are expected to reverse. A valuation allowance is established if, based on the weight of available evidence, it is more likely than not that some portion, or all of the deferred tax assets, will not be realized. In accordance with ASC740, no provision has been made for income or withholding taxes on undistributed earnings of foreign subsidiaries, such undistributed earnings being permanently reinvested. Under ASC740, the measurement of a tax position that meets the more-likely-that-not recognition threshold must take into consideration the amounts and probabilities of the outcomes that could be realized upon ultimate settlement using the facts, circumstances and information available at the reporting date. 1-17 Research and development costs Research and development costs are recorded as an expense in the period in which they are incurred. The French government provides tax credits to companies for innovative research and development. This tax credit is calculated based on a percentage of eligible research and development costs and it can be refundable in cash and is not contingent on future taxable income. As such, the Company considers the research tax credits as a grant, offsetting research and development expenses. 1-18 Advertising costs Advertising costs are recorded as an expense in the period in which they are incurred and are included in selling and administrative expenses in the accompanying consolidated statements of income (loss). Advertising costs amounted to €1,352 thousand, €929 thousand and €490 thousand for the years ended December 31, 2023, 2022 and 2021, respectively. 1-19 Foreign currency translation and transactions Translation of the financial statements of consolidated companies The reporting currency of EDAP TMS S.A. for all years presented is the euro (€). The functional currency of each subsidiary is its local currency. In accordance with ASC 830, all accounts in the financial statements are translated into euro from the functional currency at the following exchange rates: ● assets and liabilities are translated at year-end exchange rates; ● shareholders’ equity is translated at historical exchange rates (as of the date of contribution); ● statement of income (loss) items are translated at average exchange rates for the year; and ● translation gains and losses are recorded in a separate component of shareholders’ equity. Foreign currencies transactions Transactions involving foreign currencies are translated into the functional currency using the exchange rate prevailing at the time of the transactions. Receivables and payables denominated in foreign currencies are translated at year-end exchange rates. The resulting unrealized exchange gains and losses are recorded in the statement of income (loss). Presentation in the Statement of Income (loss) Aggregate foreign currency transactions gains and losses are disclosed in a single caption in the Statement of Income (loss) under section “Foreign currency exchange gain (loss), net”. 1-20 Earnings per share Basic earnings per share is computed by dividing income available to common shareholders by the weighted average number of shares of common stock outstanding for the period. Diluted earnings per share reflects potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company. The dilutive effects of the Company’s common stock options and warrants is determined using the treasury stock method to measure the number of shares that are assumed to have been repurchased using the average market price during the period, which is converted from U.S. dollars at the average exchange rate for the period. 1-21 Derivative instruments ASC 815 requires the Company to recognize all of its derivative instruments as either assets or liabilities in the statement of financial position at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, the Company must classify the hedging instrument, based upon the exposure being hedged, as fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation. Gains and losses from derivative instruments are recorded in the Statement of Income (loss). As of December 31, 2023, there are no derivative instruments. 1-22 Employee stock option and free shares plan The accounting for stock-based awards is based on the fair value of the award measured at the grant date. Accordingly, stock-based compensation cost is recognized in the consolidated statements of income (loss) and comprehensive income (loss) as an operating expense over the requisite service period. The fair value of stock options is determined using the Black-Scholes option-pricing model. The Company determines the fair value of stock option awards on the date of grant using assumptions regarding expected term, share price volatility over the expected term of the awards, risk-free interest rate, and dividend rate. The fair value of free shares is measured using the fair value of the Company's shares as if the free shares were vested and issued on the grant date. Forfeited stock-options and free shares are recognized as they occur, in accordance with ASU 2016-09. The Company recognizes compensation cost for employee awards with only service conditions that have a graded vesting schedule on a straight-line basis over the requisite service period for each separately vesting portion of the award as if the award was, in-substance, multiple awards. At December 31, 2023, the Company had three stock-based employee compensation plans and two free shares plans. 1-23 Warrants There are no warrants outstanding at December 31, 2023. 1-24 Leases Leases as a Lessee In accordance with ASC 842, Leases, and as from January 1, 2019, the Company classifies all leases at the inception of a contract and assess whether the contract is, or contains, a lease. The assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the company controls the use of the identified asset (e.g. whether the company has the right to obtain substantially all of the economic benefits from the use of the asset throughout the period, and whether the company has the right to direct the use of the asset). Leases are classified as either finance leases or operating leases. Substantially all our operating leases are comprised of office space leases, and substantially all our finance leases are comprised of office furniture and technology equipment. The Company recognizes a right-of-use (“ROU”) asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, plus prepaid lease payments, less any lease incentives received. All ROU assets are reviewed for impairment. For operating leases, the lease liability is initially measured at the present value of the unpaid lease payments at lease commencement date, discounted using the incremental borrowing rate for assets of same duration or characteristics. For finance leases the lease liability is initially measured in the same manner and date as for operating leases and is subsequently measured at amortized cost using the effective interest method For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability. Lease payments included in the measurement of the lease liability comprise the following: the fixed payments, including in-substance fixed payments over the lease term (which includes termination penalties the Company would owe if the lease term assumes the Company’s exercise of a termination option), variable lease payments that depend on an index or rate payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, the exercise price of an option to purchase the underlying asset if the company is reasonably certain to exercise the option, and amounts expected to be payable under a Company provided residual value guarantee. The company assesses the discount rate by requesting credit simulation from certain banks. Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expenses in the Company’s consolidated statements of income (loss) in the same line item as expenses arising from fixed lease payments (operating leases) or amortization of the ROU asset (finance leases). Our real estate leases generally include non-lease maintenance services. The consideration in the contract is allocated to the lease and non-lease components based on standalone selling prices. Some of our real estate leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease commencement, and changes to index and rate-based variable lease payments are recognized in profit or loss in the period of the change. Variable payments that do not depend on an index or rate, such as rental payments based on the use of the underlying asset or property taxes and insurance reimbursement, are recorded as operating expenses when incurred. Lease modifications result in remeasurement of the lease payments when that modification is not accounted for as a separate contract. Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. Lease expense for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense. The lease term for all of the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor . We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a term of 12 months or less. The effect of short-term leases on our right-of-use asset and lease liability was not material. We have elected not to review the classification for expired or existing leases, prior to January 1, 2019. Leases as a Lessor: A lessor shall classify a lease as a sales-type lease when the lease meets any of the following criteria at lease commencement: ● The lease transfers ownership of the underlying asset to the lessee by the end of the lease term. ● The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise. ● The lease term is for the major part of the remaining economic life of the underlying asset. However, if the commencement date falls at or near the end of the economic life of the underlying asset, this criterion shall not be used for purposes of classifying the lease. ● The present value of the sum of the lease payments and any residual value guaranteed by the lessee that is not already reflected in the lease payments in accordance with paragraph 842-10-30-5(f) equals or exceeds substantially all of the fair value of the underlying asset. ● The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. When none of the criteria are met: A lessor shall classify the lease as either a direct financing lease or an operating lease. A lessor shall classify the lease as an operating lease unless both of the following criteria are met, in which case the lessor shall classify the lease as a direct financing lease: ● The present value of the sum of the lease payments and any residual value guaranteed by the lessee that is not already reflected in the lease |
CASH EQUIVALENTS
CASH EQUIVALENTS | 12 Months Ended |
Dec. 31, 2023 | |
CASH EQUIVALENTS | |
CASH EQUIVALENTS | 2— CASH EQUIVALENTS Cash equivalents at December 31, 2023 and 2022 only comprise cash investments which are highly liquid and have initial maturities of 90 days or less. December 31, 2023 2022 Total cash and cash equivalents 43,471 63,136 Short term investment — — Total cash and cash equivalents 43,471 63,136 Please refer to Note 15-1 – Long-term debt |
TRADE ACCOUNTS AND NOTES RECEIV
TRADE ACCOUNTS AND NOTES RECEIVABLE, NET | 12 Months Ended |
Dec. 31, 2023 | |
TRADE ACCOUNTS AND NOTES RECEIVABLE, NET | |
TRADE ACCOUNTS AND NOTES RECEIVABLE, NET | 3— TRADE ACCOUNTS AND NOTES RECEIVABLE, NET Trade accounts and notes receivable consist of the following: December 31, 2023 2022 Trade accounts receivable 17,186 12,965 Notes receivable 896 617 Less: allowance for doubtful accounts (224) (161) Total 17,858 13,421 Less current portion (17,858) (13,421) Total long-term portion — — Notes receivable usually represent commercial bills of exchange (drafts) with initial maturities of 90 days or less. Bad debt expenses amount to a net cost of €68 thousand, a net cost of €32 thousand and €2 thousand, respectively for the years ended December 31, 2023, 2022 and 2021. |
OTHER RECEIVABLES
OTHER RECEIVABLES | 12 Months Ended |
Dec. 31, 2023 | |
OTHER RECEIVABLES. | |
OTHER RECEIVABLES. | 4— OTHER RECEIVABLES Other receivables consist of the following: December 31, 2023 2022 Research and development tax credit receivable from the French State 411 581 Value-added taxes receivable 863 894 Other receivables from Government and public authorities 22 — Others 84 46 Total 1,380 1,522 |
INVENTORIES
INVENTORIES | 12 Months Ended |
Dec. 31, 2023 | |
INVENTORIES. | |
INVENTORIES | 5— INVENTORIES December 31, 2023 2022 Components, spare parts 8,973 7,543 Work-in-progress 512 283 Finished goods – own manufactured products 2,115 1,514 Finished goods – distribution products 4,775 3,702 Total gross inventories 16,375 13,042 Less: allowance for slow-moving inventory and net realizable value (1,263) (1,262) Total 15,112 11,780 The provision for slow moving inventory relates to components and spare parts. The increase in the allowance for slow moving inventory (excluding exchange rate impact), which are classified within cost of sales, amounted to €354 thousand for the year ended December 31, 2023, €93 thousand for the year ended December 31, 2022, and €371 thousand for the year ended December 31, 2021. During 2023, we recorded a reversal allowance for slow moving inventory for €301 thousand linked to the write-off of obsolete inventory. |
OTHER ASSETS
OTHER ASSETS | 12 Months Ended |
Dec. 31, 2023 | |
OTHER ASSETS | |
OTHER ASSETS | 6— OTHER ASSETS Other assets consist of the following: December 31, 2023 2022 Prepaid expenses, current portion 659 660 Total 659 660 Prepaid expenses mainly consist of rental and future congresses and conferences expenses. |
PROPERTY AND EQUIPMENT, NET
PROPERTY AND EQUIPMENT, NET | 12 Months Ended |
Dec. 31, 2023 | |
PROPERTY AND EQUIPMENT, NET | |
PROPERTY AND EQUIPMENT, NET | 7— PROPERTY AND EQUIPMENT, NET Property and equipment consist of Property and equipment purchased or capitalized by the Company and finance leases for 2023 and 2022. 7-1 Property and Equipment, net Property and equipment consist of the following: December 31, 2023 2022 Equipment 11,900 9,553 Furniture, fixture, and fittings and other 3,672 3,108 Total gross value 15,573 12,661 Less: accumulated depreciation and amortization (9,686) (8,916) Total 5,887 3,745 Depreciation expense related to property and equipment (inclusive of depreciation expense on equipment leased to customers) amounted to €1,557 thousand, €1,194 thousand and €1,521 thousand for the years ended December 31, 2023, 2022 and 2021, respectively. Assets leased to customers: Capitalized costs on equipment leased to customers of €885 thousand and €753 thousand are included in property and equipment at December 31, 2023 and 2022, respectively. Accumulated amortization of these assets leased to third parties was €207 thousand and €264 thousand, at December 31, 2023 and 2022, respectively. Depreciation expense on equipment leased to customers amounted to €13 thousand, €37 thousand and €40 thousand, for the years ended December 31, 2023, 2022 and 2021, respectively. 7-2 Finance leases Finance lease right-of-use assets previous years December 31, 2023 2022 Facilities 242 269 Equipment 220 220 Vehicles and IT equipment 828 780 Total gross value 1,290 1,269 Less: accumulated depreciation and amortization 705 813 Total 585 455 Depreciation expense related to finance lease right-of-use assets amounted to €193 thousand, €303 thousand and €275 for the years ended December 31, 2023, 2022, 2021, respectively. |
OPERATING LEASE RIGHT-OF-USE AS
OPERATING LEASE RIGHT-OF-USE ASSETS | 12 Months Ended |
Dec. 31, 2023 | |
OPERATING LEASE RIGHT-OF-USE ASSETS. | |
OPERATING LEASE RIGHT-OF-USE ASSETS | 8— OPERATING LEASE RIGHT-OF-USE ASSETS Operating lease right-of-use assets consist of the following: December 31, 2023 2022 Facilities 1,534 1,536 Equipment 30 57 Furniture, fixture, and fittings and other 157 191 Total net operating lease right of use 1,722 1,784 Operating lease cost amounted to €1,053 thousand and €910 thousand for the years ended December 31, 2023 and 2022, respectively. Variable lease costs related to above contracts amounted to €243 thousand and €152 thousand for the years ended December 31, 2023 and 2022, respectively. Non-recognized lease liabilities for short term leases amounted to €71 thousand and €74 thousand for the years ended December 31, 2023 and 2022, respectively. |
GOODWILL AND INTANGIBLE ASSETS
GOODWILL AND INTANGIBLE ASSETS | 12 Months Ended |
Dec. 31, 2023 | |
GOODWILL AND INTANGIBLE ASSETS | |
GOODWILL AND INTANGIBLE ASSETS | 9— GOODWILL AND INTANGIBLE ASSETS As discussed in Note 1-13, ASC 350 requires that goodwill not be amortized but instead be tested at least annually for impairment, or more frequently when events or change in circumstances indicate that the asset might be impaired, by comparing the carrying value to the fair value of the reporting unit to which they are assigned. The Company considers its ASC 280 operating segments — High Intensity Focused Ultrasound (HIFU), Lithotripsy (ESWL) and Distribution services (DIST) — to be its reporting units for purposes of testing for impairment. Goodwill amounts to €496 thousand for the ESWL division, €1,271 thousand for the DIST division and to €645 thousand for the HIFU division, at December 31, 2023. The Company completed the required annual impairment test in the fourth quarter of 2023. To determine the fair value of the Company’s reporting units, the Company used the discounted cash flow approach for each of the three reportable units. In all three cases, the fair value of the reporting unit was in excess of the reporting unit’s book value, which resulted in no goodwill impairment. Intangible assets consist of the following: December 31, 2023 2022 Licenses 2,119 1,585 Trade name and trademark 333 370 Patents 412 412 Organization costs 225 225 Total gross value 3,089 2,592 Accumulated amortization for licenses (1,038) (863) Accumulated amortization for trade name and trademark (331) (368) Accumulated amortization for patents (412) (412) Accumulated amortization for organization costs (225) (225) Less: Total accumulated amortization (2,005) (1,868) Total 1,084 725 Amortization expenses related to intangible assets amounted to €175 thousand, €141 thousand and €125 thousand, for the years ended December 31, 2023, 2022 and 2021, respectively. For the five coming years, the annual estimated amortization expense will consist of the following: December 31, 2023 2024 205 2025 195 2026 192 2027 175 2028 88 2029 and thereafter 174 Total 1,029 |
TRADE ACCOUNTS AND NOTES PAYABL
TRADE ACCOUNTS AND NOTES PAYABLE | 12 Months Ended |
Dec. 31, 2023 | |
TRADE ACCOUNTS AND NOTES PAYABLE | |
TRADE ACCOUNTS AND NOTES PAYABLE | 10— TRADE ACCOUNTS AND NOTES PAYABLE Trade accounts and notes payable consist of the following: December 31, 2023 2022 Trade accounts payable 11,236 6,640 Notes payable 61 7 Total 11,297 6,647 Trade accounts payable usually represent invoices with a due date of 90 days or less and invoices to be received. Notes payable represent commercial bills of exchange (drafts) with initial maturities of 90 days or less. |
DEFERRED REVENUES
DEFERRED REVENUES | 12 Months Ended |
Dec. 31, 2023 | |
DEFERRED REVENUES | |
DEFERRED REVENUES | 11— DEFERRED REVENUES Deferred revenues consist of the following: December 31, 2023 2022 Deferred revenues on maintenance contracts 1,809 1,803 Deferred revenue on RPP 492 517 Deferred revenue on sale of devices 104 83 Deferred revenue on extension of warranty, included in sales contracts 591 535 Deferred revenue on treatment probe lease and other 1,696 1,376 Total 4,693 4,314 Less long term portion (643) (264) Current portion 4,049 4,050 Deferred revenue on extension of warranty will be recognized over the following periods: December 31, 2023 2024 224 2025 183 2026 74 2027 46 2028 30 2029 and thereafter 35 Total 591 Changes in deferred revenue on extension of warranty are as follows: Total Balance as of December 31, 2021 740 New extension of warranty 162 Recognition of revenue (367) Balance as of December 31, 2022 535 New extension of warranty 238 Recognition of revenue (181) Balance as of December 31, 2023 591 |
OTHER ACCRUED LIABILITIES
OTHER ACCRUED LIABILITIES | 12 Months Ended |
Dec. 31, 2023 | |
OTHER ACCRUED LIABILITIES. | |
OTHER ACCRUED LIABILITIES | 12— OTHER ACCRUED LIABILITIES Other accrued liabilities consist of the following: December 31, 2023 2022 Retirement indemnities 2,310 2,153 Provision for warranty costs 172 162 Accruals for payroll and associated taxes 2,256 1,848 Conditional government advances 463 463 Value added tax payable 758 531 Advances received from customers 860 861 Provision for Asset Retirement Obligation (Japan) 91 101 Provision for employee termination indemnities (Korea) 149 122 Others 522 340 Total 7,581 6,583 Less non-current portion (3,075) (2,710) Current portion 4,506 3,873 In 2021, we received conditional advances for €0.5 million from Banque Publique d’Investissement for business development programs in China and Africa. Grants that relate to expenses we incur for this research program are recognized in the line item “Research and Development Expenses” in the period in which the expenses subject to the grants have been incurred (see Note 21). Conditional advances as of December 31, 2023, mature as follows: 2024 111 2025 93 2026 93 2027 86 2028 81 2029 and thereafter — Total 463 Changes in the provision for warranty costs are as follows: 2023 2022 Beginning of year 162 252 Amount used during the year (124) (202) New warranty expenses 134 112 End of year 172 162 Less current portion (107) (100) Long term portion 65 62 |
LEASE OBLIGATIONS
LEASE OBLIGATIONS | 12 Months Ended |
Dec. 31, 2023 | |
LEASE OBLIGATIONS | |
LEASE OBLIGATIONS | 13— LEASE OBLIGATIONS 13-1 Financing leases The Company leases certain of its equipment under finance leases. At December 31, 2023, the corresponding liability associated with this lease equipment amounts to €10 thousand for medical devices and to €617 thousand for vehicles and other IT equipment. Maturities of finance leases liabilities for the years ended December 31, 2023 and 2022 are as follows: December 31, 2023 2024 214 2025 170 2026 134 2027 86 2028 52 2029 and thereafter 2 Total undiscounted minimum lease payments 659 Less: amount representing interest (33) Present value of minimum lease payments 627 Less: current portion (195) Long-term portion 433 December 31, 2022 2023 234 2024 149 2025 102 2026 63 2027 12 2028 and thereafter 6 Total undiscounted minimum lease payments 566 Less: amount representing interest (17) Present value of minimum lease payments 548 Less: current portion (224) Long-term portion 324 Interest paid under finance lease obligations was €7 thousand, €12 thousand and €55 thousand the years ended December 31, 2023, 2022 and 2021 respectively. The weighted average remaining lease term and the weighted average discount rate for finance leases were respectively 3.75 years and 3.67% at December 31, 2023 and 1.02 years and 1.32% at December 31, 2022. 13-2 Operating leases Maturities of operating lease liabilities consist of the following amounts: December 31, 2023 2024 898 2025 485 2026 240 2027 157 2028 — 2029 and thereafter — Total undiscounted minimum lease payments 1,780 Less: current portion (898) Long-term portion 882 December 31, 2022 2023 901 2024 636 2025 238 2026 24 2027 — 2028 and thereafter — Total undiscounted minimum lease payments 1,799 Less: current portion (901) Long-term portion 899 The weighted average remaining lease term and the weighted average discount rate for operating leases were respectively 2.35 years and 4.98% at December 31, 2023 and 2.18 Total rent expenses under operating leases amounted to €1,017 thousand, €912 thousand and €953 thousand, for the years ended December 31, 2023, 2022 and 2021, respectively. These total rent expenses are related to office rentals, office equipment and car rentals. |
SHORT-TERM BORROWINGS
SHORT-TERM BORROWINGS | 12 Months Ended |
Dec. 31, 2023 | |
SHORT-TERM BORROWINGS. | |
SHORT-TERM BORROWINGS | 14— SHORT-TERM BORROWINGS As of December 31, 2023 and 2022, short-term borrowings consist mainly of €2,466 thousand and €1,846 thousand of factored account receivables and for which the Company maintains the effective control, respectively. |
LONG TERM DEBT
LONG TERM DEBT | 12 Months Ended |
Dec. 31, 2023 | |
LONG TERM DEBT | |
LONG TERM DEBT | 15— LONG TERM DEBT 15-1 Long-term debt: December 31, 2023 2022 France term loan 3,222 4,593 Japanese term loan 323 558 Germany term loan — 28 USA term loan — — Korea term loan 5 8 Malaysia term loan — — Total long term debt 3,551 5,188 Less current portion (1,553) (1,601) Total long-term portion 1,997 3,587 As of December 31, 2023 and 2022, long-term debt in Japan consists of two loans in denominated in Yen and subscribed with the following conditions: Initial Frequency of Amount Maturity Fixed Interest rate principal payments EDAP Technomed Co. Ltd 80,000,000 August 2, 2026 1.98 % Monthly installment EDAP Technomed Co. Ltd 50,000,000 April 2, 2025 1.8 % Monthly installment As of December 31, 2023 and 2022, long-term debt in France consists of three loans in Euro subscribed in 2020 which terms and maturity were amended and a new loan in Euro subscribed in 2021 with the following terms: Drown Frequency of Amount Maturity Fixed Interest rate principal payments EDAP TMS FRANCE 1,066,081 July 1, 2025 0.99 % Monthly installment This loan is pledged against the Company’s cash in USD for an amount equal to the countervalue of the loan in USD. This loan constitutes a complete financial package of €1,530,000, of which €1,066,081 were drawn to finance HIFU treatment probes. This drawn amount will be reimbursed over three years until July 1, 2025. Initial Frequency of Amount Maturity Fixed Interest rate principal payments EDAP TMS FRANCE 2,000,000 July 30, 2026 0.73 % Monthly installment This loan is a COVID-related loan guaranteed by the French government entered into in 2020 with an initial one-year repayment term subsequently extended to six years. Initial Frequency of Amount Maturity Fixed Interest rate principal payments EDAP TMS FRANCE 2,000,000 August 4, 2026 0.73 % Monthly installment This loan, in Euro, is a COVID-related loan guaranteed by the French government in 2020 with an initial one year repayment term subsequently extended to six years. Initial Frequency of Amount Maturity Fixed Interest rate principal payments EDAP TMS FRANCE 72,222 July 5, 2024 0.45 % Monthly installment This loan is related to the acquisition of computer servers. As of December 31, 2022, long-term debt in Germany consists of one loan in Euro with the following terms : Initial Frequency of Amount Maturity Fixed Interest rate principal payments EDAP TMS GMBH 400,000 April 30, 2023 2.40 % Monthly installment This loan was pledged against an HIFU equipment with a purchase value of €438 thousand. 15-2 Financial instruments carried at fair value: As of December 31, 2023, there are no warrants outstanding. Refer to Note 26 for more details on the fair value of other Financial Instruments. 15-3 Long-term debt maturity: Long-term debt carried at amortized cost at December 31, 2023 matures as follows: 2024 1,553 2025 1,320 2026 677 2027 — 2028 — 2029 and thereafter — Total 3,551 |
OTHER LONG-TERM LIABILITIES
OTHER LONG-TERM LIABILITIES | 12 Months Ended |
Dec. 31, 2023 | |
OTHER LONG-TERM LIABILITIES. | |
OTHER LONG-TERM LIABILITIES | 16— OTHER LONG-TERM LIABILITIES Other long-term liabilities consist of the following: December 31, 2023 2022 Provision for retirement indemnities (Japan & France), less current portion 2,241 1,962 Provision for employee termination indemnities (Korea) less current portion 149 122 Provision for Asset Retirement Obligation (Japan) less current portion 91 101 Provision for warranty costs, less current portion 65 62 Provision for guarantee given to customer, less curent portion 66 — Conditional government advances, less current portion 463 463 Accrued interest less current portion — — Total 3,075 2,710 Provision for asset retirement obligation in Japan is related to subsidiary’s offices and warehouses. Pension, post-retirement and post-employment benefits for most of the Company’s employees are sponsored by European governments. In addition to government-sponsored plans, subsidiaries in Japan and France have defined benefit retirement plans in place. The provision for retirement indemnities at December 31, 2023 represents an accrual for lump-sum retirement benefit payments to be paid at the time an employee retires if he or she is still present at the Company at the date of retirement. This provision has been calculated taking into account the estimated payment at retirement (discounted to the current date), turnover and salary increases. The provision is management’s best estimate based on the following assumptions as of year-end: Retirement indemnities France 2023 2022 Discount rate 3.19% 3.80% Salary increase 3.00% 3.00% Retirement age 65 65 Average retirement remaining service period 23 24 Retirement indemnities Japan 2023 2022 Discount rate 1.30% 1.30% Salary increase 2.50% 2.50% Retirement age 60 60 Average retirement remaining service period 14 14 The discount rate retained is determined by reference to the high quality rates for AA- rated corporate bonds for a duration equivalent to that of the obligations. At December 31, 2023, the provision which represents the projected benefit obligation in accordance with ASC 718 consists of: France Japan Non-current liabilities 1,084 1,157 Current liabilities — 70 Total projected benefit obligation 1,084 1,227 At December 31, 2022, the provision which represents the projected benefit obligation in accordance with ASC 718 consists of: France Japan Non-current liabilities 845 1,117 Current liabilities 89 102 Total projected benefit obligation 934 1,219 The Company does not have a funded benefit plan. A detailed reconciliation of pension cost components (in thousands of euros) during fiscal year for each of the three years ending December 31, 2023 is as follows: France 2023 2022 2021 Change in benefit obligations: Projected Benefit obligations at beginning of year 934 1,080 1,111 Service cost 67 84 90 Interest cost 34 11 6 Net loss or (gain) — — — Actuarial (gain) or loss 66 (241) (72) Amortization of net prior service cost — — — Benefits paid (17) — (56) Projected Benefit obligations at end of year (1) 1,084 934 1,080 Unrecognized actuarial (gain) loss (2) (146) (219) 22 Unrecognized prior service cost (2) 13 14 16 (1) The accumulated benefit obligation was €805 thousand and €701 thousand at December 31, 2023 and 2022 respectively. (2) The amount in accumulated other comprehensive income (loss) to be recognized as components of net periodic benefit costs in 2023 is €133 thousand. Japan 2023 2022 2021 Change in benefit obligations: Projected Benefit obligations at beginning of year 1,219 1,302 1,310 Service cost 114 112 120 Interest cost 13 7 7 Amortization of net loss — — — Actuarial (gain) / loss 4 (30) — Benefits paid (76) (75) (97) Plan Amendments 74 — — Exchange rate impact (122) (95) (39) Projected Benefit obligations at end of year (1) 1,227 1,219 1,302 Unrecognized actuarial (gain) loss (2) 81 86 126 Unrecognized prior service cost (2) 74 — — (1) The accumulated benefit obligation was €1,030 thousand and €1,027 thousand at December 31, 2023 and 2022, respectively. (2) The amount in accumulated other comprehensive income (loss) to be recognized as components of net periodic benefit costs in 2023 is €156 thousand. The benefits expected to be paid in each of the next five fiscal years, and in the aggregate for the five fiscal years thereafter, are detailed in the table below: France Japan 2024 — 70 2025 — 152 2026 129 143 2027 85 67 2028 85 46 2029-2033 408 843 707 1,322 |
SHAREHOLDERS' EQUITY
SHAREHOLDERS' EQUITY | 12 Months Ended |
Dec. 31, 2023 | |
SHAREHOLDERS' EQUITY. | |
SHAREHOLDERS' EQUITY | 17— SHAREHOLDERS’ EQUITY 17-1 Common stock As of December 31, 2023, EDAP TMS S.A.’s common stock consisted of 37,373,312 issued shares fully paid and with a par value of €0.13 each. 37,103,779 of the shares were outstanding. In September 2022, the Company completed a successful common stock offering and issued 3,066,667 new common shares in the form of ADS for $7.50 per share which resulted in gross proceeds of €23,913 thousand. In connection with this offering, the Company incurred issuance costs amounting to €1,954 thousand. 17-2 Pre-emptive subscription rights Shareholders have preemptive rights to subscribe on a pro rata 17-3 Dividend rights Dividends may be distributed from the statutory retained earnings, subject to the requirements of French law and the Company’s by-laws. The Company has not distributed any dividends since its inception as the result of an accumulated statutory deficit of 11,962 thousand. Dividend distributions, if any, will be made in euros. The Company has no plans to distribute dividends in the foreseeable future. 17-4 Treasury stock As of December 31, 2023, all 269,533 shares held as treasury stock consisted of (i), 89,243 shares acquired between August and December 1998 and (ii) 180,290 shares acquired in June and July 2001 for a total of €590 thousand. All treasury stocks have been acquired to cover stock purchase options (see Note 17-5). 17-5 Stock-option and free share plans As of December 31, 2023, EDAP TMS S.A. sponsored three stock purchase and subscription option plans open to employees of EDAP TMS group: On February 18, 2016, the shareholders authorized the Board of Directors to grant up to 1,000,000 options to subscribe to 1,000,000 new shares at a fixed price to be set by the Board of Directors. Conforming to this stock option plan, the Board of Directors granted 575,000 options to subscribe to new shares to certain employees of EDAP TMS on April 26, 2016. The exercise price was fixed at €3.22 per share. Options were to begin vesting one year after the date of grant and all options were fully vested as of April 26, 2020 (i.e., four years after the date of grant). The options will expire on April 26, 2026 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of the options granted under this plan was €960 thousand. This non-cash compensation expense was recognized in the Company’s operating expenses over a period of 48 months Conforming to this February 18, 2016 stock option plan, the Board of Directors granted 260,000 options to subscribe to new shares to certain employees of EDAP TMS on April 25, 2017. The exercise price was fixed at €2.39 per share. Options were to begin vesting one year after the date of grant and all options were fully vested as of April 25, 2021 (i.e., four years after the date of grant). The options will expire on April 25, 2027 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of the options granted on April 25, 2017 under this plan was €335 thousand. This non-cash compensation expense was recognized in the Company’s operating expenses over a period of 48 months Conforming to this February 18, 2016 stock option plan, the Board of Directors granted 165,000 options to subscribe to new shares to certain employees of EDAP TMS on August 29, 2018. The exercise price was fixed at €2.65 per share. Options were to begin vesting one year after the date of grant and all options were fully vested as of August 29, 2022 (i.e., four years after the date of grant). The options will expire on August 29, 2029 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of the options granted on August 29, 2018 under this plan was €219 thousand. This non-cash compensation expense was recognized in the Company’s operating expenses over a period of 48 months Conforming to this February 18, 2016 stock option plan, the Board of Directors granted 155,000 options to subscribe to new shares to certain employees of EDAP TMS on April 4, 2019. Forfeited options corresponding to employees’ departures were re-allocated. The exercise price was fixed at €3.90 per share. Options were to begin vesting one year after the date of grant and all options were fully vested as of April 4, 2023 (i.e., four years after the date of grant). The options will expire on April 4, 2029 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of the options granted on April 4, 2019 under this plan was €299 thousand. This non-cash compensation expense is recognized in the Company’s operating expenses over a period of 48 months (using the graded vesting method). The impact of this February 18, 2016 Plan on operating income, in accordance with ASC 718, was €65 thousand, €25 thousand and €3 thousand in 2021, 2022 and 2023, respectively. Under this 2016 plan, 678,080 options are outstanding and are exercisable at December 31, 2023. On June 28, 2019, the shareholders authorized the Board of Directors to grant up to a maximum of 358,528 options to purchase pre-existing shares and to grant 1,000,000 options to subscribe to 1,000,000 new shares at a fixed price to be set by the Board of Directors. Conforming to this June 28, 2019 stock option plan, the Board of Directors granted 292,428 options to purchase pre-existing shares and 1,000,000 options to subscribe to new shares to certain employees of EDAP TMS on June 11, 2021. The exercise price was fixed at €5.59 per share. Options were to begin vesting six months after the date of grant and most options will be fully vested as of June 11, 2024 (i.e., three years after the date of grant). On March 29, 2023, the vesting of 270,000 of these options was accelerated and such options may vest immediately. The options will expire on June 11, 2031 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of subscription options granted on June 11, 2021 under this plan was €681 thousand and the total fair value of purchase options was €2,371 thousand. This non-cash compensation expense is recognized in the Company’s operating expenses over a period of 36 months The impact of this June 28, 2019 Plan on operating income, in accordance with ASC 718, was €1,484 thousand, €1,104 thousand and €410 thousand in 2021, 2022 and 2023, respectively. Under this 2019 plan, 1,244,533 options are outstanding, of which 1,037,111 are exercisable at December 31, 2023. On June 30, 2021, the shareholders authorized the Board of Directors to grant up to a maximum of 2,000,000 options to subscribe to 2,000,000 new shares at a fixed price to be set by the Board of Directors. Conforming to this June 30, 2021 stock-option plan, the Board of Directors granted: (i) 100,000 options to subscribe to new shares to certain employees of EDAP TMS on November 17, 2021. The exercise price was fixed at € 5.18 per share. Options were to begin vesting six months after the date of grant and all options will be fully vested as of November 17, 2024 (i.e., three years after the date of grant). The options will expire on November 17, 2031 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of the options granted on November 17, 2021 under this plan was € 229 thousand. This non-cash compensation expense is recognized in the Company’s operating expenses over a period of 36 months (using the graded vesting method). (ii) 144,000 options to subscribe to new shares to certain employees of EDAP TMS on May 17, 2022. The exercise price was fixed at € 6.41 per share. Options were to begin vesting six months after the date of grant and all options will be fully vested as of May 17, 2025 (i.e., three years after the date of grant). The options will expire on May 17, 2032 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of the options granted on May 17, 2022 under this plan was € 450 thousand. This non-cash compensation expense is recognized in the Company’s operating expenses over a period of 36 months (using the graded vesting method). (iii) 32,000 options to subscribe to new shares to certain employees of EDAP TMS on November 8, 2022. The exercise price was fixed at € 10.32 per share. Options were to begin vesting six months after the date of grant and all options will be fully vested as of November 8, 2025 (i.e., three years after the date of grant). The options will expire on November 8, 2032 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of the options granted on November 8, 2022 under this plan was € 161 thousand. This non-cash compensation expense was recognized in the Company’s operating expenses over a period of 36 months (using the graded vesting method). (iv) 395,000 options to subscribe to new shares to certain employees of EDAP TMS on December 15, 2022. The exercise price was fixed at € 9.94 per share. Options were to begin vesting six months after the date of grant and all options will be fully vested as of December 15, 2025 (i.e., three years after the date of grant). The options will expire on December 15, 2032 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of the options granted on December 15, 2022 under this plan was € 1,858 thousand. This non-cash compensation expense is recognized in the Company’s operating expenses over a period of 36 months (using the graded vesting method). (v) 125,000 options to subscribe to new shares to certain employees of EDAP TMS on April 5, 2023. The exercise price was fixed at €9.96 per share. Options were to begin vesting six months after the date of grant and all options will be fully vested as of April 5, 2026 (i.e., three years after the date of grant). The options will expire on April 5, 2033 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of the options granted on April 5, 2023 under this plan was €687 thousand. This non-cash compensation expense is recognized in the Company’s operating expenses over a period of 36 months (using the graded vesting method). (vi) 200,000 options to subscribe to new shares to certain employees of EDAP TMS on May 2, 2023. The exercise price was fixed at €10.10 per share. Options were to begin vesting six months after the date of grant and all options will be fully vested as of May 2, 2026 (i.e., three years after the date of grant). The options will expire on May 2, 2033 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of the options granted on May 2, 2023 under this plan was €1,183 thousand. This non-cash compensation expense is recognized in the Company’s operating expenses over a period of 36 months (using the graded vesting method). (vii) 50,000 options to subscribe to new shares to certain employees of EDAP TMS on May 31, 2023. The exercise price was fixed at €9.32 per share. Options were to begin vesting six months after the date of grant and all options will be fully vested as of May 31, 2026 (i.e., three years after the date of grant). The options will expire on May 31, 2033 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of the options granted on May 31, 2023 under this plan was €270 thousand. This non-cash compensation expense is recognized in the Company’s operating expenses over a period of 36 months (using the graded vesting method). (viii) 177,000 options to subscribe to new shares to certain employees of EDAP TMS on August 23, 2023. The exercise price was fixed at €7.53 per share. Options were to begin vesting six months after the date of grant and all options will be fully vested as of August 23, 2026 (i.e., three years after the date of grant). The options will expire on August 23, 2033 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of the options granted on August 23, 2023 under this plan was €774 thousand. This non-cash compensation expense is recognized in the Company’s operating expenses over a period of 36 months (using the graded vesting method). (ix) 80,000 options to subscribe to new shares to certain employees of EDAP TMS on September 20, 2023. The exercise price was fixed at €6.08 per share. Options were to begin vesting six months after the date of grant and all options will be fully vested as of September 20, 2026 (i.e., three years after the date of grant). The options will expire on September 20, 2033 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of the options granted on September 20, 2023 under this plan was €296 thousand. This non-cash compensation expense is recognized in the Company’s operating expenses over a period of 36 months (using the graded vesting method). (x) 20,000 options to subscribe to new shares to certain employees of EDAP TMS on November 8, 2023. The exercise price was fixed at €6.64 per share. Options were to begin vesting six months after the date of grant and all options will be fully vested as of November 8, 2026 (i.e., three years after the date of grant). The options will expire on November 8, 2033 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of the options granted on November 8, 2023 under this plan was €81 thousand. This non-cash compensation expense is recognized in the Company’s operating expenses over a period of 36 months (using the graded vesting method). (xi) 34,000 options to subscribe to new shares to certain employees of EDAP TMS on December 6, 2023. The exercise price was fixed at €4.98 per share. Options were to begin vesting six months after the date of grant and all options will be fully vested as of December 6, 2026 (i.e., three years after the date of grant). The options will expire on December 6, 2033 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. The total fair value of the options granted on December 6, 2023 under this plan was €103 thousand. This non-cash compensation expense is recognized in the Company’s operating expenses over a period of 36 months (using the graded vesting method). The impact of this June 30, 2021, Plan on operating income, in accordance with ASC 718, was €25 thousand, €442 thousand and €2,936 thousand in 2021, 2022 and 2023, respectively. Under this 2021 plan, 1,276,300 options are outstanding at December 31, 2023 and 282,475 are exercisable. Forfeited stock-options are recognized as they occur, in accordance with ASU 2016-09. The fair value of each stock option granted during the year is estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: Dec-2023 Nov-2023 Sept-2023 Aug-2023 May-2023 May-2023 Apr-2023 Weighted-average expected life (years) 5.79 5.79 5.79 5.79 5.79 5.79 5.79 Expected volatility rates (1) 63.29 % 61.09 % 60.90 % 60.60 % 60.80 % 60.90 % 61.00 % Expected dividend yield 0 % 0 % 0 % 0 % 0 % 0 % 0 % Risk-free interest rate 4.16 % 4.55 % 4.55 % 4.35 % 3.77 % 3.47 % 3.39 % Weighted-average exercise price (€) 4.98 6.64 6.08 7.53 9.32 10.10 9.96 Weighted-average fair value of options granted during the year (€) 3.03 4.05 3.70 4.37 5.40 5.92 5.49 (1) Historical volatility calculated over the weighted-average expected life. As of December 31, 2023, a summary of stock option activity to purchase or to subscribe to Shares under these plans is as follows: 2023 2022 2021 Options Weighted Options Weighted Options Weighted average average average exercice exercice exercice price (€) price (€) price (€) Outstanding on January 1, 2,613,886 5.66 2,408,508 4.38 1,186,900 2.81 Granted 686,000 8.53 571,000 9.07 1,392,428 5.56 Exercised (55,973) 4.66 (320,622) 2.14 (150,820) 2.93 Forfeited (45,000) 7.99 (45,000) 5.34 (20,000) 4.01 Expired — — — — — — Outstanding on December 31, 3,198,913 6.26 2,613,886 5.66 2,408,508 4.38 Exercisable on December 31, 1,997,666 5.23 1,362,205 4.35 1,149,401 3.25 Share purchase options available for grant on December 31, 25,000 20,000 5,000 As of December 31, 2023, 643,000 options to subscribe to new shares are available for future grants. The following table summarizes information about options to purchase existing Shares held by the Company, or to subscribe to new Shares, at December 31, 2023: Outstanding options Fully vested options (1) Weighted Weighted Weighted average average Aggregate average Aggregate remaining exercise Intrinsic exercise Intrinsic contractual price Value price Value Exercise price (€) Options life (€) (2) Options (€) (2) 10.32 20,000 8.8 10.32 — 7,222 10.32 — 10.10 200,000 9.3 10.10 — 38,889 10.10 — 9.96 117,000 9.3 9.96 — 26,000 9.96 — 9.94 395,000 9.0 9.94 — 131,667 9.94 — 9.32 50,000 9.4 9.32 — 9,722 9.32 — 7.53 177,000 9.7 7.53 — — — — 6.64 20,000 9.8 6.64 — — — — 6.41 100,000 8.3 6.41 — 52,778 6.41 — 6.08 80,000 9.8 6.08 — — — — 5.59 1,244,533 7.4 5.59 — 1,037,111 5.59 — 5.18 83,300 7.8 5.18 431,494 16,197 5.18 83,902 4.98 34,000 9.9 4.98 169,320 — — — 3.90 107,500 5.8 3.90 419,250 107,500 3.90 419,250 3.22 357,000 2.3 3.22 1,149,540 357,000 3.22 1,149,540 2.65 77,500 4.7 2.65 205,375 77,500 2.65 205,375 2.39 136,080 3.3 2.39 325,231 136,080 2.39 325,231 2.39 to 10.32 3,198,913 7.8 0.84 2,700,210 1,997,666 1.09 2,183,298 (1) Fully vested options are all exercisable options. On March 29, 2023, the Board of Directors unanimously decided to appoint Ryan Rhodes as the new Chief Executive Officer of the Company effective on May 1, 2023. Marc Oczachowski would continue to serve as Chairman of the Board of the Company. In this context, the Board decided to accelerate the vesting of all unvested options granted to Mr. Oczachowski under the 2019 option plans such that these options fully vested and became exercisable on March 29, 2023. (Ref. Note 33. Subsequent Events.) (2) The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company’s closing stock price of $5.28 at December 31, 2023, which would have been received by the option holders had all in-the-money option holders exercised their options as of that date. If closing stock price is under exercise price, then the aggregate intrinsic value is not considered. A summary of the status of the non-vested options to purchase shares or to subscribe to new shares as of December 31, 2023, and changes during the three years ended December 31, 2023, is presented below: Weighted average Grant-Date Fair Options Value (€) Non-vested at January 1, 2021 216,250 1.59 Granted 1,392,428 2.37 Vested (329,571) 2.06 Forfeited (20,000) 1.89 Non-vested at December 31, 2021 1,259,107 2.32 Granted 571,000 4.33 Vested (543,426) 2.32 Forfeited (35,000) 2.80 Non-vested at December 31, 2022 1,251,681 2.32 Granted 686,000 4.95 Vested (691,434) 3.22 Forfeited (45,000) 3.98 Non-vested at December 31, 2023 1,201,247 4.18 As of December 31, 2023, there were €2,509 thousand of total unrecognized compensation expenses related to non-vested stock-options, over a period of 2.9 years. On June 30, 2021, the shareholders authorized the Board of Directors to grant up to a maximum of 200,000 free shares to certain employees. Conforming to this June 30, 2021 authorization, the Board of Directors granted: (i) 61,500 free shares to certain employees of EDAP TMS on September 28, 2021. Free shares shall be definitively acquired by the relevant beneficiaries at the end of the vesting period (minimum one year period starting on the allocation date and ending on the acquisition date, i.e. two years starting on the allocation date). On September 28, 2022, 57,500 free shares were definitely acquired by French resident beneficiaries. The total fair value of the free shares granted on September 28, 2021 under this plan was €340 thousand. This non-cash compensation expense was recognized in the Company’s operating expenses upon allocation. (ii) 40,000 free shares to the CEO of EDAP TMS on March 30, 2022. Free shares shall be definitively acquired by the relevant beneficiaries at the end of the vesting period (minimum one year period starting on the allocation date and ending on the acquisition date, i.e. two years starting on the allocation date). The total fair value of the free shares granted on March 30, 2022 under this plan was €259 thousand. This non-cash compensation expense was recognized in the Company’s operating expenses upon allocation. Under this 2021 plan, no free shares are outstanding at December 31, 2023. On June 30, 2022, the shareholders authorized the Board of Directors to grant up to 600,000 free shares. This new resolution superseded the June 30, 2021 resolution, cancelling the unused portion of the 2021 resolution. Conforming to this June 30, 2022 authorization, the Board of Directors granted: (i) 291,500 free shares to certain employees of EDAP TMS on November 8, 2022. Free shares shall be definitively acquired by the relevant beneficiaries at the end of the vesting period, which begins six months after the date of grant and all shares will be fully vested as of November 8, 2025 (i.e. three years after the date of the grant). The total fair value of the free shares granted on November 8, 2022, under this plan was €2,963 thousand. This non-cash compensation expense is recognized in the Company’s operating expenses over a period of 36 months (using the graded vesting method). (ii) 150,000 free shares to Mr. Marc Oczachowski, Chairman and Chief Executive Officer EDAP TMS on March 29, 2023. All free shares shall be definitively acquired one year after the date of the grant. All free shares will be subject to the required 12-month conservation period following the acquisition of the shares. The total fair value of the free shares granted on March 29, 2023 under this plan was €1,542 thousand. This non-cash compensation expense was recognized in the Company’s operating expenses upon allocation. (iii) 50,000 free shares to the President of EDAP TMS France, Mr. Frédéric Pech on May 2, 2023. Free shares shall be definitively acquired at the end of the vesting period, which begins six months after the date of grant and all shares will be fully vested as of May 2, 2026 (i.e. three years after the date of the grant). The total fair value of the free shares granted on May 2, 2023, under this plan was €508 thousand. This non-cash compensation expense is recognized in the Company’s operating expenses over a period of 36 months (using the graded vesting method). 17-6 Accumulated other comprehensive income (loss) The components of accumulated other comprehensive income (loss) net of tax, for the years ended December 31, 2023, and 2022, are as follows: Year Ended December 31, 2023 Foreign currency Provision for translation retirement indemnities adjustment (net of tax) Total Beginning balance (3,973) 144 (3,829) Other comprehensive income (loss) before reclassifications — — — Reclassified from accumulated other comprehensive loss — — — Net current-period other comprehensive income (loss) (478) (180) (658) Ending balance (4,451) (37) (4,487) Year Ended December 31, 2022 Foreign currency Provision for translation retirement indemnities adjustment (net of tax) Total Beginning balance (3,377) (212) (3,589) Other comprehensive income (loss) before reclassifications — — — Reclassified from accumulated other comprehensive loss — — — Net current-period other comprehensive income (loss) (596) 355 (240) Ending balance (3,973) 144 (3,829) |
TOTAL SALES
TOTAL SALES | 12 Months Ended |
Dec. 31, 2023 | |
TOTAL SALES | |
TOTAL SALES | 18— TOTAL SALES Amount of net sales derived from our operations in Asia, France, the United States. and other geographical areas, are as follows: Year Ended December 31, Primary geographical markets (€) 2023 2022 2021 Asia 17,841 17,936 16,009 France 11,999 10,637 12,251 United States 16,717 15,036 5,524 Others geographical areas 13,865 11,500 10,276 Total Net Sales 60,423 55,108 44,060 The amount of net sales is recognized following the timing below: Year Ended December 31, Timing of revenue recognition 2023 2022 2021 Products transferred at a point in time 48,646 44,173 34,552 Products and services transferred over time 11,777 10,935 9,508 Total Net Sales 60,423 55,108 44,060 |
OTHER REVENUES
OTHER REVENUES | 12 Months Ended |
Dec. 31, 2023 | |
OTHER REVENUES | |
OTHER REVENUES | 19— OTHER REVENUES Other revenues consist of the following: Year Ended December 31, 2023 2022 2021 Licenses and others — — 6 Total — — 6 In 2021, other revenues mainly consist of sales of a license to Theraclion and training to customers. |
COSTS OF SALES
COSTS OF SALES | 12 Months Ended |
Dec. 31, 2023 | |
COSTS OF SALES | |
COSTS OF SALES | 20— COSTS OF SALES Costs of sales consist of the following: Year Ended December 31, 2023 2022 2021 Direct costs of sales (22,624) (19,814) (16,199) Indirect costs of sales (13,388) (11,102) (9,443) Total costs of sales (36,012) (30,916) (25,643) |
RESEARCH AND DEVELOPMENT EXPENS
RESEARCH AND DEVELOPMENT EXPENSES | 12 Months Ended |
Dec. 31, 2023 | |
RESEARCH AND DEVELOPMENT EXPENSES | |
RESEARCH AND DEVELOPMENT EXPENSES | 21— RESEARCH AND DEVELOPMENT EXPENSES Research and development expenses consist of the following: Year Ended December 31, 2023 2022 2021 Gross research and development expenses (7,596) (5,751) (4,757) Research Tax Credit 411 581 617 Grants 222 250 739 Net Research and development expenses (6,963) (4,920) (3,402) In 2023 and 2022, grants consisted mainly of national grants for the assessment and optimization of the focal treatments of prostate cancer (Perfuse development project). In 2021, grants consisted mainly of national grants for the assessment and optimization of the focal treatments of prostate cancer (Perfuse development project) and of a financial impact for the development of innovative imaging solutions for the focal treatment of liver cancer (HECAM Development project). Ref. Note 12. Research and development costs are expensed as incurred and include amortization of assets, costs of prototypes, salaries, benefits and other headcount related costs, contract and other outside service fees, and facilities and overhead costs. |
FINANCIAL INCOME, NET
FINANCIAL INCOME, NET | 12 Months Ended |
Dec. 31, 2023 | |
FINANCIAL INCOME, NET | |
FINANCIAL INCOME, NET | 22— FINANCIAL INCOME, NET Interest (expense) income, net consists of the following: Year Ended December 31, 2023 2022 2021 Interest income 1,311 404 10 Interest expense (232) (168) (52) Paycheck Protection Program loan forgiveness — — 187 Total 1,079 236 145 |
INCOME TAXES
INCOME TAXES | 12 Months Ended |
Dec. 31, 2023 | |
INCOME TAXES | |
INCOME TAXES | 23— INCOME TAXES 23-1 Income / (Loss) before income taxes Income / (loss) before income taxes is comprised of the following: Year Ended December 31, 2023 2022 2021 France (9,026) (418) 869 Other countries (11,507) (1,678) 24 Total (20,533) (2,096) 893 23-2 Income tax (expense)/ benefit Income tax (expense)/benefit consists of the following : Year Ended December 31, 2023 2022 2021 Current income tax expense: France (77) (485) (320) Other countries (533) (251) (436) Sub-total current income tax expense (610) (736) (756) Deferred income tax (expense) benefit: France 3 (8) 8 Other countries (37) (93) 556 Sub-total deferred income tax (expense) benefit (34) (101) 563 Total (644) (837) (193) 23-3 Deferred income taxes: Deferred income taxes reflect the impact of temporary differences between the amounts of assets and liabilities reported for financial reporting purposes and such amounts as measured in accordance with tax laws. The tax effects of temporary differences which give rise to significant deferred tax assets (liabilities) are as follows by nature : 2023 2022 Net operating loss carry forwards 16,356 13,793 Elimination of intercompany profit in inventory 689 480 Elimination of intercompany profit in fixed assets 396 256 Provisions for retirement indemnities 663 658 Capital leases treated as operating leases for tax 10 26 Other items 354 360 Total deferred tax assets 18,468 15,573 Total deferred tax liabilities — — Net deferred tax assets 18,468 15,573 Valuation allowance for deferred tax assets (17,739) (14,744) Deferred tax assets (liabilities), net of allowance 729 829 Net operating loss carryforwards available amount to €71,821 thousand as of December 31, 2023, of which €31,284 thousand relates to EDAP TMS SA, €40,310 thousand relates to Edap Technomed Inc. and €227 thousand relates to Edap Technomed Co Ltd Japan. These net operating losses generate deferred tax assets of €16,356 thousand as at December 31, 2023. Realization of these tax assets is contingent on future taxable earnings in the applicable tax jurisdictions. As of December 31, 2023, €71,594 thousand out of these €71,821 thousand net operating loss carry-forwards have no expiration date but the amount of the net operating loss carry-forward, which can be used each year to offset taxable earnings, is limited in all jurisdictions. The remaining tax loss carry-forwards expire from years 2023 through 2025. In accordance with ASC 740, a valuation allowance is established if, based on the weight of available evidence, it is more-likely-than-not that some portion or all of the deferred tax asset will not be realized. 23-4 Effective tax income (expense) A reconciliation of differences between the statutory French income tax rate and the Company’s effective tax income (loss) is as follows: 2023 2022 2021 Theoretical income tax (expense) benefit at French statutory tax rate 5,133 524 (237) Income of foreign subsidiaries taxed at different tax rates (546) (174) (95) Effect of net operating loss carry-forwards and valuation allowances (4,439) (643) 626 Non-taxable debt fair value variation — — — Permanent differences (263) (99) (258) Effect of cancellation of intra-group positions (476) (366) (130) French business tax included in income tax (CVAE) (74) (99) (85) Other 20 20 (15) Effective income tax (expense) benefit (644) (837) (193) 23-5 Uncertainty in Income Taxes According to ASC 740, the Company reviewed the tax positions of each subsidiary. On December 31, 2023 the Company believes that there is no significant uncertainty in the Company’s tax positions. The Company remains subject to examination by major tax jurisdictions. Interest and penalties on income taxes are classified as a component of the provision for income taxes. There were no interest or penalties in 2023, 2022 and 2021. |
EARNINGS (LOSS) PER SHARE
EARNINGS (LOSS) PER SHARE | 12 Months Ended |
Dec. 31, 2023 | |
EARNINGS (LOSS) PER SHARE | |
EARNINGS (LOSS) PER SHARE | 24— EARNINGS (LOSS) PER SHARE Year Ended December 31, 2023 2022 2021 Income (loss) available to common shareholders (in Euros) € (21,177,772) € (2,933,058) € 699,890 Weighted average number of shares for the computation of basic EPS 36,996,722 34,392,598 32,129,047 Basic EPS (in Euros) € (0.57) € (0.09) € 0.02 Effect of dilutive securities 2,653,050 2,502,171 293,824 Weighted average number of shares for the computation of diluted EPS 36,996,722 34,392,598 32,422,871 Diluted EPS income / (loss) (in Euros) € (0.57) € (0.09) € 0.02 Diluted EPS income / (loss) available to common shareholders is computed including all dilutive securities that are in the money. The effects of dilutive securities for the year ended December 31, 2023 and 2022 were excluded from the calculation of diluted earnings per share as a net loss was reported in this period. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 12 Months Ended |
Dec. 31, 2023 | |
COMMITMENTS AND CONTINGENCIES | |
COMMITMENTS AND CONTINGENCIES | 25— COMMITMENTS AND CONTINGENCIES 25-1 Commitments The Company currently has commitments regarding its operating leases as described in Note 13-2. 25-2 Contingencies The Company currently has contingencies relating to standard warranties provided to customers for products as described in Note 1-15 and Note 12. |
FAIR VALUE OF FINANCIAL INSTRUM
FAIR VALUE OF FINANCIAL INSTRUMENTS | 12 Months Ended |
Dec. 31, 2023 | |
FAIR VALUE OF FINANCIAL INSTRUMENTS | |
FAIR VALUE OF FINANCIAL INSTRUMENTS | 26— FAIR VALUE OF FINANCIAL INSTRUMENTS The following disclosure of the estimated fair value of financial instruments was made in accordance with the requirements of ASC 820 ‘‘Disclosure about fair value of financial instruments’’ and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value. ASC 820 defines three levels of inputs that may be used to measure fair value and requires that the assets or liabilities carried at fair value be disclosed by the input level under which they were valued. The input levels are defined as follows: Level 1: Quoted (unadjusted) prices in active markets for identical assets and liabilities that the reporting entity can access at the measurement date. Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3: Unobservable inputs for the asset or liability. The recorded amount of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term borrowings are a reasonable estimate of their fair value due to the short-term maturities of these instruments. As of December 31, 2023 and December 31, 2022, the Company did not have any other asset or liability measured at fair value. As of December 31, 2023, the fair value of the Company’s long-term debt was not materially different from the carrying value. |
CONCENTRATION OF CREDIT RISK
CONCENTRATION OF CREDIT RISK | 12 Months Ended |
Dec. 31, 2023 | |
CONCENTRATION OF CREDIT RISK | |
CONCENTRATION OF CREDIT RISK | 27— CONCENTRATION OF CREDIT RISK Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents and trade accounts and notes receivable from customers, primarily located in France, Japan and the United States. The Company maintains cash deposits with major banks. Management periodically assesses the financial condition of these institutions and believes that credit risk is limited. The Company has implemented procedures to monitor the creditworthiness of its customers. The Company obtains bank guarantees for first time or infrequent unknown customers, and in certain cases obtains insurance against the risk of a payment default by the customer. The Company reviewed individual customer balances considering current and historical loss experience and general economic conditions in determining the allowance for doubtful accounts receivable of €0.2 million and €0.2 million, for the years ended December 31, 2023 and 2022, respectively. Actual losses may vary from the current estimates, and any adjustments are reported in earnings in the periods in which they become known. In 2023, 2022 and 2021, the Company did not generate more than 10% revenue with a single customer. |
FOREIGN CURRENCY TRANSACTIONS
FOREIGN CURRENCY TRANSACTIONS | 12 Months Ended |
Dec. 31, 2023 | |
FOREIGN CURRENCY TRANSACTIONS | |
FOREIGN CURRENCY TRANSACTIONS | 28— FOREIGN CURRENCY TRANSACTIONS The Company generates a significant percentage of its revenues, and of its operating expenses, in currencies other than the euro. The Company’s operating profitability could be materially adversely affected by large fluctuations in the rate of exchange between the euro and such other currencies. The Company may engage in foreign exchange hedging activities when deemed necessary, but there can be no assurance that hedging activities will be offset by the impact of movements in exchange rates on the Company’s results of operations. As of December 31, 2023, there were no outstanding hedging instruments. |
SEGMENT INFORMATION
SEGMENT INFORMATION | 12 Months Ended |
Dec. 31, 2023 | |
SEGMENT INFORMATION | |
SEGMENT INFORMATION | 29— SEGMENT INFORMATION Our activity is organized into three divisions: HIFU, ESWL (including lithotripsy activities) and Distribution. Through these three divisions, we develop, produce, market and distribute minimally invasive medical devices, mainly for urological diseases. HIFU division includes sales of Focal One, Ablatherm and related consumables and services, ESWL division includes revenues generated by the existing Sonolith range of lithotripters and, Distribution division includes the sale of complimentary products such as lasers, micro-ultrasound systems and other products from third parties. The organization of our activities into three divisions better clarified our vision and enhanced our financial reporting of our three businesses HIFU, ESWL and Distribution. This new structure also allows for an improved measurement of our business progress. The business in which the Company operates is the development, production and distribution of minimally invasive medical devices, primarily for the treatment of urological diseases. Substantially all revenues result from the sale of medical devices and their related license and royalty payments from third parties. The segments derive their revenues from this activity. The following tables set forth the key Statement of income (loss) figures, by segment for fiscal years 2023, 2022 and 2021 and the key balance sheet figures, by segment, for fiscal years 2023, 2022 and 2021. Segment operating profit or loss and segment assets are determined in accordance with the same policies as those described in the summary of significant accounting policies and they are reviewed by the CODM, who is the CEO. Interest income and expense, current and deferred income taxes are not allocated to individual segments. A reconciliation of segment operating profit or loss to consolidated net loss is as follows: Year Ended December 31, 2023 2022 2021 Segment operating income (loss) (19,813) (4,257) (1,612) Financial income (expense), net 1,079 236 145 Foreign Currency exchange (losses) gains, net (1,799) 1,925 2,360 Income tax (expense) benefit (644) (837) (193) Consolidated net income (loss) (21,178) (2,933) 700 A summary of the Company’s operations by segment is presented below for years ended December 31, 2023, 2022 and 2021: HIFU ESWL DISTRIB Reconciling Total 2023 Division Division Division Items consolidated Sales of goods 13,510 3,844 24,980 — 42,333 Sales of RPPs & leases 4,935 955 286 — 6,176 Sales of spare parts and services 2,152 5,109 4,653 — 11,914 Total sales 20,596 9,908 29,919 — 60,423 External other revenues — — — — — Total revenues 20,596 9,908 29,919 — 60,423 Total COS (10,112) (6,268) (19,632) — (36,012) Gross profit 10,484 3,640 10,287 — 24,411 R&D expenses (5,755) (764) (444) — (6,963) Selling and marketing expenses (13,524) (1,636) (7,466) — (22,626) G&A expenses (5,983) (1,471) (2,625) (4,556) (14,634) Total expenses (25,262) (3,871) (10,535) (4,556) (44,224) Operating income (loss) from operations (14,778) (232) (248) (4,556) (19,813) Total Assets 22,443 12,798 31,400 24,908 91,548 Capital expenditures 3,577 288 479 — 4,344 Non-current assets 6,516 2,105 4,448 — 13,069 Goodwill 645 496 1,271 — 2,412 HIFU ESWL DISTRIB Reconciling Total 2022 Division Division Division Items consolidated Sales of goods 9,437 4,880 24,145 — 38,462 Sales of RPPs & leases 4,287 1,058 272 — 5,617 Sales of spare parts and services 1,909 5,630 3,491 — 11,030 Total sales 15,634 11,568 27,907 — 55,108 External other revenues — — — — — Total revenues 15,634 11,568 27,907 — 55,108 Total COS (6,788) (6,732) (17,396) — (30,916) Gross profit 8,846 4,836 10,511 — 24,193 R&D expenses (3,525) (950) (444) — (4,920) Selling and marketing expenses (8,083) (1,887) (6,409) — (16,379) G&A expenses (2,131) (1,077) (1,690) (2,254) (7,152) Total expenses (13,739) (3,914) (8,543) (2,254) (28,450) Operating income (loss) from operations (4,894) 922 1,968 (2,254) (4,257) Total Assets 16,293 12,997 26,407 45,426 101,123 Capital expenditures 1,715 307 356 — 2,378 Non-current assets 4,269 2,149 4,187 — 10,605 Goodwill 645 496 1,271 — 2,412 HIFU ESWL DISTRIB Reconciling Total 2021 Division Division Division Items consolidated Sales of goods 4,515 4,236 20,289 — 29,040 Sales of RPPs & leases 3,679 1,022 267 — 4,968 Sales of spare parts and services 1,715 5,758 2,578 — 10,052 Total sales 9,910 11,016 23,134 — 44,060 External other revenues 6 — — — 6 Total revenues 9,915 11,016 23,134 — 44,065 Total COS (5,311) (6,080) (14,252) — (25,643) Gross profit 4,604 4,936 8,882 — 18,422 R&D expenses (2,238) (835) (329) — (3,402) Selling and marketing expenses (3,910) (2,048) (4,774) — (10,732) G&A expenses (1,481) (1,161) (1,355) (1,904) (5,900) Total expenses (7,630) (4,043) (6,458) (1,904) (20,034) Operating income (loss) from operations (3,025) 893 2,424 (1,904) (1,612) Total Assets 13,597 13,596 25,344 24,690 77,226 Capital expenditures 1,234 141 261 — 1,636 Non-current assets 3,689 2,185 3,971 — 9,845 Goodwill 645 496 1,271 — 2,412 |
VALUATION ACCOUNTS
VALUATION ACCOUNTS | 12 Months Ended |
Dec. 31, 2023 | |
VALUATION ACCOUNTS | |
VALUATION ACCOUNTS | 30— VALUATION ACCOUNTS Allowance Allowance for deferred for doubtful Slow-moving Warranty tax assets accounts inventory reserve Balance as of December 31, 2020 15,508 721 1,563 369 Charges to costs and expenses 346 2 371 110 Deductions: write-off and others (1,513) 19 (464) (227) Balance as of December 31, 2021 14,341 742 1,470 252 Charges to costs and expenses 1,538 32 93 112 Deductions: write-off and others (1,135) (613) (300) (202) Balance as of December 31, 2022 14,744 161 1,262 162 Charges to costs and expenses 3,175 85 354 134 Deductions: write-off and others (180) (21) (353) (124) Balance as of December 31, 2023 17,739 224 1,263 172 |
SUPPLEMENTAL DISCLOSURES OF CAS
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | 12 Months Ended |
Dec. 31, 2023 | |
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | |
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | 31— SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Interest and income taxes paid are as follows: Year Ended December 31, 2023 2022 2021 Income taxes paid (refunds received) 509 410 307 Interest paid 265 168 114 Interest received 1,311 403 10 Non-cash transactions: Year Ended December 31, 2023 2022 2021 Financing lease obligations incurred 358 162 233 Operating lease obligations incurred 1,098 1,162 674 Cash paid for amounts included in the measurement of lease liabilities: Year Ended December 31, 2023 2022 2021 Operating cash flow used in operating leases 1,009 900 916 Operating cash flow used in finance leases 7 12 18 Financing cash flow used in finance leases 242 350 406 |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 12 Months Ended |
Dec. 31, 2023 | |
RELATED PARTY TRANSACTIONS | |
RELATED PARTY TRANSACTIONS | 32— RELATED PARTY TRANSACTIONS On August 19, 2019, EDAP Technomed Co. Ltd. (Japan) contracted a loan amounting to JPY 80,000,000. As a current practice in Japan, this loan required a personal warranty from the representative director, President and CEO of the subsidiary Mr. Jean-François Bachelard. EDAP TMS S.A., as the parent company, counter-warranted this personal loan and agreed to indemnify Mr. Bachelard, in an indemnification letter dated September 12, 2019 expiring upon loan maturity date of August 26, 2026. On April 22, 2020, EDAP Technomed Co. Ltd (Japan) contracted another loan amounting to JPY 50,000,000 requiring a personal warranty from the representative director, president and CEO of the subsidiary Mr. Jean-François Bachelard. EDAP TMS S.A., as the parent company, counter-warranted this personal loan and agreed to indemnify Mr. Bachelard, in an indemnification letter dated June 2, 2020, expiring upon loan maturity date of April 2, 2025. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 12 Months Ended |
Dec. 31, 2023 | |
SUBSEQUENT EVENTS | |
SUBSEQUENT EVENTS | 33— SUBSEQUENT EVENTS In order to align the Company’s organization to build shareholders value and expand its operational and commercial presence in the United States, the Company announced on January 2, 2024 the appointment of Ken Mobeck as its Chief Financial Officer and François Dietsch as its Chief Accounting Officer. |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 12 Months Ended |
Dec. 31, 2023 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
Nature of operations | 1-1 Nature of operations EDAP TMS S.A. and its subsidiaries (‘‘the Company’’) are engaged in the development, manufacturing, promotion and distribution of advanced minimally-invasive ultrasound technologies for both diagnosis and treatment of urological diseases. We have introduced the Focal One® Robotic HIFU (high-intensity focused ultrasound) system around the world including Europe, U.S., Latin America, and parts of Asia. With the addition of the ExactVu™ Micro-Ultrasound system, we offer customers a complete solution from diagnosis to treatment of prostate disease. The Company also produces and distributes systems for the treatment of urinary tract stones. These technologies include the Sonolith® i-move lithotripter system based on Extracorporeal ShockWave Lithotripsy (ESWL) technology and advanced surgical laser systems. We also derive revenues from the distribution of urodynamics products and urology lasers. Net sales consist primarily of direct sales to hospitals and clinics in France and Europe, export sales to third-party distributors and agents, and export sales through subsidiaries based in Germany, Italy, the United States and Asia. The Company purchases the majority of the components used in its products from a number of suppliers but for some components, relies on a single source. Delay would be caused if the supply of these components or other components was interrupted and these delays could be extended in certain situations where a component substitution may require regulatory approval. Failure to obtain adequate supplies of these components in a timely manner could have a material adverse effect on the Company’s business, financial position and results of operations. |
Basis of preparation | 1-2 Basis of preparation These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). |
Management estimates | 1-3 Management estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles (‘‘U.S. GAAP’’) requires management to make estimates and assumptions, such as business plans, stock price volatility, duration of standard warranty per market, duration and interest rate of operating leases, price of maintenance contracts used to determine the amount of revenue to be deferred and life duration of our range of products. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. |
Consolidation | 1-4 Consolidation The accompanying consolidated financial statements include the accounts of EDAP TMS S.A. and all its domestic and foreign owned subsidiaries after elimination of intercompany balances and transactions. We do not have any significant interests in any variable interest entities. |
Revenue recognition | 1-5 Revenue recognition The Company’s revenue consists of: - Sales of goods (devices and consumables), where invoicing generally takes place upon delivery. Consumables revenues included in sales contracts are deferred until delivery. - Revenue-per-Procedures (“RPP”) and leases: they comprise (i) revenues on a per treatment basis which are invoiced after each treatment, or in advance, or on a periodic basis, (ii) leases of devices, which are generally invoiced on a monthly or quarterly basis, and (iii) lease components arising from multiple-element arrangements, where specific sales terms are negotiated in accordance with each customer’s individual requirements and which are generally invoiced based on contract terms, - Sales of spare parts and services (maintenance, upgrades, mobility and others). Spare parts are invoiced when delivered. Regarding services, invoicing is performed either on a subscription basis (in advance or at the end of the period) or when performed. Sales of our medical devices and sales of disposables, sales of RPPs and leases, and sales of spare parts and services, are all net of commissions. The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due between one to three months from date of invoice. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and its customer, the rights of the goods or services and their payment terms can be identified, the contract has commercial substance, collectability of the contract consideration is probable, it is approved and the parties are committed to their obligations. Our sale arrangements may contain multiple elements, including device(s), consumables and services. For these multiple-element arrangements, the Company accounts for individual goods and services as separate performance obligations: (i) if a customer can benefit from the good or service on its own or with other resources that are readily available to the customer, and (ii) if they are a distinct good or service that is separately identifiable from other items in the multiple-element arrangement. The Company’s sale arrangements may include a combination of the following performance obligations: device(s), consumables, leases and services (such as, but not limited to, warranty extension). For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the goods or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the goods and services, geographies, and type of customer. The Company regularly reviews standalone selling prices and updates these estimates as necessary. The Company recognizes revenue when the performance obligations are satisfied by transferring control over the goods or service to a customer. The Company’s revenue consists of the following: Sales of goods: Sales of goods are and have historically been comprised of sales net of commission of medical devices (ESWL lithotripters and HIFU devices) and net sales of disposables (mostly Focalpaks in the HIFU division and electrodes in the ESWL division). Sales of goods also includes products such as micro-ultrasound devices, urology lasers and urodynamics devices distributed through our agents and third-party distributors. For devices and disposables, revenue is recognized when the Company transfers control to the customer (i.e. when the customer has the ability to direct the use of, and obtain substantially all of the remaining benefit from, the device or disposables), which is generally at the point of delivery, depending on the terms of the arrangement (i.e. when the customer can use the goods to provide services or sell or exchange the good), and based on contractual incoterms. Installation-related costs are immaterial in the context of the contract with the customer and do not constitute a distinct performance obligation. The Company’s sales arrangements do not provide a right of return. The goods are generally covered by a period of one Sales of RPPs and leases: Sales of RPP and leases include the revenues from the sale of treatment procedures and from the leasing of machines. For RPP, we provide machines to clinics and hospitals for free for a limited period, rather than selling the devices. These hospitals and clinics perform treatments using the devices and usually pay us based on the number of individual treatments provided. Revenues from leasing of machine are considered as immaterial. Revenues related to the sale of treatments invoiced on a ‘‘Revenue-Per-Procedure’’ (‘‘RPP’’) basis are recognized when the treatment procedure has been completed. Revenues from devices leased to customers under operating leases are recognized on a straight-line basis. Regarding multiple-element arrangements with a lease component, a portion of the contract is allocated to the lease component on the basis of observable market prices applied by the Company for similar devices under operating leases. The lease component is recognized on a straight line basis over the contractual period. Other immaterial components under the contract are recognized in accordance with their nature. Sales of spare parts and services: Revenues related to spare parts are recognized when spare parts are delivered to distributors who perform their own maintenance services. Spare parts used in the performance of EDAP’s own maintenance and repair services are generally not recognized separately, unless a type of spare part is specifically excluded from the maintenance contract terms. Revenues related to Services mainly consist of maintenance contracts which rarely exceed one year and are recognized on a straight line basis over the term of the service period as the customer benefits from the service equally throughout the service contract period. For services rendered when no maintenance contract is in place or for services not included in the scope of a maintenance contract, revenues are recorded when services are performed. The Company recognizes revenue for extended warranties included in the multiple-element arrangements as a separate performance obligation in Sales of services on a straight-line basis over the extended warranty period. In the majority of countries in which the Company operates, the statutory warranty period is one to two years and the extended warranty covers periods beyond this statutory period. Standard warranties do not constitute a separate performance obligation. The Company accrues for the warranty costs at the time of sale of the device through the multiple-element arrangement. Distributors: As part of its sale process in countries other than continental France, when the Company does not have a local subsidiary, sales of goods to end-customers are performed through agents and distributors. Such agents and distributors are primarily responsible for the sales’ process, bear the inventory risk, and are free to determine the sale prices. Sales of goods to agents and distributors are recognized when the control is transferred to the related agent or distributor which generally occurs based on contractual incoterms. Deferred revenue: Deferred revenue for the periods presented primarily relates to service contracts where the service fees are billed up-front, generally quarterly or annually, prior to those services having been performed, and consists primarily of billing or cash receipts in advance of services due under maintenance contracts or extended warranty contracts. The associated deferred revenue is generally recognized ratably over the service period. Disaggregation of revenue: Disaggregation by primary geographical market, and timing of revenue recognition is reported in Note 18. Contract Balances: Details on contract liabilities are reported on Note 11. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. This relates mainly to maintenance services. |
Costs of sales | 1-6 Costs of sales Costs of sales include all direct product costs, costs related to shipping, handling, duties and importation fees, as well as certain indirect costs such as service and supply chain departments expenses. Indirect costs are allocated by type of sales (goods, RPP and leases, spare parts and services) using an allocation method determined by management by type of costs and segment activities and reviewed on an annual basis. |
Shipping and handling costs | 1-7 Shipping and handling costs Shipping and handling costs are not considered as performance obligations. Shipping and handling costs are recorded as a component of cost of sales. |
Cash equivalents and short term investments | 1-8 Cash equivalents and short term investments Cash equivalents are cash investments which are highly liquid and have initial maturities of 90 days or less. Cash investments with a maturity higher than 90 days are considered as short-term investments. There is no short-term investment at December 31, 2023. |
Accounts Receivable | 1-9 Accounts Receivable The Company maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio. In establishing the required allowance, management considers historical losses adjusted to take into account current market conditions and the Company’s customers’ financial condition, the amount of receivables in dispute, and the current receivables aging and current payment patterns. The Company reviews its allowance for doubtful accounts quarterly. Past due balances over 90 days and over a specified amount are reviewed individually for collectability. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Write-offs for 2023 and 2022 approximated €1 thousand and €640 thousand, respectively. The Company does not have any off-balance-sheet credit exposure related to its customers. |
Inventories | 1-10 Inventories Inventories are valued at the lower of cost and net realizable value. Cost is either the manufacturing cost, which is principally comprised of components and labor costs for our own manufactured products, or purchase price for urology products we distribute. Cost is determined on a first-in, first-out basis for components and spare parts and by specific identification for finished goods (medical devices). The Company establishes reserves for inventory estimated to be obsolete, unmarketable or slow moving, first based on a detailed comparison between quantity in inventory and historical consumption and then based on case-by-case analysis of the difference between the cost of inventory and the related estimated market value. |
Property and equipment | 1-11 Property and equipment Property and equipment is stated at historical cost, net of accumulated depreciation and impairment. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful life of the related assets, as follows: Leasehold improvements (in years) 10 or lease term if shorter Equipment (in years) 3 — 10 Furniture, fixtures, fittings and other (in years) 2 — 10 Equipment includes industrial equipment and research equipment that has alternative future uses. Equipment also includes devices and treatment probes that are manufactured by the Company and leased to customers through operating leases related to Revenue-Per-Procedure transactions. This equipment is generally depreciated over a period of five |
Long-lived assets | 1-12 Long-lived assets The Company reviews the carrying value of its long-lived assets, including fixed assets and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be fully recoverable. Recoverability of long-lived assets is assessed by a comparison of the carrying amount of the assets (or the Group of assets, including the asset in question, that represents the lowest level of separately-identifiable cash flows) to the total estimated undiscounted cash flows expected to be generated by the asset or group of assets. If the future net undiscounted cash flows is less than the carrying amount of the asset or group of assets, the asset or group of assets is considered impaired and an expense is recognized equal to the amount required to reduce the carrying amount of the asset or group of assets to its then fair value. Fair value is determined by discounting the cash flows expected to be generated by the assets, when the quoted market prices are not available for the long-lived assets. Estimated future cash flows are based on assumptions and are subject to risk and uncertainty. |
Goodwill and intangible assets | 1-13 Goodwill and intangible assets Goodwill represents the excess of purchase price over the fair value of identifiable net assets of businesses acquired. Goodwill is not amortized but instead tested annually for impairment or more frequently when events or change in circumstances indicate that the assets might be impaired. When impairment indicators are identified, the impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, including goodwill. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. For the purpose of any impairment test, the Company relies upon projections of future undiscounted cash flows and takes into account assumptions regarding the evolution of the market and its ability to successfully develop and commercialize its products. Changes in market conditions could have a major impact on the valuation of these assets and could result in additional impairment losses. Intangible assets consist primarily of purchased patents relating to lithotripters, purchased licenses, a purchased trade name and a purchased trademark. The basis for valuation of these assets is their historical acquisition cost. Amortization of intangible assets is calculated by the straight-line method over the shorter of the contractual or estimated useful life of the assets, as follows: Patents (in years) 5 SAP Licenses (in years) 10 Other licenses (in years) 5 Trade name and trademark (in years) 7 |
Treasury Stocks | 1-14 Treasury Stocks Treasury stock purchases are accounted for at cost. The sale of treasury stocks is accounted for using the first in first out method. Gains on the sale or retirement of treasury stocks are accounted for as additional paid-in capital whereas losses on the sale or retirement of treasury stock are recorded as additional paid-in capital to the extent that previous net gains from sale or retirement of treasury stocks are included therein; otherwise the losses shall be recorded to accumulated benefit (deficit) account. Gains or losses from the sale or retirement of treasury stock do not affect reported results of operations. Treasury stocks held by a company cannot exceed 10% of the total number of shares issued. |
Warranty expenses | 1-15 Warranty expenses The Company provides customers with a warranty for each product sold and accrues warranty expense at time of sale based upon historical claims experience. Standard warranty period may vary from 1 year to 2 years depending on the market. The warranty expense is incurred at time of accrual and not when paid. Warranty expense amounted to €134 thousand, €112 thousand and €110 thousand for the years ended December 31, 2023, 2022 and 2021, respectively. |
Income taxes | 1-16 Income taxes The Company accounts for income taxes in accordance with ASC 740, ‘‘Accounting for Income Taxes’’ Under ASC 740, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured by applying enacted tax rates and laws to taxable years in which such differences are expected to reverse. A valuation allowance is established if, based on the weight of available evidence, it is more likely than not that some portion, or all of the deferred tax assets, will not be realized. In accordance with ASC740, no provision has been made for income or withholding taxes on undistributed earnings of foreign subsidiaries, such undistributed earnings being permanently reinvested. Under ASC740, the measurement of a tax position that meets the more-likely-that-not recognition threshold must take into consideration the amounts and probabilities of the outcomes that could be realized upon ultimate settlement using the facts, circumstances and information available at the reporting date. |
Research and development costs | 1-17 Research and development costs Research and development costs are recorded as an expense in the period in which they are incurred. The French government provides tax credits to companies for innovative research and development. This tax credit is calculated based on a percentage of eligible research and development costs and it can be refundable in cash and is not contingent on future taxable income. As such, the Company considers the research tax credits as a grant, offsetting research and development expenses. |
Advertising costs | 1-18 Advertising costs Advertising costs are recorded as an expense in the period in which they are incurred and are included in selling and administrative expenses in the accompanying consolidated statements of income (loss). Advertising costs amounted to €1,352 thousand, €929 thousand and €490 thousand for the years ended December 31, 2023, 2022 and 2021, respectively. |
Foreign currency translation and transactions | 1-19 Foreign currency translation and transactions Translation of the financial statements of consolidated companies The reporting currency of EDAP TMS S.A. for all years presented is the euro (€). The functional currency of each subsidiary is its local currency. In accordance with ASC 830, all accounts in the financial statements are translated into euro from the functional currency at the following exchange rates: ● assets and liabilities are translated at year-end exchange rates; ● shareholders’ equity is translated at historical exchange rates (as of the date of contribution); ● statement of income (loss) items are translated at average exchange rates for the year; and ● translation gains and losses are recorded in a separate component of shareholders’ equity. Foreign currencies transactions Transactions involving foreign currencies are translated into the functional currency using the exchange rate prevailing at the time of the transactions. Receivables and payables denominated in foreign currencies are translated at year-end exchange rates. The resulting unrealized exchange gains and losses are recorded in the statement of income (loss). Presentation in the Statement of Income (loss) Aggregate foreign currency transactions gains and losses are disclosed in a single caption in the Statement of Income (loss) under section “Foreign currency exchange gain (loss), net”. |
Earnings per share | 1-20 Earnings per share Basic earnings per share is computed by dividing income available to common shareholders by the weighted average number of shares of common stock outstanding for the period. Diluted earnings per share reflects potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company. The dilutive effects of the Company’s common stock options and warrants is determined using the treasury stock method to measure the number of shares that are assumed to have been repurchased using the average market price during the period, which is converted from U.S. dollars at the average exchange rate for the period. |
Derivative instruments | 1-21 Derivative instruments ASC 815 requires the Company to recognize all of its derivative instruments as either assets or liabilities in the statement of financial position at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, the Company must classify the hedging instrument, based upon the exposure being hedged, as fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation. Gains and losses from derivative instruments are recorded in the Statement of Income (loss). As of December 31, 2023, there are no derivative instruments. |
Employee stock option and free shares plan | 1-22 Employee stock option and free shares plan The accounting for stock-based awards is based on the fair value of the award measured at the grant date. Accordingly, stock-based compensation cost is recognized in the consolidated statements of income (loss) and comprehensive income (loss) as an operating expense over the requisite service period. The fair value of stock options is determined using the Black-Scholes option-pricing model. The Company determines the fair value of stock option awards on the date of grant using assumptions regarding expected term, share price volatility over the expected term of the awards, risk-free interest rate, and dividend rate. The fair value of free shares is measured using the fair value of the Company's shares as if the free shares were vested and issued on the grant date. Forfeited stock-options and free shares are recognized as they occur, in accordance with ASU 2016-09. The Company recognizes compensation cost for employee awards with only service conditions that have a graded vesting schedule on a straight-line basis over the requisite service period for each separately vesting portion of the award as if the award was, in-substance, multiple awards. At December 31, 2023, the Company had three stock-based employee compensation plans and two free shares plans. |
Warrants | 1-23 Warrants There are no warrants outstanding at December 31, 2023. |
Leases | 1-24 Leases Leases as a Lessee In accordance with ASC 842, Leases, and as from January 1, 2019, the Company classifies all leases at the inception of a contract and assess whether the contract is, or contains, a lease. The assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the company controls the use of the identified asset (e.g. whether the company has the right to obtain substantially all of the economic benefits from the use of the asset throughout the period, and whether the company has the right to direct the use of the asset). Leases are classified as either finance leases or operating leases. Substantially all our operating leases are comprised of office space leases, and substantially all our finance leases are comprised of office furniture and technology equipment. The Company recognizes a right-of-use (“ROU”) asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, plus prepaid lease payments, less any lease incentives received. All ROU assets are reviewed for impairment. For operating leases, the lease liability is initially measured at the present value of the unpaid lease payments at lease commencement date, discounted using the incremental borrowing rate for assets of same duration or characteristics. For finance leases the lease liability is initially measured in the same manner and date as for operating leases and is subsequently measured at amortized cost using the effective interest method For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability. Lease payments included in the measurement of the lease liability comprise the following: the fixed payments, including in-substance fixed payments over the lease term (which includes termination penalties the Company would owe if the lease term assumes the Company’s exercise of a termination option), variable lease payments that depend on an index or rate payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, the exercise price of an option to purchase the underlying asset if the company is reasonably certain to exercise the option, and amounts expected to be payable under a Company provided residual value guarantee. The company assesses the discount rate by requesting credit simulation from certain banks. Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expenses in the Company’s consolidated statements of income (loss) in the same line item as expenses arising from fixed lease payments (operating leases) or amortization of the ROU asset (finance leases). Our real estate leases generally include non-lease maintenance services. The consideration in the contract is allocated to the lease and non-lease components based on standalone selling prices. Some of our real estate leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease commencement, and changes to index and rate-based variable lease payments are recognized in profit or loss in the period of the change. Variable payments that do not depend on an index or rate, such as rental payments based on the use of the underlying asset or property taxes and insurance reimbursement, are recorded as operating expenses when incurred. Lease modifications result in remeasurement of the lease payments when that modification is not accounted for as a separate contract. Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. Lease expense for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense. The lease term for all of the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor . We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a term of 12 months or less. The effect of short-term leases on our right-of-use asset and lease liability was not material. We have elected not to review the classification for expired or existing leases, prior to January 1, 2019. Leases as a Lessor: A lessor shall classify a lease as a sales-type lease when the lease meets any of the following criteria at lease commencement: ● The lease transfers ownership of the underlying asset to the lessee by the end of the lease term. ● The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise. ● The lease term is for the major part of the remaining economic life of the underlying asset. However, if the commencement date falls at or near the end of the economic life of the underlying asset, this criterion shall not be used for purposes of classifying the lease. ● The present value of the sum of the lease payments and any residual value guaranteed by the lessee that is not already reflected in the lease payments in accordance with paragraph 842-10-30-5(f) equals or exceeds substantially all of the fair value of the underlying asset. ● The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. When none of the criteria are met: A lessor shall classify the lease as either a direct financing lease or an operating lease. A lessor shall classify the lease as an operating lease unless both of the following criteria are met, in which case the lessor shall classify the lease as a direct financing lease: ● The present value of the sum of the lease payments and any residual value guaranteed by the lessee that is not already reflected in the lease payments in accordance with paragraph 842-10-30-5(f) and/or any other third party unrelated to the lessor equals or exceeds substantially all of the fair value of the underlying asset; ● It is probable that the lessor will collect the lease payments plus any amount necessary to satisfy a residual value guarantee. |
Recent accounting pronouncements | 1-25 Recent accounting pronouncements Recently Adopted Accounting Pronouncements As of November 27, 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2023-07 (Segment reporting: Improvements to reportable segment disclosures) that improves disclosures about a public entity’s reportable segments and addresses requests from investors and other allocators of capital for additional, more detailed information about a reportable segment’s expenses. This Topic provides guidance “on how to report certain information about operating segments in complete sets of financial statements of the public entity and in condensed financial statements of interim periods issued to shareholders.” This standard is effective for the Company in fiscal years beginning after December 15, 2023. The Company is currently evaluating the impact of this guidance on its Consolidated Financial Statements. |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
Schedule of depreciation of property and equipment is estimated useful life of the related assets | Leasehold improvements (in years) 10 or lease term if shorter Equipment (in years) 3 — 10 Furniture, fixtures, fittings and other (in years) 2 — 10 |
Schedule of amortization of intangible assets is contractual or estimated useful life of the assets | Patents (in years) 5 SAP Licenses (in years) 10 Other licenses (in years) 5 Trade name and trademark (in years) 7 |
CASH EQUIVALENTS (Tables)
CASH EQUIVALENTS (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
CASH EQUIVALENTS | |
Schedule of Cash and Cash Equivalents [Table Text Block] | December 31, 2023 2022 Total cash and cash equivalents 43,471 63,136 Short term investment — — Total cash and cash equivalents 43,471 63,136 |
TRADE ACCOUNTS AND NOTES RECE_2
TRADE ACCOUNTS AND NOTES RECEIVABLE, NET (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
TRADE ACCOUNTS AND NOTES RECEIVABLE, NET | |
Schedule of trade accounts and notes receivable | December 31, 2023 2022 Trade accounts receivable 17,186 12,965 Notes receivable 896 617 Less: allowance for doubtful accounts (224) (161) Total 17,858 13,421 Less current portion (17,858) (13,421) Total long-term portion — — |
OTHER RECEIVABLES (Tables)
OTHER RECEIVABLES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
OTHER RECEIVABLES. | |
Schedule of other receivables | December 31, 2023 2022 Research and development tax credit receivable from the French State 411 581 Value-added taxes receivable 863 894 Other receivables from Government and public authorities 22 — Others 84 46 Total 1,380 1,522 |
INVENTORIES (Tables)
INVENTORIES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
INVENTORIES. | |
Schedule of Inventory, Current | December 31, 2023 2022 Components, spare parts 8,973 7,543 Work-in-progress 512 283 Finished goods – own manufactured products 2,115 1,514 Finished goods – distribution products 4,775 3,702 Total gross inventories 16,375 13,042 Less: allowance for slow-moving inventory and net realizable value (1,263) (1,262) Total 15,112 11,780 |
OTHER ASSETS (Tables)
OTHER ASSETS (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
OTHER ASSETS | |
Schedule of other assets | December 31, 2023 2022 Prepaid expenses, current portion 659 660 Total 659 660 |
PROPERTY AND EQUIPMENT, NET (Ta
PROPERTY AND EQUIPMENT, NET (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
PROPERTY AND EQUIPMENT, NET | |
Schedule of Property and equipment | December 31, 2023 2022 Equipment 11,900 9,553 Furniture, fixture, and fittings and other 3,672 3,108 Total gross value 15,573 12,661 Less: accumulated depreciation and amortization (9,686) (8,916) Total 5,887 3,745 |
Schedule of Finance lease right-of-use assets | December 31, 2023 2022 Facilities 242 269 Equipment 220 220 Vehicles and IT equipment 828 780 Total gross value 1,290 1,269 Less: accumulated depreciation and amortization 705 813 Total 585 455 |
OPERATING LEASE RIGHT-OF-USE _2
OPERATING LEASE RIGHT-OF-USE ASSETS (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
OPERATING LEASE RIGHT-OF-USE ASSETS. | |
Schedule of Operating lease right-of-use assets | December 31, 2023 2022 Facilities 1,534 1,536 Equipment 30 57 Furniture, fixture, and fittings and other 157 191 Total net operating lease right of use 1,722 1,784 |
GOODWILL AND INTANGIBLE ASSETS
GOODWILL AND INTANGIBLE ASSETS (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
GOODWILL AND INTANGIBLE ASSETS | |
Schedule of Intangible assets | December 31, 2023 2022 Licenses 2,119 1,585 Trade name and trademark 333 370 Patents 412 412 Organization costs 225 225 Total gross value 3,089 2,592 Accumulated amortization for licenses (1,038) (863) Accumulated amortization for trade name and trademark (331) (368) Accumulated amortization for patents (412) (412) Accumulated amortization for organization costs (225) (225) Less: Total accumulated amortization (2,005) (1,868) Total 1,084 725 |
Schedule of Intangible assets, annual estimated amortization expense | December 31, 2023 2024 205 2025 195 2026 192 2027 175 2028 88 2029 and thereafter 174 Total 1,029 |
TRADE ACCOUNTS AND NOTES PAYA_2
TRADE ACCOUNTS AND NOTES PAYABLE (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
TRADE ACCOUNTS AND NOTES PAYABLE | |
Schedule of trade accounts and notes payable | December 31, 2023 2022 Trade accounts payable 11,236 6,640 Notes payable 61 7 Total 11,297 6,647 |
DEFERRED REVENUES (Tables)
DEFERRED REVENUES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
DEFERRED REVENUES | |
Schedule of Deferred revenues | December 31, 2023 2022 Deferred revenues on maintenance contracts 1,809 1,803 Deferred revenue on RPP 492 517 Deferred revenue on sale of devices 104 83 Deferred revenue on extension of warranty, included in sales contracts 591 535 Deferred revenue on treatment probe lease and other 1,696 1,376 Total 4,693 4,314 Less long term portion (643) (264) Current portion 4,049 4,050 |
Schedule of Deferred revenue on extension of warranty | December 31, 2023 2024 224 2025 183 2026 74 2027 46 2028 30 2029 and thereafter 35 Total 591 |
Changes in deferred revenue on extension of warranty | Total Balance as of December 31, 2021 740 New extension of warranty 162 Recognition of revenue (367) Balance as of December 31, 2022 535 New extension of warranty 238 Recognition of revenue (181) Balance as of December 31, 2023 591 |
OTHER ACCRUED LIABILITIES (Tabl
OTHER ACCRUED LIABILITIES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
OTHER ACCRUED LIABILITIES. | |
Schedule of other accrued liabilities | December 31, 2023 2022 Retirement indemnities 2,310 2,153 Provision for warranty costs 172 162 Accruals for payroll and associated taxes 2,256 1,848 Conditional government advances 463 463 Value added tax payable 758 531 Advances received from customers 860 861 Provision for Asset Retirement Obligation (Japan) 91 101 Provision for employee termination indemnities (Korea) 149 122 Others 522 340 Total 7,581 6,583 Less non-current portion (3,075) (2,710) Current portion 4,506 3,873 |
Schedule of Conditional advances | 2024 111 2025 93 2026 93 2027 86 2028 81 2029 and thereafter — Total 463 |
Schedule of Changes in the provision for warranty costs | 2023 2022 Beginning of year 162 252 Amount used during the year (124) (202) New warranty expenses 134 112 End of year 172 162 Less current portion (107) (100) Long term portion 65 62 |
LEASE OBLIGATIONS (Tables)
LEASE OBLIGATIONS (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
LEASE OBLIGATIONS | |
Schedule of Maturities of finance leases liabilities | December 31, 2023 2024 214 2025 170 2026 134 2027 86 2028 52 2029 and thereafter 2 Total undiscounted minimum lease payments 659 Less: amount representing interest (33) Present value of minimum lease payments 627 Less: current portion (195) Long-term portion 433 December 31, 2022 2023 234 2024 149 2025 102 2026 63 2027 12 2028 and thereafter 6 Total undiscounted minimum lease payments 566 Less: amount representing interest (17) Present value of minimum lease payments 548 Less: current portion (224) Long-term portion 324 |
Schedule of Maturities of operating leases liabilities | December 31, 2023 2024 898 2025 485 2026 240 2027 157 2028 — 2029 and thereafter — Total undiscounted minimum lease payments 1,780 Less: current portion (898) Long-term portion 882 December 31, 2022 2023 901 2024 636 2025 238 2026 24 2027 — 2028 and thereafter — Total undiscounted minimum lease payments 1,799 Less: current portion (901) Long-term portion 899 |
LONG TERM DEBT (Tables)
LONG TERM DEBT (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
LONG TERM DEBT | |
Schedule of Long-term Debt | December 31, 2023 2022 France term loan 3,222 4,593 Japanese term loan 323 558 Germany term loan — 28 USA term loan — — Korea term loan 5 8 Malaysia term loan — — Total long term debt 3,551 5,188 Less current portion (1,553) (1,601) Total long-term portion 1,997 3,587 |
Schedule of Long-term Debt Instruments | Initial Frequency of Amount Maturity Fixed Interest rate principal payments EDAP Technomed Co. Ltd 80,000,000 August 2, 2026 1.98 % Monthly installment EDAP Technomed Co. Ltd 50,000,000 April 2, 2025 1.8 % Monthly installment Drown Frequency of Amount Maturity Fixed Interest rate principal payments EDAP TMS FRANCE 1,066,081 July 1, 2025 0.99 % Monthly installment Initial Frequency of Amount Maturity Fixed Interest rate principal payments EDAP TMS FRANCE 2,000,000 July 30, 2026 0.73 % Monthly installment Initial Frequency of Amount Maturity Fixed Interest rate principal payments EDAP TMS FRANCE 2,000,000 August 4, 2026 0.73 % Monthly installment Initial Frequency of Amount Maturity Fixed Interest rate principal payments EDAP TMS FRANCE 72,222 July 5, 2024 0.45 % Monthly installment Initial Frequency of Amount Maturity Fixed Interest rate principal payments EDAP TMS GMBH 400,000 April 30, 2023 2.40 % Monthly installment |
Schedule of Long-term Debt and Financial Instrument Maturities | 2024 1,553 2025 1,320 2026 677 2027 — 2028 — 2029 and thereafter — Total 3,551 |
OTHER LONG-TERM LIABILITIES (Ta
OTHER LONG-TERM LIABILITIES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
OTHER LONG-TERM LIABILITIES. | |
Schedule of Other Long-term Liabilities | December 31, 2023 2022 Provision for retirement indemnities (Japan & France), less current portion 2,241 1,962 Provision for employee termination indemnities (Korea) less current portion 149 122 Provision for Asset Retirement Obligation (Japan) less current portion 91 101 Provision for warranty costs, less current portion 65 62 Provision for guarantee given to customer, less curent portion 66 — Conditional government advances, less current portion 463 463 Accrued interest less current portion — — Total 3,075 2,710 |
Defined Benefit Plan, Assumptions | Retirement indemnities France 2023 2022 Discount rate 3.19% 3.80% Salary increase 3.00% 3.00% Retirement age 65 65 Average retirement remaining service period 23 24 Retirement indemnities Japan 2023 2022 Discount rate 1.30% 1.30% Salary increase 2.50% 2.50% Retirement age 60 60 Average retirement remaining service period 14 14 |
Schedule of Amounts Recognized in Balance Sheet | At December 31, 2023, the provision which represents the projected benefit obligation in accordance with ASC 718 consists of: France Japan Non-current liabilities 1,084 1,157 Current liabilities — 70 Total projected benefit obligation 1,084 1,227 At December 31, 2022, the provision which represents the projected benefit obligation in accordance with ASC 718 consists of: France Japan Non-current liabilities 845 1,117 Current liabilities 89 102 Total projected benefit obligation 934 1,219 |
Schedule of Defined Benefit Plans Disclosures | France 2023 2022 2021 Change in benefit obligations: Projected Benefit obligations at beginning of year 934 1,080 1,111 Service cost 67 84 90 Interest cost 34 11 6 Net loss or (gain) — — — Actuarial (gain) or loss 66 (241) (72) Amortization of net prior service cost — — — Benefits paid (17) — (56) Projected Benefit obligations at end of year (1) 1,084 934 1,080 Unrecognized actuarial (gain) loss (2) (146) (219) 22 Unrecognized prior service cost (2) 13 14 16 (1) The accumulated benefit obligation was €805 thousand and €701 thousand at December 31, 2023 and 2022 respectively. (2) The amount in accumulated other comprehensive income (loss) to be recognized as components of net periodic benefit costs in 2023 is €133 thousand. Japan 2023 2022 2021 Change in benefit obligations: Projected Benefit obligations at beginning of year 1,219 1,302 1,310 Service cost 114 112 120 Interest cost 13 7 7 Amortization of net loss — — — Actuarial (gain) / loss 4 (30) — Benefits paid (76) (75) (97) Plan Amendments 74 — — Exchange rate impact (122) (95) (39) Projected Benefit obligations at end of year (1) 1,227 1,219 1,302 Unrecognized actuarial (gain) loss (2) 81 86 126 Unrecognized prior service cost (2) 74 — — (1) The accumulated benefit obligation was €1,030 thousand and €1,027 thousand at December 31, 2023 and 2022, respectively. (2) The amount in accumulated other comprehensive income (loss) to be recognized as components of net periodic benefit costs in 2023 is €156 thousand. |
Schedule of Expected Benefit Payments | France Japan 2024 — 70 2025 — 152 2026 129 143 2027 85 67 2028 85 46 2029-2033 408 843 707 1,322 |
SHAREHOLDERS' EQUITY (Tables)
SHAREHOLDERS' EQUITY (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
SHAREHOLDERS' EQUITY. | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions | Dec-2023 Nov-2023 Sept-2023 Aug-2023 May-2023 May-2023 Apr-2023 Weighted-average expected life (years) 5.79 5.79 5.79 5.79 5.79 5.79 5.79 Expected volatility rates (1) 63.29 % 61.09 % 60.90 % 60.60 % 60.80 % 60.90 % 61.00 % Expected dividend yield 0 % 0 % 0 % 0 % 0 % 0 % 0 % Risk-free interest rate 4.16 % 4.55 % 4.55 % 4.35 % 3.77 % 3.47 % 3.39 % Weighted-average exercise price (€) 4.98 6.64 6.08 7.53 9.32 10.10 9.96 Weighted-average fair value of options granted during the year (€) 3.03 4.05 3.70 4.37 5.40 5.92 5.49 (1) Historical volatility calculated over the weighted-average expected life. |
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award | 2023 2022 2021 Options Weighted Options Weighted Options Weighted average average average exercice exercice exercice price (€) price (€) price (€) Outstanding on January 1, 2,613,886 5.66 2,408,508 4.38 1,186,900 2.81 Granted 686,000 8.53 571,000 9.07 1,392,428 5.56 Exercised (55,973) 4.66 (320,622) 2.14 (150,820) 2.93 Forfeited (45,000) 7.99 (45,000) 5.34 (20,000) 4.01 Expired — — — — — — Outstanding on December 31, 3,198,913 6.26 2,613,886 5.66 2,408,508 4.38 Exercisable on December 31, 1,997,666 5.23 1,362,205 4.35 1,149,401 3.25 Share purchase options available for grant on December 31, 25,000 20,000 5,000 As of December 31, 2023, 643,000 options to subscribe to new shares are available for future grants. |
Share-based Payment Arrangement, Option, Exercise Price Range | Outstanding options Fully vested options (1) Weighted Weighted Weighted average average Aggregate average Aggregate remaining exercise Intrinsic exercise Intrinsic contractual price Value price Value Exercise price (€) Options life (€) (2) Options (€) (2) 10.32 20,000 8.8 10.32 — 7,222 10.32 — 10.10 200,000 9.3 10.10 — 38,889 10.10 — 9.96 117,000 9.3 9.96 — 26,000 9.96 — 9.94 395,000 9.0 9.94 — 131,667 9.94 — 9.32 50,000 9.4 9.32 — 9,722 9.32 — 7.53 177,000 9.7 7.53 — — — — 6.64 20,000 9.8 6.64 — — — — 6.41 100,000 8.3 6.41 — 52,778 6.41 — 6.08 80,000 9.8 6.08 — — — — 5.59 1,244,533 7.4 5.59 — 1,037,111 5.59 — 5.18 83,300 7.8 5.18 431,494 16,197 5.18 83,902 4.98 34,000 9.9 4.98 169,320 — — — 3.90 107,500 5.8 3.90 419,250 107,500 3.90 419,250 3.22 357,000 2.3 3.22 1,149,540 357,000 3.22 1,149,540 2.65 77,500 4.7 2.65 205,375 77,500 2.65 205,375 2.39 136,080 3.3 2.39 325,231 136,080 2.39 325,231 2.39 to 10.32 3,198,913 7.8 0.84 2,700,210 1,997,666 1.09 2,183,298 (1) Fully vested options are all exercisable options. On March 29, 2023, the Board of Directors unanimously decided to appoint Ryan Rhodes as the new Chief Executive Officer of the Company effective on May 1, 2023. Marc Oczachowski would continue to serve as Chairman of the Board of the Company. In this context, the Board decided to accelerate the vesting of all unvested options granted to Mr. Oczachowski under the 2019 option plans such that these options fully vested and became exercisable on March 29, 2023. (Ref. Note 33. Subsequent Events.) (2) The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company’s closing stock price of $5.28 at December 31, 2023, which would have been received by the option holders had all in-the-money option holders exercised their options as of that date. If closing stock price is under exercise price, then the aggregate intrinsic value is not considered. |
Schedule of Nonvested Share Activity | Weighted average Grant-Date Fair Options Value (€) Non-vested at January 1, 2021 216,250 1.59 Granted 1,392,428 2.37 Vested (329,571) 2.06 Forfeited (20,000) 1.89 Non-vested at December 31, 2021 1,259,107 2.32 Granted 571,000 4.33 Vested (543,426) 2.32 Forfeited (35,000) 2.80 Non-vested at December 31, 2022 1,251,681 2.32 Granted 686,000 4.95 Vested (691,434) 3.22 Forfeited (45,000) 3.98 Non-vested at December 31, 2023 1,201,247 4.18 |
Schedule of Accumulated Other Comprehensive Income (Loss) | Year Ended December 31, 2023 Foreign currency Provision for translation retirement indemnities adjustment (net of tax) Total Beginning balance (3,973) 144 (3,829) Other comprehensive income (loss) before reclassifications — — — Reclassified from accumulated other comprehensive loss — — — Net current-period other comprehensive income (loss) (478) (180) (658) Ending balance (4,451) (37) (4,487) Year Ended December 31, 2022 Foreign currency Provision for translation retirement indemnities adjustment (net of tax) Total Beginning balance (3,377) (212) (3,589) Other comprehensive income (loss) before reclassifications — — — Reclassified from accumulated other comprehensive loss — — — Net current-period other comprehensive income (loss) (596) 355 (240) Ending balance (3,973) 144 (3,829) |
TOTAL SALES (Tables)
TOTAL SALES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
TOTAL SALES | |
Revenue from External Customers by Geographic Areas | Year Ended December 31, Primary geographical markets (€) 2023 2022 2021 Asia 17,841 17,936 16,009 France 11,999 10,637 12,251 United States 16,717 15,036 5,524 Others geographical areas 13,865 11,500 10,276 Total Net Sales 60,423 55,108 44,060 |
Disaggregation of Revenue | Year Ended December 31, Timing of revenue recognition 2023 2022 2021 Products transferred at a point in time 48,646 44,173 34,552 Products and services transferred over time 11,777 10,935 9,508 Total Net Sales 60,423 55,108 44,060 |
OTHER REVENUES (Tables)
OTHER REVENUES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
OTHER REVENUES | |
Schedule of Other Revenues | Year Ended December 31, 2023 2022 2021 Licenses and others — — 6 Total — — 6 |
COSTS OF SALES (Tables)
COSTS OF SALES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
COSTS OF SALES | |
Schedule of Costs of Sales | Year Ended December 31, 2023 2022 2021 Direct costs of sales (22,624) (19,814) (16,199) Indirect costs of sales (13,388) (11,102) (9,443) Total costs of sales (36,012) (30,916) (25,643) |
RESEARCH AND DEVELOPMENT EXPE_2
RESEARCH AND DEVELOPMENT EXPENSES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
RESEARCH AND DEVELOPMENT EXPENSES | |
Schedule of Research and Development Expenses | Year Ended December 31, 2023 2022 2021 Gross research and development expenses (7,596) (5,751) (4,757) Research Tax Credit 411 581 617 Grants 222 250 739 Net Research and development expenses (6,963) (4,920) (3,402) |
FINANCIAL INCOME, NET (Tables)
FINANCIAL INCOME, NET (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
FINANCIAL INCOME, NET | |
Schedule of Interest Income and Interest Expense | Year Ended December 31, 2023 2022 2021 Interest income 1,311 404 10 Interest expense (232) (168) (52) Paycheck Protection Program loan forgiveness — — 187 Total 1,079 236 145 |
INCOME TAXES (Tables)
INCOME TAXES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
INCOME TAXES | |
Schedule of Income before Income Tax, Domestic and Foreign | Year Ended December 31, 2023 2022 2021 France (9,026) (418) 869 Other countries (11,507) (1,678) 24 Total (20,533) (2,096) 893 |
Schedule of Components of Income Tax (Expense)/Benefit | Year Ended December 31, 2023 2022 2021 Current income tax expense: France (77) (485) (320) Other countries (533) (251) (436) Sub-total current income tax expense (610) (736) (756) Deferred income tax (expense) benefit: France 3 (8) 8 Other countries (37) (93) 556 Sub-total deferred income tax (expense) benefit (34) (101) 563 Total (644) (837) (193) |
Schedule of Deferred Tax Assets and Liabilities | 2023 2022 Net operating loss carry forwards 16,356 13,793 Elimination of intercompany profit in inventory 689 480 Elimination of intercompany profit in fixed assets 396 256 Provisions for retirement indemnities 663 658 Capital leases treated as operating leases for tax 10 26 Other items 354 360 Total deferred tax assets 18,468 15,573 Total deferred tax liabilities — — Net deferred tax assets 18,468 15,573 Valuation allowance for deferred tax assets (17,739) (14,744) Deferred tax assets (liabilities), net of allowance 729 829 |
Schedule of Effective Income Tax Rate Reconciliation | 2023 2022 2021 Theoretical income tax (expense) benefit at French statutory tax rate 5,133 524 (237) Income of foreign subsidiaries taxed at different tax rates (546) (174) (95) Effect of net operating loss carry-forwards and valuation allowances (4,439) (643) 626 Non-taxable debt fair value variation — — — Permanent differences (263) (99) (258) Effect of cancellation of intra-group positions (476) (366) (130) French business tax included in income tax (CVAE) (74) (99) (85) Other 20 20 (15) Effective income tax (expense) benefit (644) (837) (193) |
EARNINGS (LOSS) PER SHARE (Tabl
EARNINGS (LOSS) PER SHARE (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
EARNINGS (LOSS) PER SHARE | |
Schedule of Earnings Per Share, Basic and Diluted | Year Ended December 31, 2023 2022 2021 Income (loss) available to common shareholders (in Euros) € (21,177,772) € (2,933,058) € 699,890 Weighted average number of shares for the computation of basic EPS 36,996,722 34,392,598 32,129,047 Basic EPS (in Euros) € (0.57) € (0.09) € 0.02 Effect of dilutive securities 2,653,050 2,502,171 293,824 Weighted average number of shares for the computation of diluted EPS 36,996,722 34,392,598 32,422,871 Diluted EPS income / (loss) (in Euros) € (0.57) € (0.09) € 0.02 |
SEGMENT INFORMATION (Tables)
SEGMENT INFORMATION (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
SEGMENT INFORMATION | |
Schedule of Reconciliation of Operating Profit or Loss from Segments to Consolidated | Year Ended December 31, 2023 2022 2021 Segment operating income (loss) (19,813) (4,257) (1,612) Financial income (expense), net 1,079 236 145 Foreign Currency exchange (losses) gains, net (1,799) 1,925 2,360 Income tax (expense) benefit (644) (837) (193) Consolidated net income (loss) (21,178) (2,933) 700 |
Schedule of Segment Reporting Information, by Segment | HIFU ESWL DISTRIB Reconciling Total 2023 Division Division Division Items consolidated Sales of goods 13,510 3,844 24,980 — 42,333 Sales of RPPs & leases 4,935 955 286 — 6,176 Sales of spare parts and services 2,152 5,109 4,653 — 11,914 Total sales 20,596 9,908 29,919 — 60,423 External other revenues — — — — — Total revenues 20,596 9,908 29,919 — 60,423 Total COS (10,112) (6,268) (19,632) — (36,012) Gross profit 10,484 3,640 10,287 — 24,411 R&D expenses (5,755) (764) (444) — (6,963) Selling and marketing expenses (13,524) (1,636) (7,466) — (22,626) G&A expenses (5,983) (1,471) (2,625) (4,556) (14,634) Total expenses (25,262) (3,871) (10,535) (4,556) (44,224) Operating income (loss) from operations (14,778) (232) (248) (4,556) (19,813) Total Assets 22,443 12,798 31,400 24,908 91,548 Capital expenditures 3,577 288 479 — 4,344 Non-current assets 6,516 2,105 4,448 — 13,069 Goodwill 645 496 1,271 — 2,412 HIFU ESWL DISTRIB Reconciling Total 2022 Division Division Division Items consolidated Sales of goods 9,437 4,880 24,145 — 38,462 Sales of RPPs & leases 4,287 1,058 272 — 5,617 Sales of spare parts and services 1,909 5,630 3,491 — 11,030 Total sales 15,634 11,568 27,907 — 55,108 External other revenues — — — — — Total revenues 15,634 11,568 27,907 — 55,108 Total COS (6,788) (6,732) (17,396) — (30,916) Gross profit 8,846 4,836 10,511 — 24,193 R&D expenses (3,525) (950) (444) — (4,920) Selling and marketing expenses (8,083) (1,887) (6,409) — (16,379) G&A expenses (2,131) (1,077) (1,690) (2,254) (7,152) Total expenses (13,739) (3,914) (8,543) (2,254) (28,450) Operating income (loss) from operations (4,894) 922 1,968 (2,254) (4,257) Total Assets 16,293 12,997 26,407 45,426 101,123 Capital expenditures 1,715 307 356 — 2,378 Non-current assets 4,269 2,149 4,187 — 10,605 Goodwill 645 496 1,271 — 2,412 HIFU ESWL DISTRIB Reconciling Total 2021 Division Division Division Items consolidated Sales of goods 4,515 4,236 20,289 — 29,040 Sales of RPPs & leases 3,679 1,022 267 — 4,968 Sales of spare parts and services 1,715 5,758 2,578 — 10,052 Total sales 9,910 11,016 23,134 — 44,060 External other revenues 6 — — — 6 Total revenues 9,915 11,016 23,134 — 44,065 Total COS (5,311) (6,080) (14,252) — (25,643) Gross profit 4,604 4,936 8,882 — 18,422 R&D expenses (2,238) (835) (329) — (3,402) Selling and marketing expenses (3,910) (2,048) (4,774) — (10,732) G&A expenses (1,481) (1,161) (1,355) (1,904) (5,900) Total expenses (7,630) (4,043) (6,458) (1,904) (20,034) Operating income (loss) from operations (3,025) 893 2,424 (1,904) (1,612) Total Assets 13,597 13,596 25,344 24,690 77,226 Capital expenditures 1,234 141 261 — 1,636 Non-current assets 3,689 2,185 3,971 — 9,845 Goodwill 645 496 1,271 — 2,412 |
VALUATION ACCOUNTS (Tables)
VALUATION ACCOUNTS (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
VALUATION ACCOUNTS | |
Schedule of valuation accounts | Allowance Allowance for deferred for doubtful Slow-moving Warranty tax assets accounts inventory reserve Balance as of December 31, 2020 15,508 721 1,563 369 Charges to costs and expenses 346 2 371 110 Deductions: write-off and others (1,513) 19 (464) (227) Balance as of December 31, 2021 14,341 742 1,470 252 Charges to costs and expenses 1,538 32 93 112 Deductions: write-off and others (1,135) (613) (300) (202) Balance as of December 31, 2022 14,744 161 1,262 162 Charges to costs and expenses 3,175 85 354 134 Deductions: write-off and others (180) (21) (353) (124) Balance as of December 31, 2023 17,739 224 1,263 172 |
SUPPLEMENTAL DISCLOSURES OF C_2
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | |
Schedule of supplemental cash flow disclosures | Year Ended December 31, 2023 2022 2021 Income taxes paid (refunds received) 509 410 307 Interest paid 265 168 114 Interest received 1,311 403 10 Non-cash transactions: Year Ended December 31, 2023 2022 2021 Financing lease obligations incurred 358 162 233 Operating lease obligations incurred 1,098 1,162 674 Cash paid for amounts included in the measurement of lease liabilities: Year Ended December 31, 2023 2022 2021 Operating cash flow used in operating leases 1,009 900 916 Operating cash flow used in finance leases 7 12 18 Financing cash flow used in finance leases 242 350 406 |
SUMMARY OF SIGNIFICANT ACCOUN_4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Short term investment | € 0 | ||
Accounts receivable, writeoff | € 1 | € 640 | |
Derivatives | 0 | ||
Maximum treasury shares as percentage of total shares issued | 10% | ||
Warranty expense | € 134 | 112 | € 110 |
Advertising expense | 1,352 | € 929 | € 490 |
Warrants outstanding | € 0 | ||
Number of stock-based employee compensation plans | 3 | ||
Number of free share plans | 2 | ||
Minimum | |||
Warranty term | P1Y | ||
Minimum | Sale and leaseback | |||
Useful life | 5 years | ||
Maximum | |||
Warranty term | two years | ||
Maximum | Sale and leaseback | |||
Useful life | 7 years |
SUMMARY OF SIGNIFICANT ACCOUN_5
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and equipment (Details) | Dec. 31, 2023 |
Leasehold improvements | Maximum | |
Property and equipment | |
Useful life | 10 years |
Equipment | Minimum | |
Property and equipment | |
Useful life | 3 years |
Equipment | Maximum | |
Property and equipment | |
Useful life | 10 years |
Furniture, fixtures, fittings and other | Minimum | |
Property and equipment | |
Useful life | 2 years |
Furniture, fixtures, fittings and other | Maximum | |
Property and equipment | |
Useful life | 10 years |
SUMMARY OF SIGNIFICANT ACCOUN_6
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details) | Dec. 31, 2023 |
Patents | |
Intangible assets | |
Useful life (in years) | 5 years |
SAP Licenses | |
Intangible assets | |
Useful life (in years) | 10 years |
Other licenses | |
Intangible assets | |
Useful life (in years) | 5 years |
Trade name and trademark | |
Intangible assets | |
Useful life (in years) | 7 years |
CASH EQUIVALENTS - Schedule of
CASH EQUIVALENTS - Schedule of Cash Equivalents and Short Term Investments (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
CASH EQUIVALENTS | ||
Total cash and cash equivalents | € 43,471 | € 63,136 |
Short term investment | 0 | |
Total cash and cash equivalents | 43,471 | € 63,136 |
Indebtedness pledged in cash positions in USD | € 567 |
TRADE ACCOUNTS AND NOTES RECE_3
TRADE ACCOUNTS AND NOTES RECEIVABLE, NET (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
TRADE ACCOUNTS AND NOTES RECEIVABLE, NET | |||
Trade accounts receivable | € 17,186 | € 12,965 | |
Notes receivable | 896 | 617 | |
Less: allowance for doubtful accounts | (224) | (161) | |
Total | 17,858 | 13,421 | |
Less current portion | (17,858) | (13,421) | |
Bad debt expense: | |||
Bad debt expense | € 68 | € 32 | € 2 |
OTHER RECEIVABLES - (Details)
OTHER RECEIVABLES - (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
OTHER RECEIVABLES. | ||
Research and development tax credit receivable from the French State | € 411 | € 581 |
Value-added taxes receivable | 863 | 894 |
Other receivables from Government and public authorities | 22 | |
Others | 84 | 46 |
Total | € 1,380 | € 1,522 |
INVENTORIES (Details)
INVENTORIES (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
INVENTORIES. | |||
Components, spare parts | € 8,973 | € 7,543 | |
Work-in-progress | 512 | 283 | |
Finished goods - own manufactured products | 2,115 | 1,514 | |
Finished goods - distribution products | 4,775 | 3,702 | |
Total gross inventories | 16,375 | 13,042 | |
Less: allowance for slow-moving inventory and net realizable value | (1,263) | (1,262) | |
Total | 15,112 | 11,780 | |
Provision for slow moving inventory: | |||
Inventory write-down | 354 | € 93 | € 371 |
Reversal of allowance for slow-moving inventory | € 301 |
OTHER ASSETS (Details)
OTHER ASSETS (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
OTHER ASSETS | ||
Prepaid expenses, current portion | € 659 | € 660 |
Total | € 659 | € 660 |
PROPERTY AND EQUIPMENT, NET - S
PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment, net (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Property and equipment | ||
Property and equipment, gross | € 15,573 | € 12,661 |
Less: accumulated depreciation and amortization | (9,686) | (8,916) |
Total | 5,887 | 3,745 |
Equipment | ||
Property and equipment | ||
Property and equipment, gross | 11,900 | 9,553 |
Furniture, fixture, and fittings and other | ||
Property and equipment | ||
Property and equipment, gross | € 3,672 | € 3,108 |
PROPERTY AND EQUIPMENT, NET (De
PROPERTY AND EQUIPMENT, NET (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
PROPERTY AND EQUIPMENT, NET | |||
Depreciation expense | € 1,557 | € 1,194 | € 1,521 |
Depreciation expense related to financing lease right-of-use assets | 193 | 303 | 275 |
Assets leased to customers, gross | 885 | 753 | |
Assets leased to customers, accumulated amortization | 207 | 264 | |
Depreciation expense on equipment leased to customers | € 13 | € 37 | € 40 |
PROPERTY AND EQUIPMENT, NET -_2
PROPERTY AND EQUIPMENT, NET - Schedule of Financing leases right-of-use assets (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Property and equipment | ||
Total gross value | € 1,290 | € 1,269 |
Less: accumulated depreciation and amortization | 705 | 813 |
Total | € 585 | € 455 |
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] | Property and equipment, net | Property and equipment, net |
Facilities | ||
Property and equipment | ||
Total gross value | € 242 | € 269 |
Equipment | ||
Property and equipment | ||
Total gross value | 220 | 220 |
Vehicles and IT equipment | ||
Property and equipment | ||
Total gross value | € 828 | € 780 |
OPERATING LEASE RIGHT-OF-USE _3
OPERATING LEASE RIGHT-OF-USE ASSETS - Components (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Right of use assets: | ||
Operating lease, right of use | € 1,722 | € 1,784 |
Facilities | ||
Right of use assets: | ||
Operating lease, right of use | 1,534 | 1,536 |
Equipment. | ||
Right of use assets: | ||
Operating lease, right of use | 30 | 57 |
Furniture, fixture, fittings and other | ||
Right of use assets: | ||
Operating lease, right of use | € 157 | € 191 |
OPERATING LEASE RIGHT-OF-USE _4
OPERATING LEASE RIGHT-OF-USE ASSETS (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
OPERATING LEASE RIGHT-OF-USE ASSETS. | ||
Operating lease cost | € 1,053 | € 910 |
Variable lease costs | 243 | 152 |
Short-term lease costs | € 71 | € 74 |
GOODWILL AND INTANGIBLE ASSET_2
GOODWILL AND INTANGIBLE ASSETS (Details) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 EUR (€) item | Dec. 31, 2022 EUR (€) | Dec. 31, 2021 EUR (€) | |
Goodwill | |||
Goodwill | € 2,412 | € 2,412 | € 2,412 |
Reporting units | item | 3 | ||
Impairment | € 0 | ||
Amortization expense | 175 | € 141 | € 125 |
Lithotripsy (ESWL) | |||
Goodwill | |||
Goodwill | 496 | ||
Distribution Services (DIST) | |||
Goodwill | |||
Goodwill | 1,271 | ||
High Intensity Focused Ultrasound (HIFU) | |||
Goodwill | |||
Goodwill | € 645 |
GOODWILL AND INTANGIBLE ASSET_3
GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Intangible assets | ||
Intangible assets, gross | € 3,089 | € 2,592 |
Accumulated amortization | (2,005) | (1,868) |
Intangible assets, net | 1,084 | 725 |
Licenses | ||
Intangible assets | ||
Intangible assets, gross | 2,119 | 1,585 |
Accumulated amortization | (1,038) | (863) |
Trade name and trademark | ||
Intangible assets | ||
Intangible assets, gross | 333 | 370 |
Accumulated amortization | (331) | (368) |
Patents | ||
Intangible assets | ||
Intangible assets, gross | 412 | 412 |
Accumulated amortization | (412) | (412) |
Organization costs | ||
Intangible assets | ||
Intangible assets, gross | 225 | 225 |
Accumulated amortization | € (225) | € (225) |
GOODWILL AND INTANGIBLE ASSET_4
GOODWILL AND INTANGIBLE ASSETS - Estimated amortization expense (Details) € in Thousands | Dec. 31, 2023 EUR (€) |
GOODWILL AND INTANGIBLE ASSETS | |
2024 | € 205 |
2025 | 195 |
2026 | 192 |
2027 | 175 |
2028 | 88 |
2029 and thereafter | 174 |
Total | € 1,029 |
TRADE ACCOUNTS AND NOTES PAYA_3
TRADE ACCOUNTS AND NOTES PAYABLE (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
TRADE ACCOUNTS AND NOTES PAYABLE | ||
Trade accounts payable | € 11,236 | € 6,640 |
Notes payable | 61 | 7 |
Total | € 11,297 | € 6,647 |
DEFERRED REVENUES - Summary of
DEFERRED REVENUES - Summary of Deferred Revenues (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 |
Deferred revenues, total | € 4,693 | € 4,314 | |
Less long term portion | (643) | (264) | |
Current portion | 4,049 | 4,050 | |
Maintenance contracts | |||
Deferred revenues, total | 1,809 | 1,803 | |
RPP | |||
Deferred revenues, total | 492 | 517 | |
Sale of devices | |||
Deferred revenues, total | 104 | 83 | |
Extension of warranty, included in sales contracts | |||
Deferred revenues, total | 591 | 535 | € 740 |
Treatment probe lease and other | |||
Deferred revenues, total | € 1,696 | € 1,376 |
DEFERRED REVENUES - Revenue Rec
DEFERRED REVENUES - Revenue Recognition (Details) - Extension of Warranty [Member] € in Thousands | Dec. 31, 2023 EUR (€) |
2024 | € 224 |
2025 | 183 |
2026 | 74 |
2027 | 46 |
2028 | 30 |
2029 and thereafter | 35 |
Total | € 591 |
DEFERRED REVENUES - Change in D
DEFERRED REVENUES - Change in Deferred Revenue on Extension of Warranty (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Balance | € 4,314 | |
Balance | 4,693 | € 4,314 |
Extension of Warranty [Member] | ||
Balance | 535 | 740 |
New extension of warranty | 238 | 162 |
Recognition of revenue | (181) | (367) |
Balance | € 591 | € 535 |
OTHER ACCRUED LIABILITIES - Sch
OTHER ACCRUED LIABILITIES - Schedule of other accrued liabilities (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 |
Retirement indemnities | € 2,310 | € 2,153 | |
Provision for warranty costs | 172 | 162 | € 252 |
Accruals for payroll and associated taxes | 2,256 | 1,848 | |
Conditional government advances | 463 | 463 | |
Value added tax payable | 758 | 531 | |
Advances received from customers | 860 | 861 | |
Provision for Asset Retirement Obligation (Japan) | 91 | 101 | |
Others | 522 | 340 | |
Total | 7,581 | 6,583 | |
Less non-current portion | (3,075) | (2,710) | |
Current portion | 4,506 | 3,873 | |
Korea | |||
Provision for employee termination indemnities (Korea) | € 149 | € 122 |
OTHER ACCRUED LIABILITIES (Deta
OTHER ACCRUED LIABILITIES (Details) € in Millions | 12 Months Ended |
Dec. 31, 2021 EUR (€) | |
OTHER ACCRUED LIABILITIES. | |
Proceeds from conditional advances | € 0.5 |
OTHER ACCRUED LIABILITIES - Con
OTHER ACCRUED LIABILITIES - Conditional advances (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
OTHER ACCRUED LIABILITIES. | ||
2024 | € 111 | |
2025 | 93 | |
2026 | 93 | |
2027 | 86 | |
2028 | 81 | |
Total | € 463 | € 463 |
OTHER ACCRUED LIABILITIES - S_2
OTHER ACCRUED LIABILITIES - Schedule of Changes in warranty costs provision (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
OTHER ACCRUED LIABILITIES. | ||
Beginning of year | € 162 | € 252 |
Amount used during the year | (124) | (202) |
New warranty expenses | 134 | 112 |
End of year | 172 | 162 |
Less current portion | (107) | (100) |
Long term portion | € 65 | € 62 |
LEASE OBLIGATIONS (Details)
LEASE OBLIGATIONS (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Liability associated with lease equipment | € 627 | € 548 | |
Finance lease obligations | € 7 | € 12 | € 55 |
Fianance lease, weighted average remaining lease term | 3 years 9 months | 1 year 7 days | |
Fianance lease, weighted average discount rate | 3.67% | 1.32% | |
Operating lease, weighted average remaining lease term | 2 years 4 months 6 days | 2 years 2 months 4 days | |
Operating lease, weighted average discount rate | 4.98% | 2.29% | |
Total rent expenses under operating leases | € 1,017 | € 912 | € 953 |
Medical Devices [Member] | |||
Liability associated with lease equipment | 10 | ||
Vehicles and Other IT Equipment [Member] | |||
Liability associated with lease equipment | € 617 |
LEASE OBLIGATIONS - Maturities
LEASE OBLIGATIONS - Maturities of finance leases liabilities (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
LEASE OBLIGATIONS | ||
2023 / 2024 | € 214 | € 234 |
2024 / 2025 | 170 | 149 |
2025 / 2026 | 134 | 102 |
2026 / 2027 | 86 | 63 |
2027 / 2028 | 52 | 12 |
2028 / 2029 and thereafter | 2 | 6 |
Total undiscounted minimum lease payments | 659 | 566 |
Less: amount representing interest | (33) | (17) |
Present value of minimum lease payments | 627 | 548 |
Less: current portion | (195) | (224) |
Long-term portion | € 433 | € 324 |
LEASE OBLIGATIONS - Maturitie_2
LEASE OBLIGATIONS - Maturities of operating leases liabilities (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
LEASE OBLIGATIONS | ||
2023 / 2024 | € 898 | € 901 |
2024 / 2025 | 485 | 636 |
2025 / 2026 | 240 | 238 |
2026 / 2027 | 157 | 24 |
Total undiscounted minimum lease payments | 1,780 | 1,799 |
Less: current portion | (898) | (901) |
Long-term portion | € 882 | € 899 |
SHORT-TERM BORROWINGS (Details)
SHORT-TERM BORROWINGS (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Short-term borrowings | € 2,466 | € 1,846 |
Factored Account Receivables [Member] | ||
Short-term borrowings | € 2,466 | € 1,846 |
LONG TERM DEBT (Details)
LONG TERM DEBT (Details) € in Thousands | Dec. 31, 2023 EUR (€) |
Loans Payable [Member] | Germany | High Intensity Focused Ultrasound (HIFU) Equipment 2 [Member] | |
Debt Instrument, Collateral Amount | € 438 |
LONG TERM DEBT - Schedule of Lo
LONG TERM DEBT - Schedule of Long Term Debt (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Total long term debt | € 3,551 | € 5,188 |
Less current portion | (1,553) | (1,601) |
Total long-term portion | 1,997 | 3,587 |
France | ||
Total long term debt | 3,222 | 4,593 |
Japan | ||
Total long term debt | 323 | 558 |
Germany | ||
Total long term debt | 28 | |
Korea | ||
Total long term debt | € 5 | € 8 |
LONG TERM DEBT - Long-term Debt
LONG TERM DEBT - Long-term Debt (Details) | 12 Months Ended | ||||
Dec. 31, 2023 EUR (€) | Dec. 31, 2022 EUR (€) | Dec. 31, 2020 EUR (€) | Dec. 31, 2023 JPY (¥) | Dec. 31, 2022 JPY (¥) | |
Warrants outstanding | € 0 | ||||
Japan | EDAP Technomed Co Ltd. [Member] | Loan One [Member] | |||||
Debt Instrument, Face Amount | ¥ | ¥ 80,000,000 | ¥ 80,000,000 | |||
Maturity | Aug. 02, 2026 | Aug. 02, 2026 | |||
Interest rate | 1.98% | 1.98% | 1.98% | 1.98% | |
Frequency of principal payments | Monthly installment | Monthly installment | |||
Japan | EDAP Technomed Co Ltd. [Member] | Loan Two [Member] | |||||
Debt Instrument, Face Amount | ¥ | ¥ 50,000,000 | ¥ 50,000,000 | |||
Maturity | Apr. 02, 2025 | Apr. 02, 2025 | |||
Interest rate | 1.80% | 1.80% | 1.80% | 1.80% | |
Frequency of principal payments | Monthly installment | Monthly installment | |||
Germany | EDAP TMS GMBH [Member] | High Intensity Focused Ultrasound (HIFU) Equipment 1 [Member] | Loan One [Member] | |||||
Debt Instrument, Face Amount | € 400,000 | ||||
Maturity | Apr. 30, 2023 | ||||
Interest rate | 2.40% | 2.40% | |||
Frequency of principal payments | Monthly installment | ||||
France | Loan One [Member] | High Intensity Focused Ultrasound (HIFU) Equipment 1 [Member] | |||||
Debt | € 1,066,081 | ||||
Debt Instrument, Term | 3 years | ||||
France | Loan One [Member] | High Intensity Focused Ultrasound (HIFU) Equipment 1 [Member] | Maximum | |||||
Debt Instrument, Face Amount | € 1,530,000 | ||||
France | EDAP TMS France [Member] | Loan One [Member] | High Intensity Focused Ultrasound (HIFU) Equipment 1 [Member] | |||||
Maturity | Jul. 01, 2025 | Jul. 01, 2025 | |||
Interest rate | 0.99% | 0.99% | 0.99% | 0.99% | |
Frequency of principal payments | Monthly installment | Monthly installment | |||
Debt | € 1,066,081 | € 1,066,081 | |||
France | EDAP TMS France [Member] | COVID-related loan guaranteed by the French government I [Member] | |||||
Debt Instrument, Face Amount | € 2,000,000 | ||||
Maturity | Jul. 30, 2026 | ||||
Interest rate | 0.73% | ||||
Frequency of principal payments | Monthly installment | ||||
Term initiation | 1 year | ||||
Debt instrument term after extension | 6 years | ||||
France | EDAP TMS France [Member] | COVID-related loan guaranteed by the French government II [Member] | |||||
Debt Instrument, Face Amount | € 2,000,000 | ||||
Maturity | Aug. 04, 2026 | ||||
Interest rate | 0.73% | ||||
Frequency of principal payments | Monthly installment | ||||
Term initiation | 1 year | ||||
Debt instrument term after extension | 6 years | ||||
France | EDAP TMS France [Member] | Loan related to acquisition of computer servers [Member] | |||||
Debt Instrument, Face Amount | € 72,222 | ||||
Maturity | Jul. 05, 2024 | ||||
Interest rate | 0.45% | ||||
Frequency of principal payments | Monthly installment |
LONG TERM DEBT - Schedule Of _2
LONG TERM DEBT - Schedule Of Long-term Debt and Financial Instruments Maturities (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
LONG TERM DEBT | ||
2024 | € 1,553 | |
2025 | 1,320 | |
2026 | 677 | |
Total | € 3,551 | € 5,188 |
OTHER LONG-TERM LIABILITIES - O
OTHER LONG-TERM LIABILITIES - Other Long-term Liabilities (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
OTHER LONG-TERM LIABILITIES. | ||
Provision for retirement indemnities (Japan & France), less current portion | € 2,241 | € 1,962 |
Provision for employee termination indemnities (Korea) less current portion | 149 | 122 |
Provision for Asset Retirement Obligation (Japan) less current portion | 91 | 101 |
Provision for warranty costs, less current portion | 65 | 62 |
Provision for guarantee given to customer, less curent portion | 66 | |
Conditional government advances, less current portion | 463 | 463 |
Total | € 3,075 | € 2,710 |
OTHER LONG-TERM LIABILITIES - A
OTHER LONG-TERM LIABILITIES - Assumptions (Details) | Dec. 31, 2023 Y age | Dec. 31, 2022 age Y |
Defined Benefit Retirement Indemnity Plans, France [Member] | ||
Discount rate | 3.19% | 3.80% |
Salary increase | 3% | 3% |
Retirement age | age | 65 | 65 |
Average retirement remaining service period | Y | 23 | 24 |
Defined Benefit Retirement Indemnity Plans, Japan [Member] | ||
Discount rate | 1.30% | 1.30% |
Salary increase | 2.50% | 2.50% |
Retirement age | age | 60 | 60 |
Average retirement remaining service period | Y | 14 | 14 |
OTHER LONG-TERM LIABILITIES - P
OTHER LONG-TERM LIABILITIES - Provision Presentation According to ASC 715 (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Defined Benefit Retirement Indemnity Plans, France [Member] | ||
Non-current liabilities | € 1,084 | € 845 |
Current liabilities | 89 | |
Total projected benefit obligation | 1,084 | 934 |
Defined Benefit Retirement Indemnity Plans, Japan [Member] | ||
Non-current liabilities | 1,157 | 1,117 |
Current liabilities | 70 | 102 |
Total projected benefit obligation | € 1,227 | € 1,219 |
OTHER LONG-TERM LIABILITIES - R
OTHER LONG-TERM LIABILITIES - Reconciliation of Pension Cost Components (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] | us-gaap_GeneralAndAdministrativeExpense, us-gaap_ResearchAndDevelopmentExpense, us-gaap_SellingAndMarketingExpense | ||
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Amortization of Prior Service Cost (Credit), Statement of Income or Comprehensive Income [Extensible Enumeration] | us-gaap_GeneralAndAdministrativeExpense, us-gaap_ResearchAndDevelopmentExpense, us-gaap_SellingAndMarketingExpense | ||
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] | us-gaap_GeneralAndAdministrativeExpense, us-gaap_ResearchAndDevelopmentExpense, us-gaap_SellingAndMarketingExpense | ||
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement and Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] | us-gaap_GeneralAndAdministrativeExpense, us-gaap_ResearchAndDevelopmentExpense, us-gaap_SellingAndMarketingExpense | ||
Defined Benefit Retirement Indemnity Plans, France [Member] | |||
Projected Benefit obligations at beginning of year | € 934 | € 1,080 | € 1,111 |
Service cost | 67 | 84 | 90 |
Interest cost | 34 | 11 | 6 |
Actuarial (gain) or loss | 66 | (241) | (72) |
Benefits paid | (17) | (56) | |
Projected Benefit obligations at end of year | 1,084 | 934 | 1,080 |
Unrecognized actuarial (gain) loss | (146) | (219) | 22 |
Unrecognized prior service cost | 13 | 14 | 16 |
Defined Benefit Retirement Indemnity Plans, Japan [Member] | |||
Projected Benefit obligations at beginning of year | 1,219 | 1,302 | 1,310 |
Service cost | 114 | 112 | 120 |
Interest cost | 13 | 7 | 7 |
Actuarial (gain) or loss | 4 | (30) | |
Benefits paid | (76) | (75) | (97) |
Plan Amendments | 74 | ||
Exchange rate impact | (122) | (95) | (39) |
Projected Benefit obligations at end of year | 1,227 | 1,219 | 1,302 |
Unrecognized actuarial (gain) loss | 81 | € 86 | € 126 |
Unrecognized prior service cost | € 74 |
OTHER LONG-TERM LIABILITIES (De
OTHER LONG-TERM LIABILITIES (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Defined Benefit Retirement Indemnity Plans, France [Member] | ||
Accumulated Benefit Obligation | € 805 | € 701 |
Accumulated other comprehensive income (loss) | 133 | |
Defined Benefit Retirement Indemnity Plans, Japan [Member] | ||
Accumulated Benefit Obligation | 1,030 | € 1,027 |
Accumulated other comprehensive income (loss) | € 156 |
OTHER LONG-TERM LIABILITIES - E
OTHER LONG-TERM LIABILITIES - Expected Benefit Payments (Details) € in Thousands | Dec. 31, 2023 EUR (€) |
Defined Benefit Retirement Indemnity Plans, France [Member] | |
2026 | € 129 |
2027 | 85 |
2028 | 85 |
2029-2033 | 408 |
Total | 707 |
Defined Benefit Retirement Indemnity Plans, Japan [Member] | |
2024 | 70 |
2025 | 152 |
2026 | 143 |
2027 | 67 |
2028 | 46 |
2029-2033 | 843 |
Total | € 1,322 |
SHAREHOLDERS' EQUITY (Details)
SHAREHOLDERS' EQUITY (Details) | 1 Months Ended | 2 Months Ended | 5 Months Ended | 12 Months Ended | 38 Months Ended | |||||||||||||||||||||||||
Dec. 06, 2023 EUR (€) € / shares shares | Nov. 08, 2023 EUR (€) € / shares shares | Sep. 20, 2023 EUR (€) € / shares shares | Aug. 23, 2023 EUR (€) € / shares shares | May 31, 2023 EUR (€) € / shares shares | May 02, 2023 EUR (€) € / shares shares | Apr. 05, 2023 EUR (€) € / shares shares | Mar. 29, 2023 shares | Dec. 15, 2022 EUR (€) € / shares shares | Nov. 08, 2022 EUR (€) € / shares shares | May 17, 2022 EUR (€) € / shares shares | Nov. 17, 2021 EUR (€) € / shares shares | Jun. 11, 2021 EUR (€) € / shares shares | Apr. 04, 2019 EUR (€) € / shares shares | Aug. 29, 2018 EUR (€) € / shares shares | Apr. 25, 2017 EUR (€) € / shares shares | Apr. 26, 2016 EUR (€) € / shares shares | Sep. 30, 2022 EUR (€) shares | Jul. 31, 2001 shares | Dec. 31, 1998 shares | Dec. 31, 2023 EUR (€) € / shares shares | Dec. 31, 2022 EUR (€) € / shares shares | Dec. 31, 2021 EUR (€) € / shares shares | Sep. 30, 2001 EUR (€) | Dec. 31, 2023 $ / shares | Sep. 30, 2022 $ / shares | Jun. 30, 2021 shares | Dec. 31, 2020 shares | Jun. 28, 2019 shares | Feb. 18, 2016 shares | |
Common stock, shares issued | 37,373,312 | 37,197,731 | ||||||||||||||||||||||||||||
Common stock, par value | € / shares | € 0.13 | € 0.13 | ||||||||||||||||||||||||||||
Commons stock, shares outstanding | 37,103,779 | 36,910,925 | ||||||||||||||||||||||||||||
Issuance costs | € | € 1,954,000 | € 1,961,000 | ||||||||||||||||||||||||||||
Statutory Retained Earnings (Statutory Accumulated Deficit) | € | € 11,962,000 | |||||||||||||||||||||||||||||
Treasury stock | 269,533 | 286,806 | ||||||||||||||||||||||||||||
Treasury Stock, Shares, Acquired (in shares) | 180,290 | 89,243 | ||||||||||||||||||||||||||||
Treasury Stock, Value, Acquired, Par Value Method | € | € 590,000 | |||||||||||||||||||||||||||||
Number of stock-based employee compensation plans | 3 | |||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 686,000 | 571,000 | 1,392,428 | |||||||||||||||||||||||||||
Share Price | $ / shares | $ 5.28 | |||||||||||||||||||||||||||||
The 2016 Plan [Member] | ||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 1,000,000 | |||||||||||||||||||||||||||||
Share-based Payment Arrangement, Option [Member] | ||||||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in EUR per share) | € / shares | € 8.53 | € 9.07 | € 5.56 | |||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options Accelerated Vesting (in shares) | 3,198,913 | 2,613,886 | 2,408,508 | 1,186,900 | ||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 686,000 | 571,000 | 1,392,428 | |||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares) | 1,997,666 | 1,362,205 | 1,149,401 | |||||||||||||||||||||||||||
Stock issued during period shares stock options exercised | 55,973 | 320,622 | 150,820 | |||||||||||||||||||||||||||
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | € | € 2,509,000 | |||||||||||||||||||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 2 years 10 months 24 days | |||||||||||||||||||||||||||||
Share-based Payment Arrangement, Option [Member] | The 2016 Plan [Member] | ||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 1,000,000 | |||||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in EUR per share) | € / shares | € 3.90 | € 2.65 | € 2.39 | € 3.22 | ||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | 10 years | 10 years | 10 years | ||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options Accelerated Vesting (in shares) | 678,080 | |||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 155,000 | 165,000 | 260,000 | 575,000 | ||||||||||||||||||||||||||
Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture | € | € 299,000 | € 219,000 | € 335,000 | € 960,000 | ||||||||||||||||||||||||||
Recognition period of non-cash financial charges | 48 months | 48 months | 48 months | 48 months | ||||||||||||||||||||||||||
Share-based Payment Arrangement, Expense | € | € 3,000 | € 25,000 | € 65,000 | |||||||||||||||||||||||||||
Share-based Payment Arrangement, Option [Member] | The 2016 Plan [Member] | Minimum | ||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 1 year | 1 year | 1 year | 1 year | ||||||||||||||||||||||||||
Share-based Payment Arrangement, Option [Member] | The 2016 Plan [Member] | Maximum | ||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 4 years | 4 years | 4 years | 4 years | ||||||||||||||||||||||||||
Share-based Payment Arrangement, Option [Member] | The 2019 Plan [Member] | ||||||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in EUR per share) | € / shares | € 5.59 | |||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number | 270,000 | |||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | |||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options Accelerated Vesting (in shares) | 1,244,533 | |||||||||||||||||||||||||||||
Recognition period of non-cash financial charges | 36 months | |||||||||||||||||||||||||||||
Share-based Payment Arrangement, Expense | € | € 410,000 | 1,104,000 | 1,484,000 | |||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares) | 1,037,111 | |||||||||||||||||||||||||||||
Share-based Payment Arrangement, Option [Member] | The 2019 Plan [Member] | Minimum | ||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 6 months | |||||||||||||||||||||||||||||
Share-based Payment Arrangement, Option [Member] | The 2019 Plan [Member] | Maximum | ||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 3 years | |||||||||||||||||||||||||||||
Share-based Payment Arrangement, Option [Member] | The 2019 Plan, options to purchase pre-existing shares | ||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 358,528 | |||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 292,428 | |||||||||||||||||||||||||||||
Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture | € | € 2,371,000 | |||||||||||||||||||||||||||||
Share-based Payment Arrangement, Option [Member] | The 2019 Plan, options to purchase new shares | ||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 1,000,000 | |||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 1,000,000 | |||||||||||||||||||||||||||||
Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture | € | € 681,000 | |||||||||||||||||||||||||||||
Share-based Payment Arrangement, Option [Member] | The 2021 Plan [Member] | ||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 2,000,000 | |||||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in EUR per share) | € / shares | € 4.98 | € 6.64 | € 6.08 | € 7.53 | € 9.32 | € 10.10 | € 9.96 | € 9.94 | € 10.32 | € 6.41 | € 5.18 | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | 10 years | 10 years | 10 years | 10 years | 10 years | 10 years | 10 years | 10 years | 10 years | 10 years | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options Accelerated Vesting (in shares) | 1,276,300 | |||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 34,000 | 20,000 | 80,000 | 177,000 | 50,000 | 200,000 | 125,000 | 395,000 | 32,000 | 144,000 | 100,000 | |||||||||||||||||||
Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture | € | € 103,000 | € 81,000 | € 296,000 | € 774,000 | € 270,000 | € 1,183,000 | € 687,000 | € 1,858,000 | € 161,000 | € 450,000 | € 229,000 | |||||||||||||||||||
Recognition period of non-cash financial charges | 36 months | 36 months | 36 months | 36 months | 36 months | 36 months | 36 months | 36 months | 36 months | 36 months | 36 months | |||||||||||||||||||
Share-based Payment Arrangement, Expense | € | € 2,936,000 | € 442,000 | € 25,000 | |||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares) | 282,475 | |||||||||||||||||||||||||||||
Share-based Payment Arrangement, Option [Member] | The 2021 Plan [Member] | Minimum | ||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 6 months | 6 months | 6 months | 6 months | 6 months | 6 months | 6 months | 6 months | 6 months | 6 months | 6 months | |||||||||||||||||||
Share-based Payment Arrangement, Option [Member] | The 2021 Plan [Member] | Maximum | ||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 3 years | 3 years | 3 years | 3 years | 3 years | 3 years | 3 years | 3 years | 3 years | 3 years | 3 years | |||||||||||||||||||
Common stock | ||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 192,854 | 3,444,789 | 4,300,820 | |||||||||||||||||||||||||||
Common stock | American Depository Shares (ADS) [Member] | ||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 3,066,667 | |||||||||||||||||||||||||||||
Price per share | $ / shares | $ 7.50 | |||||||||||||||||||||||||||||
Gross Proceeds From Issuance of Stock | € | € 23,913,000 | |||||||||||||||||||||||||||||
Issuance costs | € | € 1,954,000 |
SHAREHOLDERS' EQUITY - Stock Op
SHAREHOLDERS' EQUITY - Stock Option Assumptions (Details) - € / shares | 1 Months Ended | 12 Months Ended | |||||||
Dec. 31, 2023 | Nov. 30, 2023 | Sep. 30, 2023 | Aug. 31, 2023 | May 31, 2023 | Apr. 30, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Weighted-average fair value of options granted during the year | € 4.95 | € 4.33 | € 2.37 | ||||||
December 2023 grant | |||||||||
Weighted-average expected life (years) (Year) | 5 years 9 months 14 days | ||||||||
Expected volatility rates(1) | 63.29% | ||||||||
Expected dividend yield | 0% | ||||||||
Risk-free interest rate | 4.16% | ||||||||
Weighted-average exercise price (in EUR per share) | € 4.98 | € 4.98 | |||||||
Weighted-average fair value of options granted during the year | € 3.03 | ||||||||
November 2023 grant | |||||||||
Weighted-average expected life (years) (Year) | 5 years 9 months 14 days | ||||||||
Expected volatility rates(1) | 61.09% | ||||||||
Expected dividend yield | 0% | ||||||||
Risk-free interest rate | 4.55% | ||||||||
Weighted-average exercise price (in EUR per share) | € 6.64 | ||||||||
Weighted-average fair value of options granted during the year | € 4.05 | ||||||||
September 2023 grant | |||||||||
Weighted-average expected life (years) (Year) | 5 years 9 months 14 days | ||||||||
Expected volatility rates(1) | 60.90% | ||||||||
Expected dividend yield | 0% | ||||||||
Risk-free interest rate | 4.55% | ||||||||
Weighted-average exercise price (in EUR per share) | € 6.08 | ||||||||
Weighted-average fair value of options granted during the year | € 3.70 | ||||||||
August 2023 grant | |||||||||
Weighted-average expected life (years) (Year) | 5 years 9 months 14 days | ||||||||
Expected volatility rates(1) | 60.60% | ||||||||
Expected dividend yield | 0% | ||||||||
Risk-free interest rate | 4.35% | ||||||||
Weighted-average exercise price (in EUR per share) | € 7.53 | ||||||||
Weighted-average fair value of options granted during the year | € 4.37 | ||||||||
May 2023 Grant I | |||||||||
Weighted-average expected life (years) (Year) | 5 years 9 months 14 days | ||||||||
Expected volatility rates(1) | 60.80% | ||||||||
Expected dividend yield | 0% | ||||||||
Risk-free interest rate | 3.77% | ||||||||
Weighted-average exercise price (in EUR per share) | € 9.32 | ||||||||
Weighted-average fair value of options granted during the year | € 5.40 | ||||||||
May 2023 Grant II | |||||||||
Weighted-average expected life (years) (Year) | 5 years 9 months 14 days | ||||||||
Expected volatility rates(1) | 60.90% | ||||||||
Expected dividend yield | 0% | ||||||||
Risk-free interest rate | 3.47% | ||||||||
Weighted-average exercise price (in EUR per share) | € 10.10 | ||||||||
Weighted-average fair value of options granted during the year | € 5.92 | ||||||||
April 2023 grant | |||||||||
Weighted-average expected life (years) (Year) | 5 years 9 months 14 days | ||||||||
Expected volatility rates(1) | 61% | ||||||||
Expected dividend yield | 0% | ||||||||
Risk-free interest rate | 3.39% | ||||||||
Weighted-average exercise price (in EUR per share) | € 9.96 | ||||||||
Weighted-average fair value of options granted during the year | € 5.49 |
SHAREHOLDERS' EQUITY - Disclosu
SHAREHOLDERS' EQUITY - Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details) - € / shares | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Non-vested options granted (in shares) | 686,000 | 571,000 | 1,392,428 |
Share-based Payment Arrangement, Option [Member] | |||
Outstanding - number (in shares) | 2,613,886 | 2,408,508 | 1,186,900 |
Outstanding - Weighted average exercise price (in EUR per share) | € 5.66 | € 4.38 | € 2.81 |
Non-vested options granted (in shares) | 686,000 | 571,000 | 1,392,428 |
Granted - Weighted average exercise price (in EUR per share) | € 8.53 | € 9.07 | € 5.56 |
Exercised - number (in shares) | (55,973) | (320,622) | (150,820) |
Exercised - Weighted average exercise price (in EUR per share) | € 4.66 | € 2.14 | € 2.93 |
Forfeited - number (in shares) | (45,000) | (45,000) | (20,000) |
Forfeited - Weighted average exercise price (in EUR per share) | € 7.99 | € 5.34 | € 4.01 |
Outstanding - number (in shares) | 3,198,913 | 2,613,886 | 2,408,508 |
Outstanding - Weighted average exercise price (in EUR per share) | € 6.26 | € 5.66 | € 4.38 |
Exercisable - number (in shares) | 1,997,666 | 1,362,205 | 1,149,401 |
Exercisable - Weighted average exercise price (in EUR per share) | € 5.23 | € 4.35 | € 3.25 |
Share purchase options available for grant - number (in shares) | 25,000 | 20,000 | 5,000 |
Number of options to subscribe to new shares available for future grant | 643,000 |
SHAREHOLDERS' EQUITY - Schedule
SHAREHOLDERS' EQUITY - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range (Details) | 12 Months Ended |
Dec. 31, 2023 EUR (€) € / shares shares | |
Range 1 [Member] | |
Outstanding options - Number (in shares) | shares | 20,000 |
Outstanding options - Weighted average remaining contractual life (Year) | 8 years 9 months 18 days |
Outstanding options - Weighted average exercise price (in EUR per share) | € 10.32 |
Exercisable options - Number (in shares) | shares | 7,222 |
Exercisable options - Weighted average exercise price (in EUR per share) | € 10.32 |
Exercise price, Lower range (in EUR per share) | € 10.32 |
Range 2 [Member] | |
Outstanding options - Number (in shares) | shares | 200,000 |
Outstanding options - Weighted average remaining contractual life (Year) | 9 years 3 months 18 days |
Outstanding options - Weighted average exercise price (in EUR per share) | € 10.10 |
Exercisable options - Number (in shares) | shares | 38,889 |
Exercisable options - Weighted average exercise price (in EUR per share) | € 10.10 |
Exercise price, Lower range (in EUR per share) | € 10.10 |
Range 3 [Member] | |
Outstanding options - Number (in shares) | shares | 117,000 |
Outstanding options - Weighted average remaining contractual life (Year) | 9 years 3 months 18 days |
Outstanding options - Weighted average exercise price (in EUR per share) | € 9.96 |
Exercisable options - Number (in shares) | shares | 26,000 |
Exercisable options - Weighted average exercise price (in EUR per share) | € 9.96 |
Exercise price, Lower range (in EUR per share) | € 9.96 |
Range 4 [member] | |
Outstanding options - Number (in shares) | shares | 395,000 |
Outstanding options - Weighted average remaining contractual life (Year) | 9 years |
Outstanding options - Weighted average exercise price (in EUR per share) | € 9.94 |
Exercisable options - Number (in shares) | shares | 131,667 |
Exercisable options - Weighted average exercise price (in EUR per share) | € 9.94 |
Exercise price, Lower range (in EUR per share) | € 9.94 |
Range 5 [Member] | |
Outstanding options - Number (in shares) | shares | 50,000 |
Outstanding options - Weighted average remaining contractual life (Year) | 9 years 4 months 24 days |
Outstanding options - Weighted average exercise price (in EUR per share) | € 9.32 |
Exercisable options - Number (in shares) | shares | 9,722 |
Exercisable options - Weighted average exercise price (in EUR per share) | € 9.32 |
Exercise price, Lower range (in EUR per share) | € 9.32 |
Range 6 [Member] | |
Outstanding options - Number (in shares) | shares | 177,000 |
Outstanding options - Weighted average remaining contractual life (Year) | 9 years 8 months 12 days |
Outstanding options - Weighted average exercise price (in EUR per share) | € 7.53 |
Exercise price, Lower range (in EUR per share) | € 7.53 |
Range 7 [Member] | |
Outstanding options - Number (in shares) | shares | 20,000 |
Outstanding options - Weighted average remaining contractual life (Year) | 9 years 9 months 18 days |
Outstanding options - Weighted average exercise price (in EUR per share) | € 6.64 |
Exercise price, Lower range (in EUR per share) | € 6.64 |
Range 8 [Member] | |
Outstanding options - Number (in shares) | shares | 100,000 |
Outstanding options - Weighted average remaining contractual life (Year) | 8 years 3 months 18 days |
Outstanding options - Weighted average exercise price (in EUR per share) | € 6.41 |
Exercisable options - Number (in shares) | shares | 52,778 |
Exercisable options - Weighted average exercise price (in EUR per share) | € 6.41 |
Exercise price, Lower range (in EUR per share) | € 6.41 |
Range 9 [Member] | |
Outstanding options - Number (in shares) | shares | 80,000 |
Outstanding options - Weighted average remaining contractual life (Year) | 9 years 9 months 18 days |
Outstanding options - Weighted average exercise price (in EUR per share) | € 6.08 |
Exercise price, Lower range (in EUR per share) | € 6.08 |
Range 10 [Member] | |
Outstanding options - Number (in shares) | shares | 1,244,533 |
Outstanding options - Weighted average remaining contractual life (Year) | 7 years 4 months 24 days |
Outstanding options - Weighted average exercise price (in EUR per share) | € 5.59 |
Exercisable options - Number (in shares) | shares | 1,037,111 |
Exercisable options - Weighted average exercise price (in EUR per share) | € 5.59 |
Exercise price, Lower range (in EUR per share) | € 5.59 |
Range 11 [Member] | |
Outstanding options - Number (in shares) | shares | 83,300 |
Outstanding options - Weighted average remaining contractual life (Year) | 7 years 9 months 18 days |
Outstanding options - Weighted average exercise price (in EUR per share) | € 5.18 |
Outstanding options - Aggregate intrinsic value | € | € 431,494 |
Exercisable options - Number (in shares) | shares | 16,197 |
Exercisable options - Weighted average exercise price (in EUR per share) | € 5.18 |
Exercisable options - Aggregate intrinsic value | € | € 83,902 |
Exercise price, Lower range (in EUR per share) | € 5.18 |
Range 12 [Member] | |
Outstanding options - Number (in shares) | shares | 34,000 |
Outstanding options - Weighted average remaining contractual life (Year) | 9 years 10 months 24 days |
Outstanding options - Weighted average exercise price (in EUR per share) | € 4.98 |
Outstanding options - Aggregate intrinsic value | € | € 169,320 |
Exercise price, Lower range (in EUR per share) | € 4.98 |
Range 13 [Member] | |
Outstanding options - Number (in shares) | shares | 107,500 |
Outstanding options - Weighted average remaining contractual life (Year) | 5 years 9 months 18 days |
Outstanding options - Weighted average exercise price (in EUR per share) | € 3.90 |
Outstanding options - Aggregate intrinsic value | € | € 419,250 |
Exercisable options - Number (in shares) | shares | 107,500 |
Exercisable options - Weighted average exercise price (in EUR per share) | € 3.90 |
Exercisable options - Aggregate intrinsic value | € | € 419,250 |
Exercise price, Lower range (in EUR per share) | € 3.90 |
Range 14 [Member] | |
Outstanding options - Number (in shares) | shares | 357,000 |
Outstanding options - Weighted average remaining contractual life (Year) | 2 years 3 months 18 days |
Outstanding options - Weighted average exercise price (in EUR per share) | € 3.22 |
Outstanding options - Aggregate intrinsic value | € | € 1,149,540 |
Exercisable options - Number (in shares) | shares | 357,000 |
Exercisable options - Weighted average exercise price (in EUR per share) | € 3.22 |
Exercisable options - Aggregate intrinsic value | € | € 1,149,540 |
Exercise price, Lower range (in EUR per share) | € 3.22 |
Range 15 [Member] | |
Outstanding options - Number (in shares) | shares | 77,500 |
Outstanding options - Weighted average remaining contractual life (Year) | 4 years 8 months 12 days |
Outstanding options - Weighted average exercise price (in EUR per share) | € 2.65 |
Outstanding options - Aggregate intrinsic value | € | € 205,375 |
Exercisable options - Number (in shares) | shares | 77,500 |
Exercisable options - Weighted average exercise price (in EUR per share) | € 2.65 |
Exercisable options - Aggregate intrinsic value | € | € 205,375 |
Exercise price, Lower range (in EUR per share) | € 2.65 |
Range 16 [Member] | |
Outstanding options - Number (in shares) | shares | 136,080 |
Outstanding options - Weighted average remaining contractual life (Year) | 3 years 3 months 18 days |
Outstanding options - Weighted average exercise price (in EUR per share) | € 2.39 |
Outstanding options - Aggregate intrinsic value | € | € 325,231 |
Exercisable options - Number (in shares) | shares | 136,080 |
Exercisable options - Weighted average exercise price (in EUR per share) | € 2.39 |
Exercisable options - Aggregate intrinsic value | € | € 325,231 |
Exercise price, Lower range (in EUR per share) | € 2.39 |
Range 17 [Member] | |
Outstanding options - Number (in shares) | shares | 3,198,913 |
Outstanding options - Weighted average remaining contractual life (Year) | 7 years 9 months 18 days |
Outstanding options - Weighted average exercise price (in EUR per share) | € 0.84 |
Outstanding options - Aggregate intrinsic value | € | € 2,700,210 |
Exercisable options - Number (in shares) | shares | 1,997,666 |
Exercisable options - Weighted average exercise price (in EUR per share) | € 1.09 |
Exercisable options - Aggregate intrinsic value | € | € 2,183,298 |
Exercise price, Lower range (in EUR per share) | € 2.39 |
Exercise price, Upper range (in EUR per share) | € 10.32 |
SHAREHOLDERS' EQUITY - Non-vest
SHAREHOLDERS' EQUITY - Non-vested Options Activity (Details) - € / shares | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
SHAREHOLDERS' EQUITY. | |||
Non-vested options outstanding (in shares) | 1,251,681 | 1,259,107 | 216,250 |
Non-vested options outstanding, weighted average grant-date fair value (in EUR per share) | € 2.32 | € 2.32 | € 1.59 |
Non-vested options granted (in shares) | 686,000 | 571,000 | 1,392,428 |
Non-vested options granted, weighted average grant-date fair value (in EUR per share) | € 4.95 | € 4.33 | € 2.37 |
Non-vested options vested (in shares) | (691,434) | (543,426) | (329,571) |
Non-vested options vested, weighted average grant-date fair value (in EUR per share) | € 3.22 | € 2.32 | € 2.06 |
Non-vested options forfeited (in shares) | (45,000) | (35,000) | (20,000) |
Non-vested options forfeited, weighted average grant-date fair value (in EUR per share) | € 3.98 | € 2.80 | € 1.89 |
Non-vested options outstanding (in shares) | 1,201,247 | 1,251,681 | 1,259,107 |
Non-vested options outstanding, weighted average grant-date fair value (in EUR per share) | € 4.18 | € 2.32 | € 2.32 |
SHAREHOLDERS' EQUITY - Componen
SHAREHOLDERS' EQUITY - Components of Accumulated Other Comprehensive Income (Loss) Net of Tax (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Balance | € 71,632 | € 50,054 |
Balance | 56,922 | 71,632 |
Accumulated Foreign Currency Adjustment Attributable to Parent [Member] | ||
Balance | (3,973) | (3,377) |
Net current-period other comprehensive income (loss) | (478) | (596) |
Balance | (4,451) | (3,973) |
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] | ||
Balance | 144 | (212) |
Net current-period other comprehensive income (loss) | (180) | 355 |
Balance | (37) | 144 |
Other comprehensive income (loss) | ||
Balance | (3,829) | (3,589) |
Net current-period other comprehensive income (loss) | (658) | (240) |
Balance | € (4,487) | € (3,829) |
SHAREHOLDERS' EQUITY - Free sha
SHAREHOLDERS' EQUITY - Free share awards (Details) - Free share awards - EUR (€) € in Thousands | May 02, 2023 | Mar. 29, 2023 | Nov. 08, 2022 | Sep. 28, 2022 | Jun. 30, 2022 | Mar. 30, 2022 | Sep. 28, 2021 | Dec. 31, 2023 | Jun. 30, 2021 |
The 2021 Plan [Member] | |||||||||
Awards available for grant - number (in shares) | 200,000 | ||||||||
Shares granted | 61,500 | ||||||||
Awards outstanding | 0 | ||||||||
2021 Plan, grants to employees | |||||||||
Shares granted | 61,500 | ||||||||
Shares exercised | 57,500 | ||||||||
Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture | € 340 | ||||||||
2021 Plan, grants to employees | Minimum | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 1 year | ||||||||
2021 Plan, grants to employees | Maximum | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 2 years | ||||||||
2021 Plan, grants to CEO | |||||||||
Shares granted | 40,000 | ||||||||
Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture | € 259 | ||||||||
2021 Plan, grants to CEO | Minimum | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 1 year | ||||||||
2021 Plan, grants to CEO | Maximum | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 2 years | ||||||||
The 2022 Plan | |||||||||
Awards available for grant - number (in shares) | 600,000 | ||||||||
Awards outstanding | 273,500 | ||||||||
2022 Plan, grants to employees | |||||||||
Shares granted | 291,500 | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 3 years | ||||||||
Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture | € 2,963 | ||||||||
Period between date of grant and start of vesting period | 6 months | ||||||||
Recognition period of non-cash financial charges | 36 months | ||||||||
2022 Plan, grants to CEO | |||||||||
Shares granted | 150,000 | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 1 year | ||||||||
Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture | € 1,542 | ||||||||
2022 Plan, grants to president | |||||||||
Shares granted | 50,000 | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 3 years | ||||||||
Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture | € 508 | ||||||||
Period between date of grant and start of vesting period | 6 months | ||||||||
Recognition period of non-cash financial charges | 36 months |
TOTAL SALES - Sales by Geograph
TOTAL SALES - Sales by Geographical Area (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenues | € 60,423 | € 55,108 | € 44,065 |
Product | |||
Revenues | 60,423 | 55,108 | 44,060 |
Asia | Product | |||
Revenues | 17,841 | 17,936 | 16,009 |
France | Product | |||
Revenues | 11,999 | 10,637 | 12,251 |
United States | Product | |||
Revenues | 16,717 | 15,036 | 5,524 |
Other geographical areas | Product | |||
Revenues | € 13,865 | € 11,500 | € 10,276 |
TOTAL SALES - Timing of Revenue
TOTAL SALES - Timing of Revenue Recognition (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenues | € 60,423 | € 55,108 | € 44,065 |
Product | |||
Revenues | 60,423 | 55,108 | 44,060 |
Products transferred at a point in time | Product | |||
Revenues | 48,646 | 44,173 | 34,552 |
Products and services transferred over time | Product | |||
Revenues | € 11,777 | € 10,935 | € 9,508 |
OTHER REVENUES - Other Revenues
OTHER REVENUES - Other Revenues (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Other revenues | |||
Revenues | € 60,423 | € 55,108 | € 44,065 |
Other revenues | |||
Other revenues | |||
Revenues | 6 | ||
Licenses and others | |||
Other revenues | |||
Revenues | € 6 |
COSTS OF SALES - Schedule of Co
COSTS OF SALES - Schedule of Costs of Sales (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
COSTS OF SALES | |||
Direct costs of sales | € (22,624) | € (19,814) | € (16,199) |
Indirect costs of sales | (13,388) | (11,102) | (9,443) |
Total cost of sales | € (36,012) | € (30,916) | € (25,643) |
RESEARCH AND DEVELOPMENT EXPE_3
RESEARCH AND DEVELOPMENT EXPENSES - Research and Development Expenses (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
RESEARCH AND DEVELOPMENT EXPENSES | |||
Gross research and development expenses | € (7,596) | € (5,751) | € (4,757) |
Research Tax Credit | 411 | 581 | 617 |
Grants | 222 | 250 | 739 |
Net Research and development expenses | € (6,963) | € (4,920) | € (3,402) |
FINANCIAL INCOME, NET - Schedul
FINANCIAL INCOME, NET - Schedule of Financial Income (Expense) (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
FINANCIAL INCOME, NET | |||
Interest income | € 1,311 | € 404 | € 10 |
Interest expense | (232) | (168) | (52) |
Paycheck Protection Program loan forgiveness | 187 | ||
Total | € 1,079 | € 236 | € 145 |
INCOME TAXES (Details)
INCOME TAXES (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Operating Loss Carryforwards, Total | € 71,821 | ||
Income tax interest and penalties | 0 | € 0 | € 0 |
EDAP TMS S.A. [Member] | |||
Operating Loss Carryforwards, Total | 31,284 | ||
EDAP Technomed Inc. [Member] | |||
Operating Loss Carryforwards, Total | 40,310 | ||
Edap Technomed Co Ltd Japan [Member] | |||
Operating Loss Carryforwards, Total | € 227 |
INCOME TAXES - Income (Loss) Be
INCOME TAXES - Income (Loss) Before Income Taxes (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income (loss) | € (20,533) | € (2,096) | € 893 |
France | |||
Income (loss) | (9,026) | (418) | 869 |
Other countries | |||
Income (loss) | € (11,507) | € (1,678) | € 24 |
INCOME TAXES - Income Tax Benef
INCOME TAXES - Income Tax Benefit (Expense) (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Current income tax expense | € (610) | € (736) | € (756) |
Deferred income tax (expense) benefit | (34) | (101) | 563 |
Effective income tax (expense) benefit | (644) | (837) | (193) |
France | |||
Current income tax expense | (77) | (485) | (320) |
Deferred income tax (expense) benefit | 3 | (8) | 8 |
Other countries | |||
Current income tax expense | (533) | (251) | (436) |
Deferred income tax (expense) benefit | € (37) | € (93) | € 556 |
INCOME TAXES - Deferred Tax Ass
INCOME TAXES - Deferred Tax Assets and Liabilities (Details) - EUR (€) € in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
INCOME TAXES | ||
Net operating loss carry forwards | € 16,356 | € 13,793 |
Net operating loss carry forwards with no expiration date | 71,594 | |
Elimination of intercompany profit in inventory | 689 | 480 |
Elimination of intercompany profit in fixed assets | 396 | 256 |
Provisions for retirement indemnities | 663 | 658 |
Capital leases treated as operating leases for tax | 10 | 26 |
Other items | 354 | 360 |
Total deferred tax assets | 18,468 | 15,573 |
Net deferred tax assets | 18,468 | 15,573 |
Valuation allowance for deferred tax assets | (17,739) | (14,744) |
Deferred tax assets (liabilities), net of allowance | € 729 | € 829 |
INCOME TAXES - Effective Tax Ra
INCOME TAXES - Effective Tax Rate Reconciliation (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
INCOME TAXES | |||
Theoretical income tax (expense) benefit at French statutory tax rate | € 5,133 | € 524 | € (237) |
Income of foreign subsidiaries taxed at different tax rates | (546) | (174) | (95) |
Effect of net operating loss carry-forwards and valuation allowances | (4,439) | (643) | 626 |
Permanent differences | (263) | (99) | (258) |
Effect of cancellation of intra-group positions | (476) | (366) | (130) |
French business tax included in income tax (CVAE) | (74) | (99) | (85) |
Other | 20 | 20 | (15) |
Effective income tax (expense) benefit | € (644) | € (837) | € (193) |
EARNINGS (LOSS) PER SHARE - Sch
EARNINGS (LOSS) PER SHARE - Schedule of Earnings Per Share, Basic and Diluted (Details) - EUR (€) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
EARNINGS (LOSS) PER SHARE | |||
Net income (loss) | € (21,177,772) | € (2,933,058) | € 699,890 |
Weighted average number of shares for the computation of basic EPS | 36,996,722 | 34,392,598 | 32,129,047 |
Basic EPS (in Euros) | € (0.57) | € (0.09) | € 0.02 |
Effect of dilutive securities (in shares) | 2,653,050 | 2,502,171 | 293,824 |
Weighted average number of shares for the computation of diluted EPS | 36,996,722 | 34,392,598 | 32,422,871 |
Diluted EPS income / (loss) (in Euros) | € (0.57) | € (0.09) | € 0.02 |
CONCENTRATION OF CREDIT RISK (D
CONCENTRATION OF CREDIT RISK (Details) - EUR (€) € in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
CONCENTRATION OF CREDIT RISK | ||
Allowance for doubtful accounts receivable | € 0.2 | € 0.2 |
SEGMENT INFORMATION (Details)
SEGMENT INFORMATION (Details) | 12 Months Ended |
Dec. 31, 2023 segment | |
SEGMENT INFORMATION | |
Reportable segments | 3 |
SEGMENT INFORMATION - Reconcili
SEGMENT INFORMATION - Reconciliation of segment operating profit or loss to consolidated net loss (Details) - EUR (€) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
SEGMENT INFORMATION | |||
Segment operating income (loss) | € (19,813,000) | € (4,257,000) | € (1,612,000) |
Financial income (expense), net | 1,079,000 | 236,000 | 145,000 |
Foreign Currency exchange (losses) gains, net | (1,799,000) | 1,925,000 | 2,360,000 |
Income tax (expense) benefit | (644,000) | (837,000) | (193,000) |
Net income (loss) | € (21,177,772) | € (2,933,058) | € 699,890 |
SEGMENT INFORMATION - Schedule
SEGMENT INFORMATION - Schedule of Segment Reporting Information By Segment (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenues | € 60,423 | € 55,108 | € 44,065 |
Cost of sales | (36,012) | (30,916) | (25,643) |
Gross profit | 24,411 | 24,193 | 18,422 |
R&D expenses | (6,963) | (4,920) | (3,402) |
Selling and marketing expenses | (22,626) | (16,379) | (10,732) |
G&A expenses | (14,634) | (7,152) | (5,900) |
Total expenses | (44,224) | (28,450) | (20,034) |
Operating income (loss) from operations | (19,813) | (4,257) | (1,612) |
Total Assets | 91,548 | 101,123 | 77,226 |
Capital expenditures | 4,344 | 2,378 | 1,636 |
Non-current assets | 13,069 | 10,605 | 9,845 |
Goodwill | 2,412 | 2,412 | 2,412 |
Product | |||
Revenues | 60,423 | 55,108 | 44,060 |
Goods | |||
Revenues | 42,333 | 38,462 | 29,040 |
Cost of sales | (23,302) | (20,528) | (16,181) |
RPP's and leases | |||
Revenues | 6,176 | 5,617 | 4,968 |
Cost of sales | (4,541) | (3,387) | (3,108) |
Spare parts and services | |||
Revenues | 11,914 | 11,030 | 10,052 |
Cost of sales | (8,169) | (7,000) | (6,354) |
External other revenues | |||
Revenues | 6 | ||
Operating Segments | High Intensity Focused Ultrasound (HIFU) | |||
Revenues | 20,596 | 15,634 | 9,915 |
Cost of sales | (10,112) | (6,788) | (5,311) |
Gross profit | 10,484 | 8,846 | 4,604 |
R&D expenses | (5,755) | (3,525) | (2,238) |
Selling and marketing expenses | (13,524) | (8,083) | (3,910) |
G&A expenses | (5,983) | (2,131) | (1,481) |
Total expenses | (25,262) | (13,739) | (7,630) |
Operating income (loss) from operations | (14,778) | (4,894) | (3,025) |
Total Assets | 22,443 | 16,293 | 13,597 |
Capital expenditures | 3,577 | 1,715 | 1,234 |
Non-current assets | 6,516 | 4,269 | 3,689 |
Goodwill | 645 | 645 | 645 |
Operating Segments | High Intensity Focused Ultrasound (HIFU) | Product | |||
Revenues | 20,596 | 15,634 | 9,910 |
Operating Segments | High Intensity Focused Ultrasound (HIFU) | Goods | |||
Revenues | 13,510 | 9,437 | 4,515 |
Operating Segments | High Intensity Focused Ultrasound (HIFU) | RPP's and leases | |||
Revenues | 4,935 | 4,287 | 3,679 |
Operating Segments | High Intensity Focused Ultrasound (HIFU) | Spare parts and services | |||
Revenues | 2,152 | 1,909 | 1,715 |
Operating Segments | High Intensity Focused Ultrasound (HIFU) | External other revenues | |||
Revenues | 6 | ||
Operating Segments | Lithotripsy (ESWL) | |||
Revenues | 9,908 | 11,568 | 11,016 |
Cost of sales | (6,268) | (6,732) | (6,080) |
Gross profit | 3,640 | 4,836 | 4,936 |
R&D expenses | (764) | (950) | (835) |
Selling and marketing expenses | (1,636) | (1,887) | (2,048) |
G&A expenses | (1,471) | (1,077) | (1,161) |
Total expenses | (3,871) | (3,914) | (4,043) |
Operating income (loss) from operations | (232) | 922 | 893 |
Total Assets | 12,798 | 12,997 | 13,596 |
Capital expenditures | 288 | 307 | 141 |
Non-current assets | 2,105 | 2,149 | 2,185 |
Goodwill | 496 | 496 | 496 |
Operating Segments | Lithotripsy (ESWL) | Product | |||
Revenues | 9,908 | 11,568 | 11,016 |
Operating Segments | Lithotripsy (ESWL) | Goods | |||
Revenues | 3,844 | 4,880 | 4,236 |
Operating Segments | Lithotripsy (ESWL) | RPP's and leases | |||
Revenues | 955 | 1,058 | 1,022 |
Operating Segments | Lithotripsy (ESWL) | Spare parts and services | |||
Revenues | 5,109 | 5,630 | 5,758 |
Operating Segments | DISTRIB Division | |||
Revenues | 29,919 | 27,907 | 23,134 |
Cost of sales | (19,632) | (17,396) | (14,252) |
Gross profit | 10,287 | 10,511 | 8,882 |
R&D expenses | (444) | (444) | (329) |
Selling and marketing expenses | (7,466) | (6,409) | (4,774) |
G&A expenses | (2,625) | (1,690) | (1,355) |
Total expenses | (10,535) | (8,543) | (6,458) |
Operating income (loss) from operations | (248) | 1,968 | 2,424 |
Total Assets | 31,400 | 26,407 | 25,344 |
Capital expenditures | 479 | 356 | 261 |
Non-current assets | 4,448 | 4,187 | 3,971 |
Goodwill | 1,271 | 1,271 | 1,271 |
Operating Segments | DISTRIB Division | Product | |||
Revenues | 29,919 | 27,907 | 23,134 |
Operating Segments | DISTRIB Division | Goods | |||
Revenues | 24,980 | 24,145 | 20,289 |
Operating Segments | DISTRIB Division | RPP's and leases | |||
Revenues | 286 | 272 | 267 |
Operating Segments | DISTRIB Division | Spare parts and services | |||
Revenues | 4,653 | 3,491 | 2,578 |
Reconciling Items | |||
G&A expenses | (4,556) | (2,254) | (1,904) |
Total expenses | (4,556) | (2,254) | (1,904) |
Operating income (loss) from operations | (4,556) | (2,254) | (1,904) |
Total Assets | € 24,908 | € 45,426 | € 24,690 |
VALUATION ACCOUNTS (Details)
VALUATION ACCOUNTS (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Allowance for deferred tax assets | |||
Balance | € 14,744 | € 14,341 | € 15,508 |
Charges to costs and expenses | 3,175 | 1,538 | 346 |
Deductions: write-off and others | (180) | (1,135) | (1,513) |
Balance | 17,739 | 14,744 | 14,341 |
Allowance for doubtful accounts | |||
Balance | 161 | 742 | 721 |
Charges to costs and expenses | 85 | 32 | 2 |
Deductions: write-off and others | (21) | (613) | 19 |
Balance | 224 | 161 | 742 |
Slow-moving inventory | |||
Balance | 1,262 | 1,470 | 1,563 |
Charges to costs and expenses | 354 | 93 | 371 |
Deductions: write-off and others | (353) | (300) | (464) |
Balance | 1,263 | 1,262 | 1,470 |
Warranty reserve | |||
Balance | 162 | 252 | 369 |
Charges to costs and expenses | 134 | 112 | 110 |
Deductions: write-off and others | (124) | (202) | (227) |
Balance | € 172 | € 162 | € 252 |
SUPPLEMENTAL DISCLOSURES OF C_3
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | |||
Income taxes paid (refunds received) | € 509 | € 410 | € 307 |
Interest paid | 265 | 168 | 114 |
Interest received | 1,311 | 403 | 10 |
Financing lease obligations incurred | 358 | 162 | 233 |
Operating lease obligations incurred | 1,098 | 1,162 | 674 |
Operating cash flow used in operating leases | 1,009 | 900 | 916 |
Operating cash flow used in finance leases | 7 | 12 | 18 |
Financing cash flow used in finance leases | € 242 | € 350 | € 406 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details) - Subsidiaries - Japan - Guarantee of Indebtedness of Others - Parent Company [Member] - JPY (¥) | Apr. 22, 2020 | Aug. 19, 2019 |
EDAP Technomed Co. Ltd, August 19, 2019 loan | ||
Related Party Transaction [Line Items] | ||
Amount warranted | ¥ 80,000,000 | |
EDAP Technomed Co. Ltd, April 22, 2020 loan | ||
Related Party Transaction [Line Items] | ||
Amount warranted | ¥ 50,000,000 |